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Summary  
The global burden of Malaria remains high with a 2.2 billion people estimated to live 
in endemic areas (Snow et al, 2005). Prompt and efficacious chemotherapy remains 
an important cornerstone in the fight against malaria. Development of resistance is 
the parasite’s mechanisms to respond to massive drug pressure. 
In this study I analysed drug-parasites interactions in vivo and in vitro using discreet 
experimental approaches. I started by studying parasite survival in vivo, 7 days after 
treatment intervention. In the following, I analysed parasites isolates in vitro that had 
been exposed to various drugs over the last years in the community. In the final part 
of the project, I attempted to gain insight in the evolution of drug resistance in vitro. 
For this work, I set up induction of resistance experiments in vitro and analysed in a 
time course mechanisms of resistance. Of particular interest was here the 
relationship between gene amplification and the emergence of single nucleotide 
polymorphisms. 
The results presented in this work show that 7 days after start of treatment 
(artemisinin combination therapy or amodiaquine) subpatent parasite populations 
were detected in 64/156 patients (41%) with high sensitivity. However, persistence of 
parasites was not associated with recrudescent infection at the individual level but 
showed instead correlation with initial parasite density in potentially less immune 
patients.  
Analysis of field isolates revealed high prevalence of anti-folate resistance due to 
triple and double mutant Pfdhfr. In theses parasites, no gene copy number variations 
were detected for genes involved in the folate pathway. 
However, induction of pyrimethamine resistance in vitro, lead to Pfdhfr amplification 
in two laboratory strains 3D7 (31 fold) and FCR3 (9 fold) associated with high cross-
resistance to cycloguanil and trimethoprim but not to chloroquine. Further, I was able 
to identify gene amplification as a mechanism for acquisition of S108N in Pfdhfr. 
My findings of persistent subpatent parasitaemia after treatment underline the need 
of understanding clearance rate, persistence and elimination of parasites after anti-
malarial treatment, particularly in regard to recent reports of emerging artemisinin 
resistance in western Cambodia (Dondorp et al, 2009), My results also suggest that 
resistant phenotypes may persist in parasite populations, once introduced. And 
finally, my data suggest gene amplification as an intermediate step in the acquisition 
of resistance conferring point mutations in P. falciparum. 
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Zusammenfassung 
Die globale Bedrohung für die menschliche Gesundheit durch Malaria bleibt weiterhin 
bestehen. Geschätzte 2.2 Millionen Menschen leben in endemischen Gebieten 
(Snow et al, 2005). Schnelle und effektive Behandlung sind entscheidend bei der 
Malariabekämpfung. Auf den Selektionsdruck durch Wirkstoffe reagiert der Parasit,  
Plasmodium falciparum, durch die Bildung von Resistenzen. 
In dieser Studie habe ich die Wechselwirkungen zwischen Wirkstoff und Parasit 
durch umsichtig geplante experimentelle Ansätze in vivo und in vitro untersucht. Zu 
Beginn wurden die Überlebenschancen des Parasiten in vivo, 7 Tage nach einer 
Behandlung analysiert. Anschließend wurden Isolate von Parasiten, die während der 
letzten Jahre unterschiedlichen Wirkstoffen in der Gemeinde von Pingilikani 
ausgesetzt waren, in vitro charakterisiert. Im letzten Teil der Arbeit habe ich versucht 
Einblicke in die Entstehung von Resistenzen in vitro zu erlangen. Resistenz wurde in 
vitro induziert um Resistenzmechanismen über einen Zeitraum von mehreren 
Monaten hin analysieren zu können. Besonders interessant war hier der 
Zusammenhang zwischen Vervielfältigung von Genen und das Auftreten von 
Punktmutationen. 
Die vorliegenden Ergebnisse zeigen, dass durch eine hoch sensitive Methode 7 
Tage nach Behandlungsbeginn (Artemisinin Kombinationspräparate oder 
Amodiaquin) in 64 von 156 Fällen (41%), noch Parasiten in a-symptomatischen 
Patienten nachgewiesen werden konnten. Die persistierende Parasitämie war jedoch 
nicht mit einem Risiko von wieder auftretenden Symptomen verbunden. Ein 
Zusammenhang mit der Parasitendichte zu Begin der Behandlung konnte jedoch in 
weniger immunen Patienten festgestellt werden.  
Die Analyse von Parasiten Isolaten wies auf eine starke Verbreitung von Anti-Folat 
Resistenz hin, hervorgerufen durch Mutationen in Pfdhfr. Gen Vervielfältigung wurde 
in den Genen des Folat Stoffwechsels nicht gefunden. Im Gegensatz dazu führten 
die Resistenz-Induktions-Experimente durch Pyrimethamin in vitro zu einer 
deutlichen Vervielfältigung von Pfdhfr in 3D7 (31-fach) und FCR3 (9-fach), die mit 
ausgeprägter Cross-Resistenz (Cycloguanil und Trimethoprim) verbunden war. 
Außerdem ist es mir gelungen, Vervielfältigung von Genen als mechanistische 
Grundlage für die Entstehung von Punktmutationen in P. falciparum zu beschreiben.  
Meine Daten zu persistierenden Parasiten nach Behandlung erlangen besondere 
Bedeutung, gerade im Hinblick auf kürzlich veröffentlichte Berichte über das 
Zusammenfassung 
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Auftreten von Artemisin Resistenz im westlichen Kambodscha (Dondorp et al, 2009). 
Meine Ergebnisse weisen auch darauf hin, dass einmal in einer Population etablierte 
resistente Phänotypen bestehen bleiben. 
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1. Introduction 
1.1 Malaria’s past and present epidemiology 
Malaria is a human disease caused by a protozoan pathogen. Four species infecting 
humans are identified: Plasmodium falciparum, Plasmodium vivax, Plasmodium 
malariae and Plasmodium ovale. Recently, Plasmodium knowlesi, a primate malaria 
parasite, was identified as the fifth human Plasmodium species (Singh et al, 2004). 
Evidence suggests its evolution from a free-living, chloroplast-containing protozoan, 
which first became adapted to aquatic invertebrates (Wilson & Williamson, 1997), 
before evolving into a human intracellular parasite in vertebrate hosts. The closest 
relative to P. falciparum is the malaria parasite of chimpanzees, P. reichenowi 
(Escalante & Ayala, 1994). Molecular evidence confirm that the clad formed by these 
two species is only remotely related to other Plasmodium species and diverged 
around 130 million years ago (Escalante & Ayala, 1995). It is estimates that five 
million years ago, when the human line and the African great apes diverged, P. 
falciparum and P. reichenowi were also separated (Carter & Mendis, 2002). 
The agrarian revolution in Africa resulted in intensified parasite transmission vie the 
Anopheles vector. Human populations increased in numbers and lived in 
agglomerations close to water sources or containers. For mosquitoes, a constant 
supply of blood and abundant breeding sites were created (Carter & Mendis, 2002).  
The first appearance of malaria in historical references dates back to the Chinese 
Canon of Medicine (Nei Ching), 4700 year ago, which mentions symptoms, typical for 
malaria, as the periodicity of fever for example. Later, Hippocrates (460 to 377 B.C.) 
described the different recurring forms of fever and left no doubt about the presence 
of malaria in Greece. Only in the second century B.C., malaria reached the mainland 
of Italy. However during the prosperity of the Roman Empire, swamps surrounding 
Rome were drained and malaria was not a major thread. Only with the decline of the 
empire (400 A.C.) malaria established around the shores of the Mediterranean, from 
where it spread probably during the Dark or Middle age to northern Europe. After 
malaria had reached its widest geographical expansion in the 19th century, during 
which half of the world’s population lived at significant risk of infection, it was 
eliminated from North America and Northern and Western Europe after World War II 
(Carter & Mendis, 2002). 
Today, the global burden of malaria remains high. In 2002 2.2 billion people are 
estimated to live in endemic areas (Figure 1) in the year 2002 (Snow et al, 2005). In 
the same year an estimated 515 million clinical events (range 300 – 660) were 
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caused by Plasmodium falciparum of which 70% were occurring in African regions 
(Snow et al, 2005), mostly in children under the age of 5 years. Not only the 
prevalence is highest but also severe life threatening manifestations of malaria were 
tenfold higher in Africa than in similar malaria endemic areas (Snow et al, 2005).  
  
Very recent observations have shown a decline in malaria transmission and burden 
in Zanzibar (Bhattarai et al, 2007) and The Gambia (Ceesay et al, 2008). These 
reductions occurred after the introduction of artemisinin combination therapies (ACT) 
between 2002 and 2003. With the decline in transmission, fewer cases of severe 
malaria and associated morbidity were also reported for Kilifi District Hospital, Kenya 
(O'Meara et al, 2008). Furthermore the proportion of patients presenting with 
positives slides decreased significantly (indicator of parasite prevalence in the 
population). In accordance to the hypothesis of a direct correlation of immunity and 
parasite prevalence, a significant increase in the mean age of slide positive patients 
was observed (O'Meara et al, 2008). 
The samples for this work were collected at the Pingilikani study site (Figure 1-1). This 
study site has been established as part of a Heidelberg University-initiated 
collaboration with the Kenya Medical Research Institute (KEMRI), Centre for 
Geographic Medicine Research-Coast (CGMR-C). The site is located 20 km south of 
the town of Kilifi, on the Kenyan cost. The study area is characterised by perennial 
transmission of P. falciparum with bi-annual peaks after the long (April-June) and 
short (November-December) rainy seasons. Before the recent reductions in 
Figure 1 Plasmodium falciparum endemicity map 2007 (Hay et al, 2009)  
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transmission intensity, the risk of infection was estimated at 22 to 53 infective bites 
per person per year (Mbogo et al, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Life cycle 
Plasmodium falciparum, a unicellular haploid eukaryote of the Phyllum Apicomplexa 
has co-evolved with its human and mosquito hosts over millions of years. Its complex 
life cycle (Figure 1-2) encompasses three stages of two distinct proliferation forms 
with massive mandatory intracellular asexual multiplication, sporogony (mosquito 
midgut) and schizogony (liver and blood). 
During a blood meal, an infected Anopheles mosquito injects with its saliva 
sporozoites into the skin of the human host. Sporozoites, a banana shaped motile 
stage, migrate through the skin around the bite site until they reach a blood vessel, 
which they actively invade. With the blood stream, they are then passively 
transported to the sinusoid endothelium of the liver. Here they enter the liver tissue 
through Kupffer cells (Frevert et al, 2005) and migrate through a number of liver cells 
until they invade a hepatocyte and establish themselves in a parasitophorous 
vacuole. From a single sporozoites up to 50 000 merozoites are formed by clinically 
silent schizogony. Merosomes are membranous structures that contain large 
numbers of merozoites (Sturm et al, 2006). They bud from the hepatocyte into the 
blood stream, accumulate in the lung (shown in P. berghei) (Baer et al, 2007) where 
they burst and release the merozoites, which then ultimately invade erythrocytes 
(Sturm et al, 2006) and thereby, establish pathogenic blood stage infection. Within 
Figure 1-1 (left) Map of Kilifi district, Kenya. (right) Pingilikani dispensary. 
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the erythrocytes, early ring stages develop to trophozoites, the metabolically most 
active form of the blood stages with massive replication of DNA. Trophozoites 
develop into schizonts, carrying 24 merozoites. Merozoites are released by active 
egress into the blood and initiate the next cycle of erythrocyte infection. The 
replication cycle in the blood stream takes approximately 48 hours but unlike other 
Plasmodia, Plasmodium falciparum replication cycles are not synchronised across a 
massive population of up to 1012 parasites per infection. Symptoms, associated with 
P. falciparum infections, are therefore not subjected to a clear periodicity (Baer et al, 
2007). 
Due to yet poorly characterised external stimuli a proportion of ring form parasites 
eventually commit within 10 to 14 days to gametocytogenesis. With the ingested 
blood meal, female and male gametocytes reach the gut of the female Anopheles 
mosquito, where they mate and form a zygote, the only diploid stage of the 
Plasmodium falciparum life cycle. The zygote transforms into a motile ookinete, 
which traverses the midgut epithelium and forms an oocyste between the epithelial 
lining and the basal lamina. Within its boundaries thousands of sporozoites are 
produced by mitotic replication. Midgut sporozoites egress actively from the oocyste 
(Aly & Matuschewski, 2005), reach the salivary gland through the haemolymph and 
invade the salivary gland to be injected with the next blood meal back into the human 
host. The development within the mosquito is temperature-dependant and takes 
between 10 and 14 days.  
 
Figure 1-2 Plasmodium falciparum life cycle (Menard, 2005). 
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1.3 Clinical manifestations in endemic areas and definition 
The clinical manifestations of Plasmodium differ not only among species but also 
between different endemic areas. For the purpose of this work, I will focus on the 
characteristic symptoms for P. falciparum malaria in endemic areas. 
The case definition of malaria is compounded by (i) gradual acquisition of immunity 
as a function of repeated exposure and (ii) lack of specificity of clinical symptoms, 
mainly fever. Residents of areas with high transmission of P. falciparum acquire a 
partial immunity (“semi-immunity”), which develops progressively upon repeated 
exposure to the parasites. Protection against severe malaria is acquired relatively 
early, whereas defence against uncomplicated malaria and the parasite itself builds 
up very slowly, throughout life (Langhorne et al, 2008). Because of variable degrees 
of stage-specific immunity, a simple correlation of parasite density to severity of 
disease is not applicable. Also, in areas of high transmission where the prevalence of 
parasites in the population reaches up to 80% in children ≤ 10 years old (Smith et al, 
1993) nonspecific symptoms (fever) do not necessarily imply that clinical malaria is 
present. Regarding the evaluation of new interventions, a precise definition of clinical 
cases though is important. It has been proposed to use the parasite density cut off of 
2,500 parasites / µl of blood in association with fever ≥ 37.5 °C in children between 1 
and 15 years to define a clinical case of malaria in endemic areas (Mwangi et al, 
2005). For young infants (≤ 1 year) and for adults from the age of 15 onwards, the 
simple presence of parasites in association with fever is sufficient to define a clinical 
case of malaria (Mwangi et al, 2005). 
Severe malaria, which includes cerebral malaria, can mainly be defined by coma or 
impaired consciousness and respiratory distress. Mortality is highest when these 
three symptoms overlap (Marsh et al, 1995). Poor outcome is further accompanied 
by hypoglycaemia, whereas severe anaemia and jaundice are signs of severe 
disease but do not show a significant correlation with mortality (Marsh et al, 1995). 
Co-morbidity can be an additional risk factor or a consequence of severe malaria. To 
improve specificity of the severe malaria definition, children with meningitis, lower 
respiratory tract infection, bacteraemia and gastroenteritis with severe dehydration, 
should be excluded. In contrast the exclusion of children with HIV or malnutrition did 
not improve case definition (Bejon et al, 2007). If additionally a parasite threshold of  
≤ 2500 parasite / µl of blood was applied, the malaria-attributable fraction of children 
presenting with severe disease increased up to 95 % with a sensitivity of 85% (Bejon 
et al, 2007).  
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1.4 Malaria control strategies and the emergence of drug-
resistance in Plasmodium falciparum 
In the absence of a highly protective anti-malarial vaccine in the foreseeable future, 
malaria control continues to rely mainly on prompt and effective treatment of 
uncomplicated disease episodes. Efficient public health care facilities, use of 
insecticide treated bed nets (ITNs), and vector and larval control will also remain part 
of a comprehensive control strategy. An overview of the various control 
measurements is given in the following paragraph as well as an estimation of their 
potential impact. 
Like for any infectious disease, prevention is the most efficient strategy for reducing 
disease burden. Vector and larval control is one arm of this policy. Especially vector 
control using massive spraying of DDT (Dichlorodiphenyldichloroethylene) has 
contributed to dramatically reduced malaria incidences and even elimination of 
malaria from parts of the world in the 1960s. After the publication of “Silent Spring” by 
Rachel Carson in 1962, in which the devastating effects on the environment were 
depicted, DDT was banned and WHO abandoned malaria elimination as a policy 
goal, shifting its focus on “control”. The history of DDT usage has been reviewed in 
detail (Eskenazi et al, 2009). The re-emergence of malaria after the stop of massive 
vector control efforts showed the consequences of over-reliance on a single 
intervention. Larval control in tropical geographic settings is a very ambitious task as 
potential breeding sites are numerous, often covered by vegetation, small and thus 
difficult to detect, to survey and to control. 
Beside vector and larval control as preventive measurements, insecticide treated bed 
nets (ITNs) also reduce transmission, morbidity and both malaria-specific as well as 
all-cause mortality. Coverage has been very patchy but combined efforts and free 
distribution has led to an almost complete coverage of ITNs in some regions and 
countries. But as long as the prevalence of parasites in the population is high and 
mosquitoes are not significantly reduced in population size, the chance of getting 
infected especially at dawn is still considerable. It is unrealistic to assume that from 
early dawn on, which in sub Sub-Saharan Africa occurs between 17h30 and 18h30, 
all people at risk would place themselves under bed nets.  
A more recent prevention strategy is based on intermittent preventive treatment in 
pregnancy (IPTp) and infants (IPTi). Pregnant woman and infants are the highest risk 
groups due to a lack of antibody-mediated recognition of parasite-encoded variant 
erythrocyte surface molecules conferring cytoadherence to endothelial cells or 
placental syncytiotrophoblasts in the placenta, respectively, expressed during 
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infections in immunologically naïve individuals (Bull & Marsh, 2002). 
Chemoprophylaxis is one instrument to protect this vulnerable group but as the name 
implies, relies on efficacious preventive treatment. 
The improvement of public health care facilities is part of the major effort to reduce 
the incidence of severe malaria. Early access to treatment needs to be ensured by 
facilitating access to affordable and freely available drugs. 
Overview of antimalarial drugs 
The traditional Chinese medicine knew about the anti-fever qualities of “Qinghao” 
(Chinese for Artemesia annua) and used the plants extract for more than 2000 years. 
Similarly in South America, Incan herbalists used the bitter bark from the Cinchona 
tree (Cinchona succirubra) to treat the fever. Quinine the active component of the 
Cinchona bark was only discovered and isolated in 1820 and artemisinin combination 
therapies (ACT) were developed for scalable industrial production only in the 21st 
century. Until today a substantial effort is invested in the discovery of new therapeutic 
principles from the study of traditional herbal medicine. 
The production of synthetic compounds in the beginning of the 20th century and 
random screening of large chemical compound libraries led to the discovery of 4-
aminoquinolines. Chloroquine, the most prominent derivative, was massively used 
over 40 years because of its excellent safety, low cost, rapid action and 
advantageous pharmacokinetic profile. However, parasite resistance spread globally, 
including to Africa.  
Parallel research led to the discovery of anti-folates as potent anti-cancers and anti 
bacterial drugs. Subsequently their activity against Plasmodium could also be shown. 
Sulfadoxine-pyrimethamine (SP; Fansidar®) is the most prominent anti-folate 
combination. SP was introduced as first line treatment soon after chloroquine had 
failed and was distributed until its own failure a few years later. Today multi-drug 
resistance is wide spread. Following WHO recommendations artemisinin based 
combinations (ACTs) are now used as first-line treatment in all endemic countries. 
Given the importance of ACTs and the absence of variable therapeutic alternatives, 
the recent reports of declining efficacy (Alker et al, 2007; Denis et al, 2006a; Denis et 
al, 2006b; Noedl et al, 2008) and artemisinin-resistant malaria (Dondorp et al, 2009) 
in western Cambodia are rising the prospects of a renewed public health crisis: 
untreatable malaria.  
History proves that the malaria parasite can develop resistance to all classes of 
inhibitors. Various mechanisms of resistance are known. Mechanistically and from an 
evolutionary perspective, phenotypic alterations have to be differentiated from 
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heritable genetic changes. A classical phenotypic, non-heritable change is the over-
expression of drug targets or drug transporters. 
Genetic alterations that translate into the selectable phenotypic changes include 
single nucleotide polymorphisms (SNPs) and gene amplifications. Genetic changes 
can lead to altered drug-binding sites in target or transporter proteins and/or stable 
over-expression of such proteins. 
1.5 Gene duplication and amplification 
Gene amplification is a common adaptive mechanism with various biological 
functions. In the following paragraph an overview of gene amplification and its 
implication in development and differentiation, in evolution and in drug resistance is 
given. At the end the molecular basis for the emergence of duplication and further 
amplification are summarized.  
Gene amplification in development 
The need of high amounts of a particular gene product during development, 
proliferation or cell differentiation has favoured gene amplification as an adaptive 
strategy in various organisms. For instance, in amphibians, the gene encoding for 
ribosomal RNA is selectively amplified during oogenesis (Gall, 1968) and in oocytes 
(Brown & Dawid, 1968) and thus ensures synthesis of high amounts of proteins, 
which are essential for development of the embryo. Some Dipteran flies 
Rhynchosciara americana (Glover et al, 1982; Santelli et al, 2004), Bradysia hygida 
(Laicine et al, 1984) and Sciara coprophila (Wu et al, 1993) use gene amplification in 
their salivary glands to produces high amounts of structural proteins. Gene 
amplification in Drosophila melanogaster has also been described. Two cluster of 
chorion (eggshell) are amplified in follicle cells (Spradling, 1981; Spradling et al, 
1980) and two additional amplicons were recently identified in a genomic 
hybridization array (Claycomb et al, 2004).  
Gene amplification in evolution 
In the 1970 book “Evolution by Gene Amplification” by Ohno’s described the 
occurrence and the necessity of extensive gene amplification events during the 
evolution of vertebrates. The expansion of whole genomes was only possible by 
previous amplification of large chromosomal regions and subsequent divergence. In 
contrast smaller-scale copy number variations (CNV) between closely related 
species are an indicator for more recent and ongoing evolution. Recently, a genome-
wide study of five hominoid species, including humans was performed. The majority 
of gene amplifications were found to have occurred over the last 15 million years, i.e. 
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during the evolution of great apes and humans (Fortna et al, 2004). Within single 
species, the presence of gene families is a convincing example for the importance of 
amplification in evolution. Often gene families cluster in the genome and share a 
common ancestor. In summary, gene amplification can give rise to new genes with 
similar or divergent functions. The exact mechanisms of selection and its driving 
force, however, are still debated. 
The evolutionary trajectory of an amplification event depends on whether its result is 
selectively neutral (=no change in phenotype) or provides an immediate fitness 
benefit (=phenotypic adaptation). According to the neutral hypothesis (Kimura, 1968), 
genetic diversity is maintained by a balance between random mutations or 
amplifications and genetic drift, which occurs due to chance in the distribution of 
allele frequencies from generation to generation. Once a selectively neutral gene 
duplication has accidently occurred, the probability of fixation or loss in a population 
is determined by random genetic drift (Bergthorsson et al, 2007). This is a direct 
function of population size: the larger the population, the less likely is fixation as 
outcome (Lynch et al, 2001). With regard to the additional genomic copy, Ohno 
predicted that only selectively neutral amplicons could diverge and gain new 
functions. (I) The subsequent fate of the additional copy can be depicted in three 
scenarios. (1) Mutations can render the additional copy non-functional by the 
introduction of a STOP codon or by point mutation in key structures of the protein 
(non-functionalization); or (2) the copy gains a beneficial function (neo-
functionalization) or (3) sub-functionalization occurs and the two newly arisen copies 
partition the task of the ancestral gene (Force et al, 1999; Lynch & Force, 2000). With 
sub-functionalization, two new genes with distinct functions are created.  
(II) Alternatively one minor activity of the protein could suddenly gain increasing 
importance in variable ecological conditions (Bergthorsson et al, 2007). Or important 
for this work, if the initial amplification results in a phenotypic change, the allele can 
be under positive selection pressure. Both mechanisms would assure the 
maintenance of the additional copy without the above-described functionalization.  
The role of gene amplification in drug resistance 
Gene amplification is a common mechanism in drug resistance of bacteria, protozoan 
and mammals. In bacteria plasmid borne gene amplification is distinguished from 
amplification occurring on chromosomes. Proteus mirabilis was the first organism, 
grown in the presence of antibiotics, which was found to display an increase in 
plasmid size conferring resistance (Rownd et al, 1971; Rownd & Mickel, 1971). A few 
years later a chromosomal gene amplification with up to 30 additional copies was 
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found in Escherichia coli conferring high levels of ampicillin resistance (Normark et al, 
1977). For both mechanisms various examples followed the initial discovery. In 
protozoa gene amplification was also shown to play a specific role in the emergence 
of resistance. In Leishmania species, antimony-resistant strains were found to have 
increased copy numbers of various genes implicated in resistance (Leprohon et al, 
2009; Lin et al, 2008). The most prominent example for gene amplification in 
Plasmodium falciparum is probably mdr, which encodes for Pgh1, a homologue to 
the human P glycoprotein 1. The trans-membranous protein is located at the 
parasite’s food vacuole (Cowman et al, 1991) and confers resistance to several anti-
malaria drugs (Reed et al, 2000). Recently amplification of the GTP cyclohydrolase 
was discovered first in laboratory P. falciparum strains (Kidgell et al, 2006) and later 
in P. falciparum field strains from south East Asia (Nair et al, 2008). GTP 
cyclohydrolase is the first enzyme of the folate pathway. The biological relevance of 
its amplification is not yet understood but thought to be associated with anti-folate 
resistance.  
In mammalian cancer cells resistance to methotrexate was associated by 
amplification of the dhfr gene in murine cells (Kaufman et al, 1978; Schimke et al, 
1978a; Schimke et al, 1978b) in hamster ovary (Kaufman & Schimke, 1981) and 
finally in leukaemia patients treated with methotrexate (Horns et al, 1984). 
 
Molecular mechanism 
The known molecular mechanisms for gene amplification are as diverse as their roles 
in cellular processes. In principle four major mechanisms can be distinguished: 
NAHR (non allelic homologous recombination), NHEJ (non homologous end joining), 
FoSTeS (Fork Stalling and template switching) and retrotransposition. In the 
following the four mechanisms are briefly described and explained.  
NAHR (non allelic homologous recombination) 
NAHR is a mechanism of chromosomal DNA rearrangement, which is facilitated by 
low copy repeats (LCR) (Shaw & Lupski, 2004; Stankiewicz & Lupski, 2002), by Alu 
repeat elements (Babcock et al, 2003; Han et al, 2008) and by pseudogenes (Kim et 
al, 2008; Stankiewicz & Lupski, 2002). The rearrangement can occur during meiosis 
and mitosis. The minimal sequence homology required in both cell division cycles is 
different. Whereas chromosomal rearrangement during mitosis occurs already at 
sequences, which share high homologies over only 200 to 300 bp (Waldman & 
Liskay, 1988), is the minimal requirement for rearrangement during meiotic cell 
division more stringent (sequence homology over 300 to 500 bp) (Reiter et al, 1998). 
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NHAR can result in deletion, duplications or inversion of genomic DNA sequences 
depending on which parts of chromosomes are involved. Important for the 
understanding of NAHR is the formation of a crossing over junction, which during the 
subsequent dissociation process can create a loss on one DNA strand and a gain on 
the other strand (rearrangement). The replication machinery is not involved. An 
interchromosomal NAHR is the formation of a crossing over junction between two 
homologous chromosomes at a non-allelic sequence site and can be direct, inverted 
or complex. NAHR is also occurring between chromatids (interchromatid) and within 
one chromatid (intrachromatid) (Figure 1-3) (Lupski, 1998; Stankiewicz & Lupski, 
2002). Following cell division, the chromosomes with either lost or gained DNA 
sequences are distributed randomly to the daughter cell. The outcomes of NAHR are 
therefore only apparent after S1 phase has occurred. 
 
NHEJ (non homologous end joining) 
Non-homologous end joining (NHEJ) is a mechanism used by eukaryotic cells to 
repair a double strand break. Double strand breaks can be introduced by reactive 
oxygen species, by ionising radiation and by DNA replication over a nick in one DNA 
stand (Lieber et al, 2003). In contrast to NAHR, NHEJ occurs independent of repeat 
units, but structural features of genomic regions might facilitate a double strand 
break. In and around breakpoints, where NHEJ had occurred, short sequence 
homologies, 2 – 4 base pair repeats, palindromic sequences and sequences able to 
Interchromosome Intrachromosome Interchromatid 
Deletion Duplication Deletion Duplication Deletion 
Figure 1-3 Non allelic homologous recombination (NAHR) adapted from (Stankiewicz 
& Lupski, 2002). An example of each of the three principal recombination events is shown. 
A,B and C indicate three genes located on the chromatids. The green cross represents a 
crossing over event.  Deletion, duplication and inversions are the results of NAHR, which can 
occur interchromosomal, intrachromosomal and interchromatidal. The deletion in the 
intechromatid NAHR event can also result in a translocation or inversion, if the fragment is 
reintegrated. 
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form a intrastrand hairpin (TTTAAA) were discovered (Toffolatti et al, 2002). After a 
double strand break (DSB), exonucleases create on both loose ends of the break 
single stranded DNA (Figure 1-4). In the case of DSB repair without recombination, 
the two loose ends invade a homologous chromosome and copy the missing 
sequence. The resulting holiday junction is resolved without recombination. But if 
DSB repair leads to recombination, two possible mechanisms are distinguished. (1) A 
second DSB generates two additional loose ends and random joining of the ends 
leads to recombination of large DNA sequences.  (2) The strand of one end invades 
either a non homologous, foreign or an upstream region of the same strand and by 
replication using the invaded strand as template an additional copy of that genomic 
region is created. Strand invasion often results in tandem orientation of the 
duplicated region, a so-called head to tail arrangement (Lee et al, 2006). But it can 
also result in translocation, inversion or loss, if a second DSB separates, during the 
process of strand invasion and replication, the newly synthesised DNA fragment from 
the template and from its own strand (Lee et al, 2006). Important for the 
understanding of NHEJ is that this process can result in duplication when a template 
is present from where the additional DNA can be read and copied from. This is a 
fundamental difference to NAHR, by which only rearrangements of chromosomal 
regions occur. 
 
 
 
 
 
 
 
 
 
 
 
5‘ 
3‘ 
5‘ 
3‘ 
5‘ 
3‘ 
Figure 1-4 Non homologous end joining (NHEJ) adapted from (Gu 
et al, 2008). A double strand break (DSB) is repaired by creating first a 
single stranded end on both sides of the break, induced by 
exonuclease activity. The loose ends can invade a homologous strand 
to copy the missing sequence to fill the gap and the two ends are 
rejoined. Often some nucleotides are missing at the junction site. 
Recombination occurs if the single strand invades a foreign double 
helix or if two unrelated ends are joined. 
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DNA amplification during replication 
Another common mechanism of gene amplification is through the process of DNA 
replication. As mentioned above, Dipteran flies use gene amplification during their 
development to produce high amount of structural proteins. The mechanism by which 
they achieve amplification is repeated firing of a replication initiation zones and 
bidirectional replication fork movement 
(Delidakis & Kafatos, 1989; Heck & Spradling, 
1990; Liang & Gerbi, 1994; Liang et al, 1993; 
Osheim et al, 1988; Yokosawa et al, 1999). 
With one firing after the other and the 
movement of the replication fork in both 
directions two bubbles are created within the 
previous one. The model has been fittingly 
dubbed ‘onionskin’ (Figure 1-5) (Liang et al, 
1993). Characteristic for this model is the 
gradual decline of amplification the further 
apart a sequence is located from the initiation 
zone. The target of amplification has to be in close proximity to the initiation zone. 
Surrounding genes are often only partially amplified and not functional by having lost 
parts of theirs open reading frame or promoter regions.  
Fork Stalling and Template switching (FoSTeS) 
Another process in which DNA replication is involved and gene amplification is 
created is the Fork Stalling and Template switching (FoSTeS) mechanism (Figure 
1-6). The model is based on stalling of the replication fork during which the lagging 
strand disengages from its template and invades another replication fork in proximity 
(Lee et al, 2007). Depending on whether the new replication fork is situated 
downstream or upstream of the original one, gene duplication or deletion are the 
consequences. The orientation of the newly synthesised gene depends on which 
strand of the new replication fork is used as template. If the invading strand places 
itself on the leading strand a tandem repeat of the genes is created, if the strand 
places itself on the lagging strand an inverse orientation of the two duplicated genes 
is generated. This process of fork pausing and template switching can occur several 
times in a row and thus creates complex sequence duplication, triplication in both 
possible orientations and deletions (Lee et al, 2007). The requirements for strand 
switching during replication were proposed to consist of small homology regions, 
such as small direct or inverted repeats (Lee et al, 2007). 
Figure 1-5 Onionskin model adapted 
from (Claycomb & Orr-Weaver, 2005). 
Repeated firing of an initiation site 
created bidirectional replication forks 
within each other. 
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Transposable elements 
Two majors classes or transposable elements have to be distinguished: DNA 
transposons, which jump by a cut and paste mechanism and RNA retrotransposons, 
which move by a copy and paste mechanism. DNA transposons jump as DNA from 
place to place within chromosomes and RNA transposons move via an RNA 
intermediate. In the first step they are transcribed into RNA and then reverse 
transcribed back into DNA by a self-encoded enzyme. Various degradations and 
inactive forms, as well as a few active forms are found in all eukaryotic genomes. 
During the movement of a transposable element, surrounding sequences or exons 
(exon shuffling) or genes are accidently co-transported to a different location. In 
human cells the only still active autonomous transposon is the long interspersed 
element-1 (L1), which covers about 15% to 18 % (Goodier & Kazazian, 2008; 
Kazazian & Moran, 1998) of the human genome. 
Frequency of copy number variation 
The frequency by which point mutations occur in mammals is estimated around 10-9 
per generation (Drake et al, 1998). The spontaneous appearance of copy number 
B A 
C D 
C D 
D 
C B 
D 
Damage or 
structural obstacles  
Figure 1-6 Fork Stalling and Template Switching (FoSTeS) adapted from (Gu et al, 
2008). The replication fork pauses at damages or at structural obstacle in the DNA and 
the lagging strand disengages from its template and invades a neighbouring replication 
fork. Here an example is shown in which the neighbouring replication fork is still behind 
the original and gene D and C are copied again. Depending on which strand is used as 
template and in which direction the synthesis starts, are tandem and inverse orientation 
of the new gene possible. This process can occur multiple times before the strand finds 
back on its original template, creating very complex new structures and amplifications. 
Important is the fact that the real situation is three-dimensional, which shortens the 
possible distances between the forks significantly.  
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variations (CNVs) is up to 5 orders of magnitude higher, 10-4 per generation (Inoue & 
Lupski, 2002).  
In a recent publication on mutation rates in Plasmodium falciparum, it was estimated 
that a single point mutation at position 108 in the Pfdhfr gene occurred between 3 x 
10-11 and 2,5 x 10-9 per generation (Paget-McNicol & Saul, 2001). Mutation rates may 
vary from organism to organism and the actual rate is extensively dependent on the 
DNA repair machinery, but it is unquestionable that in eukaryotes CNVs occur 
several magnitudes more frequently than spontaneous single point mutations. 
The stability and the maintenance of newly acquired amplifications is dependant on 
their beneficial or detrimental effects and can vary significantly. 
1.6 Folate pathway 
The de novo folate synthesis pathway in Plasmodium falciparum has been identified 
and characterized extensively (Figure 1-7). The only remaining unidentified missing 
link, the PTPS (PFF1360w), which catalyzes the step between the first enzyme and 
the third enzyme of the pathway, was also recently described (Dittrich et al, 2008; 
Pribat et al, 2009). The first enzyme of the folate pathway was identified in 1985. The 
GTP cyclohydrolase (PFL1155w) catalyzes the conversion from GTP to 7,8-
dihydroneopterin3’-triphosphate (DHN-PPP) (Krungkrai et al, 1985). The apparent 
absence of a dihydroneopterin aldolase (DHNA) activity in Plasmodium falciparum 
cell extracts could only recently be solved by the identification of 6-
pyruvoyltetrahydropterin synthase (PTPS) (Dittrich et al, 2008). PTPS is 
conventionally involved in the tetrahybiopterin (BH4) (Thony et al, 2000) pathway but 
the presence of a glutamic acid instead of a cysteine residue in the active site 
possibly explains the gain of a different or additional function in Plasmodium 
falciparum, i.e. converting DHN-PPP into 6-hydroxymethyl-7,8-dihydropterin (Dittrich 
et al, 2008). The catalytic activity of PPPK and DHPS, which catalyse the two 
following steps in the folate pathway, were found to be encoded by a single gene in 
Plasmodium falciparum, named Pfdhps (Triglia & Cowman, 1994). First the 
pyrophosphokinase (PPPK) adds a pyrophosphate (PPi) through hydrolysis of ATP to 
AMP and thereby generates 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
(DHPP). In the second catalytic step para-aminobenzoic acid is added by DHPS to 
form 7,8-dihydropteroate (DHP) (Brooks et al, 1994; Triglia & Cowman, 1994), the 
substrate of DHFS. The following poly-glutamylation is an essential step in 
prokaryotes and eukaryotes. Four to seven glutamyl residues are added resulting in 
altered transport properties of the co-factor in the cell and changed enzyme kinetics 
(Schirch & Strong, 1989). Conventionally, two different enzymes catalyze addition of 
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the first and subsequent addition of glutamates. In Plasmodium falciparum the 
bifunctional enzyme DHFS, encoded by Pfdhfs, fulfils both activities and thus 
generates 7,8-dihydrofolate (H2Folate) (Lee et al, 2001; Salcedo et al, 2001). DHFR, 
which catalyzes the NADPH-dependant reduction of H2Folate to tetrafolate 
(H4Folate) was identified in Plasmodium falciparum already in the late nineties (Bzik 
et al, 1987). Tetrafolate contributes to the one-carbon pool and functions as co-
enzyme in the cell. 
Of note, the gene Pfdhfr encodes also for a bifunctional enzyme. After the addition of 
a methyl group on H4Folate by the serinehydroxymethyltransferase (SHMT), the 
second function of DHFR-TS is the transfer of this methyl group on a dUMP molecule 
to generate dTMP, essential for DNA replication. The enzyme is called thymidylate 
synthase (TS). 
 
 
Folate derivatives are essential co-factors in cellular processes. The synthesis of 
nucleotides and the metabolism of several amino acids depend on it. Especially 
heavily dividing cells rely on the synthesis of folate for DNA replication. In fact, even 
before the discovery of the involved genes and the characterisation of their 
enzymatic activities, the folate pathway has been targeted in malaria parasites, in 
Figure 1-7 Folate biosynthesis pathway in Plasmodium falciparum. (black) enzyme 
names, (grey) substrates and products, (=>) catalysed reaction. The enzymes of the folate 
pathway are listed in order of their sequential activity. The biosynthesis starts with GTP, 
which is converted to DHN-PPP. The following enzymes generate through the intermediates 
of DHPP and DHP, H2 Folate and H4 Folate. Two enzymes in this pathway are known drug 
targets for inhibitors (in red).    
1. PfGCH:  GTP cyclohydrolase EC 3.5.4.16 
 GTP ! 7,8-Dihydroneopterin triphosphate (DHN-PPP) 
2. PfPTPS:  6 Pyruvoyltetrahydropterin Synthase EC 4.2.3.12 
   ! 6 Pyruvoylyl-5,6,7,8- tetraydropterin 
   DHN-PPP ! 6 hydroxymethyl- 7,8- dihydropterin 
3. PfDHPS:  Bifunctional enzyme:  
 Hydroxymethyldihydropteridine pyrophosphokinase (PPPK) EC 2.7.6.3 
   ! Dihydropteridine-CH2O-PP (DHPP) 
    Dihydropterotate synthase (DHPS) EC 2.5.1.15 
   DHPP ! Dihydropterotate (DHP) 
4. PfDHFS:  Dihydrolfolate synthase EC 6.3.2.12 
   ! 7,8- dihydrofolate (H2Folate) 
5. PfDHFR:   Dihydrofolate reduktase EC 1.5.1.3 
   ! tetrafolate (H4Folate) 
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cancer and in bacterial infections. In the 1930s the search for synthetic antimalarials 
led to the discovery of pyrimethamine and proguanil, a prodrug that is rapidly 
converted in vivo to its active metabolite cycloguanil (McGready et al, 2003). In the 
1940 sulfanilamide was found to inhibit growth of monkey malarian parasites 
(Coggeshall, 1940). A few years later in the 1960s trimethoprim was introduced for 
clinical use in the treatment against bacterial infections in Western Europe, but soon 
after its introduction first cases of resistance were reported, as reviewed by (Skold, 
2001). 
Sulfonamides target the DHPS, whereas pyrimethamine, cycloguanil and 
trimethoprim are DHFR inhibitors. Soon after their introduction to treat malaria, first 
clinical failures were reported, even after single exposures (Martin & Arnold, 1968) 
and resistance to these drugs was found to be conferred by mutations in both genes 
encoding for the respective enzymes. Resistance against sulfadoxine, a sulfonamide 
used in fixed-dose combination with pyrimethamine (SP) in the treatment against 
malaria, was directly associated to point mutations in dhps, which decrease the 
inhibition efficiency of both drugs (Triglia et al, 1997). In East Africa, mutations at 
codons A437G and K540E of DHPS, together with the triple mutations of dhfr were 
shown to be significant predictors of SP treatment failure in Kenya, Malawi and 
Uganda (Kublin et al, 2002; Omar et al, 2001; Staedke et al, 2004). 
The three mentioned DHFR inhibitors selected for various mutations in dhfr. 
Pyrimethamine was the most widely used drug and various groups soon reported 
particular SNPs or SNP combinations (haplotypes) as underlying mechanism of 
resistance (Cowman et al, 1988; Peterson et al, 1988). The most prominent and most 
relevant point mutations of dhfr are at the amino acid positions 108, 51, 59, 16 and 
164. Although cross-resistance to anti-folates is commonly found, particular point 
mutation confer differential resistance patterns. The amino acid substitution at 
position 16 (A16V) was always found to be associated with S108T and results in high 
cycloguanil resistance (up to 1,000 fold) (Sirawaraporn et al, 1997), without altering 
pyrimethamine sensitivity (Foote et al, 1990; Peterson et al, 1990). The laboratory 
strain FCR3 is a representative for this group of parasites. In the field, very few 
parasites are reported with this particular combination of point mutations (Biswas et 
al, 2000). The low catalytic activity of the enzyme carrying A16V alone or in 
combination with S108T (Sirawaraporn et al, 1997) is, together with extensive use of 
pyrimethamine, most likely the reason for its rareness. Sirawaraporn et al. have 
investigated dhfr mutations in isolation or as haplotypes and assessed their catalytic 
efficiency and the degree to which they confer resistance against pyrimethamine and 
cycloguanil. The findings are summarized in the following paragraph. The mutation 
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S108N alone shows the best balance between establishment of pyrimethamine 
resistance and conserving highest catalytic activity. All other three mutations at 
position N51I, C59R and I164L only marginally decrease sensitivity to pyrimethamine 
and moderately alter cycloguanil sensitivity. All three SNPs show significantly 
reduced enzyme activity, when present alone. In combination, however parasites 
carrying double mutant N51I/S108N displays an ideal balance of high resistance and 
high enzyme efficiency, which is even greater than S108N alone. The triple mutant 
N51I/C59R/S108N displays again a significant loss of enzyme efficiency (20 fold) but 
gains at least 10 fold pyrimethamine and cycloguanil resistance. Triple mutant DHFR 
enzyme will thus only confer a survival benefit to parasites in a population under high 
continuous pyrimethamine drug pressure. The quadruple mutant 
N51I/C59R/S108N/I164L restores part of its enzyme efficiency and shows highest 
attainable resistance pattern for both, pyrimethamine and cycloguanil (Sirawaraporn 
et al, 1997).  
In contrast to this detailed analysis of mutated enzyme activities compared to wild 
type is a recently published work. In a comparative study on the catalytic activity of 
wild type and mutated DHFR enzyme the authors could show the opposite effect. An 
even higher catalytic activity of the mutated enzyme compared to wild type DHFR 
was measured (Sandefur et al, 2007). The authors concluded that their findings 
would explain the persistence of mutated dhfr in Africa even after removal of SP. 
Trimethoprim-sulfamethoxazole was found to reduce morbidity and mortality in HIV 
infected patients in sub-Saharan Africa, when given as chemoprophylaxis against 
opportunistic infections (Anglaret et al, 1999; Mermin et al, 2006; Wiktor et al, 1999) 
and was therefore recommended by UNAIDS. The overlapping use of two anti-
folates targeting DHFR in a single population is of great concern. It was 
demonstrated that parasites carrying one to three mutations in DHFR were less 
susceptible to trimethoprim (Iyer et al, 2001) and resistance of trimethoprim was 
found to be highly correlated to pyrimethamine (Khalil et al, 2003). 
In addition to the mentioned amino acid substitution in response to anti-folate drug 
pressure, gene amplification of dhfr was described in cancer (Carman et al, 1984; 
Horns et al, 1984; Trent et al, 1984) and in rodent malaria (Cowman & Lew, 1989). In 
Plasmodium falciparum, two studies suggested dhfr gene duplication following 
selection for pyrimethamine resistance in vitro as a potential resistance mechanism 
(Inselburg et al, 1987; Thaithong et al, 2001). Intriguingly, dhfr gene duplication or 
amplification, however, has never been reported in P. falciparum field isolates. 
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1.7 Detection of drug resistance in vivo  
In general two major methods are used to determine drug sensitivity and resistance; 
the in vitro test and the in vivo test. Specificity and sensitivity are increased when 
theses two complementary tests are used side by side. 
The activity of an anti-malarial drug against reference laboratory-adapted strains of 
parasite isolates obtained from patients can be performed in vitro by determining the 
drug concentration required to inhibit 50% of maximal growth in unexposed control 
cultures (IC50). A patent isolate can consist of several clones with different genetic 
background and evolutionary histories. The in vitro method can be calibrated against 
reference strains with known sensitivities and it generates reproducible phenotypes 
under optimal artificial conditions. Drug parasite interactions are directly measured 
due to the absence of in vivo confounding factors, e.g. pharmacokinetics, innate and 
adaptive immunity and initial parasite load, just to give a few examples. Therefore a 
direct correlation of IC50 values and treatment failure at the individual level is often 
not observed (Sasi et al, 2009). 
In the in vivo test the rate of treatment failure is determined by monitoring parasite 
persistence or reappearance for up to 8 weeks through microscopic analysis of blood 
smears. The test addresses the clinically relevant questions of whether an 
antimalarial treatment can lead to complete elimination of blood stage infections 
(Borrmann et al, 2008), but the sensitivity of this method is limited to the detection 
limit of the microscope, i.e. ∼ 20 parasites/µl corresponding to a total body biomass 
of ≤ 108 parasites. Beside the sensitivity, the definition of treatment failure is also 
critical. In high transmission areas, reappearance of parasites in the blood requires 
PCR-based molecular techniques to distinguish recrudescent from re-infection. 
These techniques have limited resolution power even under hypothetical ideal assay 
conditions due to the finite allele diversity of local parasite populations. This leads to 
unreliable treatment outcome estimates. In summary, the in vivo test is clinically 
indispensable but its sensitivity, especially for determining complete parasite removal 
is too variable to serve as a phenotype for classifying drug-resistant infections (even 
when drug exposure is controlled for). 
As emerging or spreading of parasite resistance to commonly used drugs is 
associated with failure of chemotherapeutic regimens to completely eliminate primary 
asexual blood stage infections, the importance of early detection and monitoring 
becomes obvious. An early and reliable detection of failing drugs is particularly 
important in regard to the recent reports of declining artemisinin efficacy in Thailand 
(Alker et al, 2007) and Cambodia (Denis et al, 2006a; Denis et al, 2006b; Noedl et al, 
Introduction 
	   23	  
2008). In addition, the fact that incompletely eliminated infections are variably 
suppressed by acquired immune responses raises the intriguing question of whether 
even susceptible blood stage infections can survive maximal drug pressure during 
treatment at or below a hypothetical minimum infectious intra-host population size 
(∼50,000 parasites; corresponding to the inoculum of liver stage merozoites into the 
circulation). This may be important since wild type parasites are predicted to outgrow 
resistant parasite due to fitness benefits. It would also influence the rate with which 
de novo resistance can be selected for during treatment, i.e. at peak plasma drug 
concentrations, as opposed to blood stage infections arising during convalescence 
when plasma concentrations of long-half life drugs have dropped below the minimal 
inhibitory concentration. 
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1.8 Aim of the study 
The survival of the parasite depends on numerous factors, such as transmission 
efficiency, vector behaviour and control on the one hand and host genetics, innate 
immunity and the efficacy of human interventions (Figure 1-8).  
 
 
Prompt and efficacious chemotherapy remains an important cornerstone in the fight 
against malaria. Drug-parasites interactions are the major determinant of outcome. 
The study aims at dissecting biological correlates of this interaction using discreet 
experimental approaches in vitro and in vivo. 
I started by studying parasite survival in vivo. This was also important for designing 
subsequent experiments that are relevant and provide insight in the molecular events 
leading to emergence of parasite resistance in malaria endemic areas. 
Closely related to this question, I then analysed parasites isolates that had been 
exposed to various drugs over the last years in the community for drug susceptibility 
in vitro. The genetic background of these parasites is expected to be shaped by 
balancing fitness costs and benefits under varying drug pressure (Figure 1-8). Here 
resistance has developed in vivo but the phenotype was assessed in vitro.  
In the final part of the project, I attempted to gain insight in the evolution of drug 
resistance in vitro, i.e. in isolation. Cell culture conditions are controlled and so cause 
Parasite  
elimination rate 
Gametocytes Drug resistance 
Host factors: 
immunity, genetic 
polymorphisms 
Susceptibility / 
Refractoriness 
Vector behaviour 
Vector control 
ITNs 
Drug properties 
Pharmacokinetics 
Pharmacodynamics 
Parasite fitness 
Figure 1-8 Parasites survival determined by vector, host and drug interactions.  
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and effect con be more clearly assigned. In particular, I focused on the molecular 
mechanisms with an evolutionary perspective. For this work, I set up induction of 
resistance experiments in vitro and analysed the time course and sequence of 
resistance mechanisms.  
For the in vivo studies, I analysed data from patients who received amodiaquine in 
the beginning and later artemisinin combination therapies (ACTs) after 
implementation as first-line treatment in the study area in November 2006. The two 
combination therapies were artemether-lumefantrine (Coartem) and 
dihydroartemisinin-piperaquine (Eurartesim). 
For the in vitro work, I used pyrimethamine, because SP (Fansidar®) was used in the 
previous years as first-line treatment and the parasite population under investigation 
was therefore massively exposed to the drug. Importantly, initial studies had shown 
that induction of resistance in vitro is feasible (Paget-McNicol & Saul, 2001; 
Thaithong et al, 2001). Of particular interest was the relationship between gene 
amplification and the emergence of single nucleotide polymorphisms. 
Material and Methods 
	   26	  
2. Material and methods 
2.1 Materials 
2.1.1 Chemicals 
Acetic acid      J.T. Baker, Deventer, NL 
Agarose      Invitrogen GmbH, Karlsruhe, DE 
Albumax  II      Gibco Invitrogen, Karlsruhe, DE 
Ampicillin      Sigma Aldrich, Taufkirchen, DE 
BactoTM Agar      BD, Heidelberg, DE 
BactoTM Pepton     BD, Heidelberg, DE 
Chloroquine diphosphate salt    Sigma Aldrich, Taufkirchen, DE 
D-(+) Glucose      Sigma Aldrich, Taufkirche, DE 
D-Sorbitol      Fluka, Sigma Aldrich 
Dimethylsulfoxide (DMSO)    Sigma Aldrich, Taufkirchen, DE 
Dodecylsulfat-Na-salt (SDS)    Serva, Heidelberg, DE 
Ethylendiamintetraacetic acid) EDTA  Acros 
Ethanol absolute 100%    J.T. Baker, Denventer, NL 
Ethanol 96%      JT Baker, Deventer, NL 
Ethidiumbromide 1% (10mg/ml)   Carl Roth GmbH, Karlsruhe 
Ethidiumbromide      Sigma Aldrich, Taufkirchen, DE 
Gentamicin 50mg/ml     Gibco Invitrogen, Karlsruhe, DE 
Giemsa Solution     Merck, Darmstadt, DE 
Glycerol      Carl Roth GmbH, Karlsruhe, DE 
HEPES      Carl Roth GmbH, Karlsruhe 
Human AB Serum     Blood bank, Uniclinic Heidelberg 
Hydrogenchloride     Merck, Darmstadt, DE 
Hypoxanthine 10mM     ccpro, Oberdorla, DE 
Potassiumacetat     VWR, Darmstadt, DE 
Potassiumchloride     AppliChem GmbH, Darmstadt 
Kaliumhydrogenphosphat-Trihydrat   Merck, Darmstadt, DE 
Maleic acid      Carl Roth GmbH, Karlsruhe, DE 
Methanol      J.T. Baker, Deventer, NL 
Sodiumacetat      Grüssing, Filsum, DE 
Sodiumchlorid      Riedel, Hannover, DE 
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Tri-sodiumcitrat-dihydrate    Carl Roth GmbH, Karlsruhe 
Sodiumhydrogencarbonate    Grüssing, Filsum, DE 
Sodiumhydroxid     Merck, Darmstadt, DE 
Phosphate buffered saline    Sigma Aldrich, Taufkirchen, DE 
Pyrimethamine     Sigma Aldrich, Taufkirchen, DE 
RNA DNA Stabilization reagent for blood  Roche, Mannheim, DE 
and bone marrow     Roche Mannheim, DE 
RPMI with L Glutamine    Gibco, Invitrogen, Karlsruhe, DE 
RPMI 1640 Medium without Glutamine   Sigma Aldrich, Taufkirchen, DE 
Dodecylsulfat-Sodium salt SDS    Serva, Heidelberg, DE 
Sybr Safe DNA Gel stain 10.000 x in DMSO  Invitrogen GmbH, Karlsruhe, DE 
Hydrochlirid acid     Merck, Darmstadt, DE 
Saponin      Sigma Aldrich, Taufkirchen, DE 
Sybr Green I stock solution 10,000 x (DMSO) Invitrogen GmbH, Karslruhe, DE 
Trimethoprime      Sigma Aldrich, Taufkirchen, DE 
Tris       Carl Roth GmbH, Karlsruhe, D 
Trishydrochlorid     Carl Roth GmbH, Karlsruhe, D 
Triton x 100      Carl Roth GmbH, Karlsruhe, D 
Tween 20 Gerbu Biochemicals GmbH, 
Gaiberg, DE 
 
2.1.2 Commercial Kits 
DIG High Primer DNA Labeling  
and Detection starter Kit II    Roche, Mannheim, DE 
Fast Sybr Master Mix     Applied bioystems (ABI) 
mRNA Isolation Kit for blood  
and bone marrow     Roche, Mannheim, DE 
QIAamp DNA-Blood Kit     QIAGEN, Hilden, DE 
QIAgen PCR Purification Kit     QIAGEN, Hilden, DE 
QIAquick Gel extraction Kit    QIAGEN, Hilden, DE 
RETROscript       Ambion, Huntingdon, UK 
RNeasy Mini Kit      QIAGEN, Hilden, DE 
RNase-Free DNase Set    QIAGEN, Hilden, DE 
SuperScript III one-step RT-PCR System  Invitrogen GmbH, Karlsruhe, DE 
TOPO TA cloning® kit     Invitrogen GmbH, Karlsruhe, DE 
Turbo DNA free Kit     Ambion, Huntingdon, UK 
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2.1.3 Consumables 
ABgene PCR plates     Thermo Scientific, Waltham,USA 
Amersham HyperfilmTM ECL    GE Healthcare, Buckinghamshire 
Cryotobes      Nunc, Langenselbold, DE 
Cover for 96 well plate    Greiner Bio-one, Firckenhausen 
FIA-Plate, black, 96 well plate   Greiner bio-one, Frickenhausen 
Filter Tip 10E, 20, 100, 200, 1000   Greiner bio-one, Frickenhausen 
Filter Cap cell culture flask, 25cm2, 175cm2  Greiner Bio-one, Firckenhausen 
Kodak BioMax MR film    Sigma Aldrich, Taufkirchen, DE 
Hybond N+ - membrane    GE Healthcare, Buckinghamshire 
Universal Tips, yellow, blue    Greiner bio-one, Frickenhausen 
PP test tube, 15ml, 50ml    Cellstar, Greiner bio-one 
Pipette, 1ml, 2ml, 5ml, 10ml, 25ml   Cellstar, Greiner bio-one 
Safe lock tubes 1,5 ml    Eppendorf, Hamburg 
RNase free Biopure 1,5 ml     Eppendorf, Hamburg 
PCR softstrips 0,2ml, colour Biozym Scientific GmbH, 
Oldendorf 
epT.I.P.S. Reloads 2-200µl    Eppendorf, Hamburg 
epT.I.P.S. Reloads 20-300µl    Eppendorf, Hamburg 
96 well plate (black and clear    Greiner Bio-one, Firckenhausen 
 
2.1.4 Equipment 
AdventurerProTM balance    Ohaus 
Computer hardware     iMac 
Computer software 
7500 System software   Applied biosystems 
Bioedit      Ibis Therapeutics, Carlsbad 
Endnote     Thomson Reuters 
 EnzymeX3.1     Mekentosj.cin 
 Microsoft office 2008    Microsoft, 
Quantity one®     BIO-RAD 
 Primer Express    Applied biosystems 
 Prism 5     GrahpPad Software 
Centrifuge 
Microcentrifuge GALAXY mini  vWR 
Biofuge pico     Hereus, Kendro, Langensolbold 
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Fresco 21     Hereus Instruments, Hanau 
Megafuge 1.0 R    Heraeus 
Databases 
 GeneDB     www.genedb.org 
PlasmoDB     www.plasmobd.org 
 NCBI      www.ncbi.nlm.nih.gov/pubmed/ 
DNA Workstation (DNA/RNA UV cleaner)  G.Kisker, Steinfurt 
Eclipse E 200 Microscope     Nikon 
Electrophoresis System    BIO-RAD, Munich 
Freezer  
-80°C      Heraeus GmbH, Hanau
 Premium no frost (-20°C)   Liebherr, Biberach, DE 
 Premium (4°C)    Liebherr, Biberach, DE 
Geldoc XR      Biorad, Munich, DE 
Herasafe bench     Heraeus GmbH, Hanau, DE 
Incubator Heracell 150    Heraeus / Thermo 
Isotherm System 3880    Eppendorf, Hamburg 
Microwave      LG 
Mini PROTEAN 3     BIO-RAD, Munich 
Mini Sub cell      BIO-RAD, Munich 
Multipipette, 10µl, 100µl, 300µl   Eppendorf, Hamburg 
Mastercycler epgradient    Eppendorf, Hamburg 
Mini-PROTEAN® 3 CELL     BIO-RAD, Munich 
Ph Meter      Schott 
Pipette controller accu jet pro    Brand GmbH, Wertheim 
Pipettes, 0,1-2,5µl, 2-20µl,  
20µl-200µl, 100µl-1000µl     Eppendorf, Hamburg 
PowerPacTM Bsic Power Supply   BIO-RAD, Munich 
PowerPacTM HC Power Supply   BIO-RAD, Munich 
Printer hpdeskjet 6122    Hewlett Packard, Heidelberg, DE 
7500 Real time PCR system    Applied biosystems, Foster City 
Sub-cell GT      BIO-RAD, Munich, DE 
Sub-Cell® GT Agarose Gel     BIO-RAD, Munich, DE 
Thermomixer compact    Eppendorf, Hamburg, DE 
Thermostatt Waterbath    Mendingen 
TransBlot Semi-Dry Transfer cell   BIO-RAD, Munich, DE 
Vortex Mixter      neoLab 
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2.1.5 Buffer, ladder, medium and solutions 
Buffer 
Blocking solution     10 x blocking solution 
       Diluted in maleic acid buffer 
Denaturing solution     1,5M NaCl 
0,5M NaOH  
Detection buffer     0,1M Tris-HCL 
0,1M NaCl 
pH 9,5 
0,5 M EDTA (1 L)     186,1 g Na2EDTA 
       pH = 8 (NaOH) 
Freezing solution (50 ml)    3 % sorbitol (1,5 g) 
       0,65 % NaCl (0,325 g) 
       28 % 14 glycerol (14 ml) 
       Filtered 
Maleic acid buffer     0,1M maleic acid 
0,15M NaCl 
       pH 7,5 
MSF Lysis buffer     20mM Trise base 
       pH 7,5 
       5mM EDTA 
0,008 % (w/v) Saponin 
0,08% (w/v) Triton X-100 
Filter 
Neutralising solution     1,5M NaCl 
0,5M Tris-HCL 
20 x SSC      3M NaCl 
0,3M Sodiumcitrat 
1mM EDTA 
Step 1 washing solution    3 x SSC 
0,5% SDS 
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Step 2 washing solution    2 x SSC 
0,5 % SDS 
50 x TAE buffer (1L)     2 M Tris base (242 g) 
       1 M glacial acetic acid (57,1 ml) 
       0,05 M EDTA, pH=8 
10 x TBE buffer (1L)     890 mM Tris base (108 g) 
       890 mM boric acid (55 g) 
       20mM EDTA, pH=8 
Thawing solution 1     12 % NaCl 
       Filtered steril 
Thawing solution 2     1,6 % NaCl 
       Filtered steril 
Thawing solution 3     0,9 % NaCl 
       0,2 % Glucose 
       Filtered steril 
Washing buffer     0,1M maleic acid 
0,15M NaCl 
0,3% Tween 
       pH 7,5 
DNA Ladder 
GenerulerTM 1kb DNA Lader    Fermentas 
100bp DNA Ladder     Invitrogen 
DNA Molecular weight Marker III  
(Digoxigenin-labeled)     Roche, Mannheim 
Medium 
Complete cell culture medium (500 ml) RPMI with L Glutamine (Gibco) 
      12 ml AB Serum (heat inactivated 56°C) 
      0,1 mM Hypoxanthine 
      250 µl Gentamicin (Stock 50mg/ml) 
      2,5 g Albumax (filtered sterile) 
 
 
Material and Methods 
	   32	  
LB Medium for bacterial culture (1 L)  5 g Yeast extract 
      5 g NaCl 
      10 g Trypton 
      (15 g Agar for plates) 
      (Ampicillin 0,1 mg/ml for selection) 
 
2.1.6 Plasmodium falciparum parasites strains 
Laboratory strains 
Table 2-1 lists the P. falciparum laboratory strains used in in vitro cultures in this work. 
 
Table 2-1 P.falciparum strains, origins and donated from 
P. falciparum lab strains Country of origin Donated from 
Dd2 Indochina Prof. Lanzer 
D10 Papua New Guinea Prof. Lanzer 
3D7  Prof. Lanzer 
Hb3 Honduras Prof. Lanzer 
FCR3 The Gambia Prof. Lanzer 
 
Plasmodium falciparum field isolates 
Field isolates were collected in the course of a clinical audit of amodiaquine in Kilifi, 
Kenya (Sasi et al, 2009) (2.2.4.2) and from a comparative study on ACT 
(unpublished) (2.2.4.1). Blood samples were taken from patients suffering from mild 
malaria with a parasitaemia of 2000 to 200 000 parasites/µl on day 0 before 
treatment and on the day of parasite recurrence. The erythrocytes were isolated from 
the whole blood and the parasites were adapted to in vitro cultures for further 
experiments. 
2.1.7 Enzymes 
All restriction enzymes and corresponding buffers were purchased from New 
England Biolabs. 
DNase was purchased from Ambion, Huntingdon, UK, Taq poylermase from 
Fermentas, St Leon Rot, DE. 
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2.1.8 Oligonucleotides and sequencing reaction 
2.1.8.1 Oligonucleotides 
Primers were purchased from Eurofins MWG operon or Invitrogen. 
	  
Table 2-2 Oligonucleotides If no accession numbers are available exact chromosomal 
locations are indicated. These primer pairs are all in proximity to the dhfr locus und therefore 
on chromosome 4. 
Primer name (gene) Sequence 5 ‘ to 3 ‘ Accession number 
RESA A (for) ATGAGACCTTTTCATGCATATAG PFA0110w 
RESA B (for) CTATATATCATTTTAAATGGTAATCTTGG PFA0110w 
RESA C (rev) CCAAGCGATTTGGTTCAACACAGTC PFA0110w 
RESA D (rev) CTAAGTATACACCATCTTTTACGG PFA0110w 
Pfgch Southern for CAATAATCAAAGTTACAGG PFL1155w 
Pfgch Southern rev AGCATCGTGCTCTTTAACTCCCC PFL1155w 
Pfgch RT for GGAGTTAAAGAGCACGATGCT PFL1155w 
Pfgch RT rev ACTGTAGGATTCTCTTTTTCTGCTT PFL1155w 
PfgchSNP’s for AACGAATGTGAGAAGGAAGACC PFL1155w 
Pfgch SNP’s rev CCTGTAACTTTGATTATTG PFL1155w 
Pfgch compl Seq for1 ATTTTTCATTTAATGGACTGG PFL1155w 
Pfgch compl Seq rev1 CCTTCCTTATTTTCTTCTTTGG PFL1155w 
Pfgch compl Seq for2 CCAAAGAAGAAAATAAGGAAGG PFL1155w 
Pfgch compl Seq rev2 ATACATAAATGTTTAGCTAC PFF1360w 
Pfptps Seq for TCCTATTGTTAATCTGACC PFF1360w 
Pfptps Seq rev TAACCTATTTTTATATATACC PFF1360w 
Pfptps RT for CCCAGAAAGAGATTGTATAAAACTTCCT PFF1360w 
Pfptps RT rev ACATCCATTTCTTCTATTAGTTGGTTAAGA PFF1360w 
Pfdhps Seq for TGAAATGATAAATGAAGGTGC PF08_0095 
Pfdhps Seq rev GCTGTAGGAAGCAATTGCTAATCC PF08_0095 
Pfdhps RT for ACAAATGATAGAAGAAACGCTGTGTT PF08_0095 
Pfdhps RT rev  AAGCCTTTCATACAAGTAGGAGCTATT PF08_0095 
Pfdhps Seq for TTTGTTGAACCTAAACGTGC PF08_0095 
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Primer name (gene) Sequence 5 ‘ to 3 ‘ Accession number 
Pfdhps Seq rev  AAAGTTGATCCTTGTCTTTCC PF08_0095 
Pfdhps Seq for neu  TTTGTTGAACCTAAACGTGC PF08_0095 
Pfdhps Seq rev neu  AAAGTTGATCCTTGTCTTTCC PF08_0095 
Pfdhfs Seq for AGAGGTAGCACAATATTTACC PF13_0140 
Pfdhfs Seq rev ATCTAAGCGCCCTCCAATCCC PF13_0140 
Pfdhfs RT for ACAAAGCCGAGAAACTTGAGTGT PF13_0140 
Pfdhfs RT rev TCCTTTAAGGTGTCGCCAAATT PF13_0140 
Pfdhfr Southern for CAAAGTGATCGAACGGGAGTAGG PFD0830w 
Pfdhfr Southern rev CAAGGAGGTAATGCCATTTGG  PFD0830w 
Pfdhfr RT for AAGATCATGTGATTTAGGGCTAGGA PFD0830w 
Pfdhfr RT rev TGCGCAGGTTGCAAATTACA PFD0830w 
Pfdhfr 5UTR for CCAACATTTTCAAGATTGATAC PFD0830w 
Pfdhfr SNP’s for  ATGATGGAACAAGTCTGC PFD0830w 
Pfdhfr SNP’s rev  GTTACTAGTATATACATCGC PFD0830w 
Pfdhfr Seq(Probe) for TAAGGATATGGGAAGCTAATGG PFD0830w 
Pfdhfr Seq(Probe) rev TAAGTGTTGGGAATGGATAGGG PFD0830w 
Pfdhfr Seq 5UTR for CCAACATTTTCAAGATTGATAC PFD0830w 
Pfdhfr Seq mid for GATCTAATAGTTTTACTTGGG PFD0830w 
Pfdhfr Seq mid rev ACGTATTACCATTTGTTTCTCC PFD0830w 
Pfdhfr Seq 3UTR rev2 AAAAATTCTTAACCGTTCAGG PFD0830w 
Gln tRNA RT for CTTCGGGTGGATCAGCTAGC PFD0780w 
Gln tRNA RT for GCAGCAGGAGTTCTGATGGAA PFD0780w 
PFD0795w RT for CTGCAGCAGTATTAATGCTCGTAAC PFD0795w 
PFD0795w RT for CCTTTGGTCCATACGTTTAGGG PFD0795w 
PFD0840w RT A1 GAATCTCCTGAAGCAGAGGGAA PFD0840w 
smGTP bind RT for ACACGTGCCTACCCTACACC PFD0810w 
smGTP bind RT rev ATTTTACCCACAACCAATTCTTCC PFD0810w 
PFD0810w rev neu1 TTGTGATAATCCCTAAATGTGC PFD0810w 
PFD0810w rev neu2 ATATATAACAATTATGAGG PFD0810w 
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Primer name (gene) Sequence 5 ‘ to 3 ‘ Accession number 
PFD0815 RT for ATGGAAAAGTTCCATTAACTTCCG PFD0815c 
PFD0815 RT rev CCTCCACGTATTTGGGAACG PFD0815c 
PFD0820w for TGGTATGAAATGCCGACTCCT PFD0820w 
PFD0820w rev TATGAGGGCCAACCTGTTTGTCTAC PFD0820w 
RNA binding-RTfor AAAGAATATATGAAATAGGAAACGAGCA PFD0825c 
RNA binding-RTrev GCTCATTCAATCTGTTAATTTGTTGC PFD0825c 
LETM RT for GCAAAAGAGCAGCTAGCCAAA PFD0835c 
LETM RT rev TTCCTTTTCTTCTATGAGCTGTTGTAAA PFD0835c 
BP FCR3 rechts rev1 AAAGGTACGTTTCACACACC PFD0835c 
BP FCR3 rechts rev1 AATGTTTTGACAAAACCGTAGG PFD0835c 
LETM-840 RT for TGATAGTTCAGACGAGCAGATAACTTTT 762908-762935 
LETM-840 RT rev TGTTAACTGTTCGTTACACTTTTTCAAAA 762933-762961 
PFD0840w RT A1 GAATCTCCTGAAGCAGAGGGAA PFD0840w 
PFD0840w RT A2  TTAGTAGGCAACTCACTTGTTAATACCTT PFD0840w 
PFD0840w RT A for GTGGTGCGGCGATCATTATA PFD0840w 
PFD0840w RT A rev AACAAAGTTATCCACCTTAAATTTGAAGT PFD0840w 
PFD0840w RT B1 AGGATTAAGGAGAACAGGAACGG PFD0840w 
PFD0840w RT B2 ATATGACCCCCTTCTTGCGA PFD0840w 
PFD840-RT-mid-for CATAACGAAAACCCTAAGGATGTTC 776154-776178 
PFD840-RT-mid-rev TCAAAGGGTACGCTAAAAAAAATATTT 776245-776269 
Cdc rKinase RT for CAGAATTTCAGCACAGGAAGCA PFD0865c 
Cdc rKinase RT rev GGGAATTCGTTAAAGTAAGGATGG PFD0865c 
PFD0840Z1for CGAGAAACCAAACGAACTCGC PFD0840w 
PFD0840Z2for GTTGATGGATTACGGTCAACTCG PFD0840w 
PFD0840Z3for CCACGTGTATGTCGTACGAACC PFD0840w 
PFD0840Z4for GTTATTCGGACGAAGCGCACG PFD0840w 
PFD0840Z5for ATCCACGTGGGATTTCGTAAGC PFD0840w 
PFD0840Z6for GTCGTGTTCTTGCGGTGTGC PFD0840w 
LETM-5-rev AGAATATGACACAAATTAGTAGG 762744-762766 
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Primer name (gene) Sequence 5 ‘ to 3 ‘ Accession number 
3D7-3’for1  GATGACAAAATTACCTGAACG 756926-756946 
3D7-3’for2 CGTCAGTTTTTTTATCTTCGGG PFD0835c 
3D7-5’rev1 TTACATTATTGAAATGCACC 739147-739166 
3D7-5’rev2 CTGTAAAATAGCCAAAATTTGG 739311-739332 
3D7-5’rev3  ACTCATTTGTATTATCTCTTCC 748949-748970 
FCR3-3’for1  AAGGTACGTTTCACACACCC 760617-760636 
FCR3-5’rev1  GATATTTCTACCCATAATTAAGC 732650-732670 
FCR3-5’rev2  GTATTTATATGATTAGATTGTCC 735530-735552 
Actin southern for CAAGCTTTAGTTGTTGACAACG PFL2215w 
Actin southern rer GGAGCTTCTGTTAATAACACTGG PFL2215w 
Tubulin RT for TGATGTGCGCAAGTGATCC PF10_0080 
Tubulin RT rev TCCTTTGTGGACATTCTTCCTC PF10_0080 
 
 
 
Table 2-3 Probes designed for real time PCR analysis 
Name Accession number MAL Label – Sequence – quencher  
GCH PFL1155w MAL 12 FAM-ACTATAACGTATGCATCTTA-TAMRA 
PTPS PFF1360 MAL 6 FAM-TTCTACTGAAGAAATTGG-TAMRA 
DHPS PF08_0095 MAL 8 FAM-TTCTAGAAACTGCTCTGC-TAMRA 
DHFS PF13_0140 MAL 13 FAM-TTCCATCCGTTCATAGCT-TAMRA 
DHFR PFD0830w MAL 4 FAM-TTTACTCATATGATTGCACAAGT-
TAMRA 
β tubulin PF10_0080 MAL 10 JOE-TAGCACATGCCGTTAAA TATCTTCCATGTCT-TAMRA 
gapdh PF14_0598 MAL 14 JOE-AAGGAATCTTAGGATACA-TAMRA 
 
2.1.8.2 Sequencing reaction 
Sequencing was performed by GATC, Konstanz, Germany and is described in more 
detail in 2.2.1.11. 
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2.2 Methods 
2.2.1 Molecular methods 
2.2.1.1 Plasmodium falciparum gDNA isolation 
Parasites were harvested from blood culture and the erythrocyte plasma membrane 
was ruptured as described in paragraph 2.2.3.3. The obtained parasite pellet was re-
suspended in 200µl 1 x PBS and the parasite genomic DNA was isolated with the 
DNA QIAamp DNA Blood Kit. The instructions were followed as indicated in the 
protocol of the manufacturer. The DNA was eluted from the column in 80 – 120 µl 
elution buffer depending on the size of the parasite pellet obtained from the culture. 
2.2.1.2 Plasmodium falciparum total RNA isolation 
Parasites were harvested from blood culture and the erythrocyte plasma membrane 
was ruptured as described in paragraph 2.2.3.3. The parasite pellet was re-
suspended in 200µl RLT buffer (Qiagen RNeasy Kit) and parasite total RNA was 
isolated with the Qiagen Rneasy Kit. The instructions were followed as indicated in 
the protocol of the manufacturer. The DNase digest was included in the protocol 
during the washing steps. Total RNA was eluted from the column in 30 – 50 µl of 
double distilled water. 
2.2.1.3 Plasmodium falciparum mRNA isolation 
mRNA was isolated with the mRNA Isolation Kit (Roche, Mannheim). 1ml of whole 
blood from each patient of the study was given into a 14ml falcon tube with 10ml of 
Roche mRNA stabilisation solution. The lysat was carefully mixed and stored at 4°C 
until transport from the satellite site in Pingilikani to KEMRI in Kilifi town, where the 
samples were stored at -80°C until purification. Blood sampling and transport to 
KEMRI generally occurred on the same day. 
The isolation of the mRNA was then performed with the mRNA Isolation Kit for blood  
and bone marrow (Roche, Mannheim, DE). The instructions were followed as 
indicated in the protocol of the manufacturer. 
2.2.1.4 Plasmid preparation from bacteria 
A bacterial over night culture of 5ml supplemented with 0,1 mg/ml Ampicillin was 
centrifuged in two steps in a 2 ml Eppendorff tube. The bacterial pellet was re-
suspended in the 250µl P1 buffer and the instructions were followed as indicated in 
the protocol of the manufacturer. 
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2.2.1.5 DNase treatment 
The mRNA isolation protocol from Roche did not include a DNase digest during 
purification. The mRNA isolation is based on oligo dT magnetic beads and the 
manufacturer claims this sufficient to separate mRNA from genomic DNA. In 
Plasmodium falciparum though, runs of 30 adenines are common. Therefore an 
additional DNase digest was performed after purification to eliminate the possibility of 
genomic DNA contamination, which would falsify analysis and results.  
DNase treatment was preformed with the Turbo DNA free Kit from Ambion and the 
instructions were followed as indicated in the protocol of the manufacturer. 
2.2.1.6 Precipitation and purification of nucleic acid 
Precipitation of DNA is a common method to concentrate and purify DNA. Through 
the addition of salt and ethanol the DNA looses its solubility and can be precipitated 
by centrifugation. 
The standard protocol, which was used, is described in the following paragraph: 
To 1 volume of DNA  1/10 volume of 3 M Sodium Acetate pH = 4,8 and  
    2,5 volumes of 100% Ethanol 
were added and well mixed. The samples was incubated for 2h at -80°C, centrifuged 
at 13 000 rpm in a table top centrifuge for 20 min at 4°C. The pellet was washed with 
500µl of 70% Ethanol and centrifuge again at 13 000 rpm for 10 min at 4°C. The 
white DNA pellet was dried at 37°C for 5 to 10 min and re-suspended in the desired 
volume of double distilled water.  
For purification of PCR products the QIAgen PCR Purification Kit was used and the 
instructions were followed as indicated in the protocol by the manufacturer. 
If DNA was separated with gel electrophoresis, the desired fragment was excised of 
the agarose gel under UV light and purified with the QIAquick Gel extraction Kit. The 
instructions were followed as indicated in the protocol by the manufacturer. 
2.2.1.7 Reverse Transcription (cDNA Synthesis) 
Total RNA or mRNA was transcribed into cDNA with the RETROscript from Ambion. 
Oligo d’T primers were used to initiate cDNA synthesis and the instructions were 
followed as indicated in the protocol by the manufacturer. 
2.2.1.8 One step reverse transcription PCR (Invitrogen) 
For one step reverse transcription and amplification of a specific DNA fragment the 
SuperScript III one-step RT-PCR System from Invitrogen was used. In the first step 
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the mRNA is specifically transcribed into cDNA for 45 min at 42 °C and then directly 
amplified in a polymerase chain reaction (2.2.1.9). 
2.2.1.9 Polymerase chain reaction (PCR) 
Polymerase chain reaction was established to amplify a particular gene or sequence 
of interest with specifically designed oligonucleotides. Sequence information was 
downloaded from databases www.plasmodb.org and www.genedb.org. Due to the 
high AT content in the genome of Plasmodium falciparum, oligonucelotides were 
designed in regions with possibly high GC content. One universal PCR protocol was 
used for all reaction with minor changes, mentioned in the respective paragraphs. 
Genomic DNA, cDNA, Plasmid or bacterial colony served as template.  
1 x Reaction buffer    Roche, Mannheim 
200µM d’NTP’s Mix    Fermentas 
2mM MgCl2     Roche, Mannheim 
1µM Oligonucleotide each   MWG or Invitrogen 
2,5u/50µl Taq Polymerase   Fermentas 
Final volume of the reaction was 25µl or 50µl depending on the subsequent 
experiments. 
An Eppendorff Thermocylcler was used and the cycling conditions are listed in the 
table bellow. 35 cylces (Step 2 – Step 4) for one reaction were the standard protocol. 
Extension time was adapted to template length (1kb/1min). 
 
    Table 2-4 Standard PCR cycling conditions. 
 
PCR to reveal breakpoints of 3D7 and FCR3 amplicons 
FCR3 and 3D7 were subjected to numerous PCR analyses to reveal breakpoint of 
amplicon, which are described in 3.3.1.5. 
Initial denaturation of the template DNA 3:00 min 94°C 
Denaturation of the DNA (Step 2) 0:45 min 94°C 
Annealing of the oligonucleotides (Step 3) 0:30 min 58°C 
Extension of the fragments by the Taq polymerase (Step 4) 1:00 min 60°C 
Final Extension to ensure complete amplification 10:00 min 60°C 
Pause  4°C 
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The primer used for 3D7 are listed in table Table 2-2 and are marked with the names 
3D7 3’ for and 3D7 5’rev. 3’ and 5’ indicate the possible breakpoints on either side of 
dhfr. In addition the group of primers marked with PFD0840Z1-6 for were combined 
with primers upstream of dhfr. 
The analysis of the gap in 3D7 amplicon was performed with Pfdhfr primers labelled 
with forward, 3D7 3’ for, LETM RT for/rev and LETM 5’rev (5’ is here 5’ of LETM). 
The FCR3 breakpoint was analysed with FCR3 5’rev and FCR3 3’for and later with 
PFD0815c RT rev, PFD0815c new rev1/2 and BP FCR3 right rev1/2. 
2.2.1.10 Agarose gel electrophoresis 
Gel electrophoresis allows the distinct separation of DNA fragments of different sizes 
and their visualisation. Agarose dissolved by heating in a buffer forms a gel matrix 
with pores when it cools down. These pores are wide enough for DNA fragments to 
run through when a constant electric current is applied between the two poles of a 
suitable chamber.  
In this work different percentages of Agarose were used depending on the size of the 
DNA fragments to be separated. Higher percentage for a denser matrix and smaller 
fragments and lower percentage for longer fragments and wider pores. The agarose 
(0,5 % - 2 %) was dissolved and heated in 1 x TAE buffer or 1 x TBE buffer. 0,01 % 
Sybre safe was added and the fluid gel was casted in a tray before it had cooled 
down. A comb was put on one end of the gel where it forms small pockets in which 
the DNA was loaded once the gel had solidified. A power supply produces between 
80 V and 130 V between the poles and the gel was run between 45 min and 2h 
depending on the size of the fragments to be separated and the lengths of the gel. 
A picture was taken with Gel Doc XR from Biorad. 
2.2.1.11 Sequencing of PCR fragments 
The five enzymes of the folate pathway were sequenced in the 20 field isolates from 
Kilifi, Kenya and in the parasites lines resulting from the drug pressure experiments. 
Sequencing was performed with GATC biothech in Konstanz, Germany (www.gatc-
biothech.com). PCR fragments were purified, solved in water and send with the 
oligonucleotide for sequencing in the following concentrations and volumes. 
PCR product  10 – 50 ng/µl (in 30µl) 
Plasmid DNA  30 – 100 ng/µl (in 30µl) 
Oligonucleotide 10 pmol/µl (in 30µl) 
Sequences were analyses and aligned with Bioedit. The 3D7 genome from 
Plasmodb served as reference genome. 
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Pfgch (PFL1155w), Pfptps (PFF1360w) and Pfdhfr (PFD0830w) were fully 
sequenced, Pfdhps (PF08_0095) and Pfdhfs (PF13_0140) only partially with primer 
covering at least all annotated SNPs in the open reading frames. The sequence of 
Pfptps was covered with one primer pair, so were the regions of annotated SNPs in 
Pfdhps and Pfdhfs.  For Pfgch and Pfdhfr three overlapping PCR fragments were 
generated with the designed oligonucleotides listed in Table 2-2. Primer names are 
composed as follows: gene accession number, comp (complete), seq 
(sequencing)/SNP and for (forward)/rev (reverse). 
2.2.1.12 Ligation of PCR fragments for bacterial cloning 
The standard PCR reaction with the Fermentas Taq polymerase was used, through 
which an extra A at the 3’ end of each PCR fragment is added. 50 µl of PCR product 
were purified and solved in water and the ligation of vector and PCR fragment was 
performed at RT for 1 to 5h and with the addition of a salt. 
7 µl of PCR product 
2 µl salt solution (provided) 
1µl of TOPO vector (provided) 
The ligation was then used in bacterial transformation or stored at -20°C. 
2.2.1.13 Real time PCR 
Real time PCR assays were used for gene copy number quantification, amplicon size 
determination and transcriptional analysis. 
For the gene copy number quantification and the transcriptional analysis a Taqman 
Probe (ABI and MWG) was designed whereas for the determination of the amplicon 
size a sybr green based assay was established. 
For analysis of the results the ΔΔct method was used. β-tubulin and gapdh served as 
endogenous controls and at least one reference genome (3D7, Dd2, D10 or FCR3) 
was run on every experiment on each 96 well plate.  
Real time PCR with Taqman probe to analyse copy number and transcription  
All primer and probes were designed with Primer Express 3.0 Software from ABI. 
Probes were labelled 5’ with FAM (Pfgch, Pfptps, Pfdhps, Pfdhfs and Pfdhfr) or with 
JOE (β tubulin and gapdh) and the quencher TAMRA was attached 3’. Primer and 
probe were ordered from ABI, MWG and Invitrogen and are listed in detail in Table 
2-2 and Table 2-3. Primer names are composed of gene accession numbers, RT (real 
time) and for (forward)/rev (reverse). 
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900nM of each primer and 300nM of each probe were used in the TaqMan universal 
PCR master mix (ABI).  
To determine the copy number, genomic DNA was isolated (2.2.1.1) from the 
parasite culture and used for the reaction. To analyse the transcriptional profile total 
RNA (2.2.1.2) or mRNA (2.2.1.3) was isolated and transcribed into cDNA (2.2.1.7) 
and used in the assay. A negative control containing only water was run on each 
plate and in the expression experiments, mRNA or total RNA were also run on a 
plate to exclude gDNA contamination. The reaction was set up as follows in a total 
reaction volume of 25µl. 
Taqman universal PCR master mix 2 x    12,5µl 
DNA/mRNA       50ng 
Endogenous control  Forward primer   900nM 
   Reverse primer   900nM 
   MGB Taqman Probe   300nM 
Gene of interest Forward primer   900nM 
   Reverse primer   900nM 
   MGB Taqman Probe   300nM   
 
All measurements were performed in duplicates and the cycling conditions are shown 
in Table 2-5. Stage 3 was repeated 50 times. Data collection as performed in stage 3 
step 2. 
 
Table 2-5 Standard real time PCR cycling conditions (probe) 
Stage Repetitions Temperature Time 
1 1 50.0 °C 02:00 
2 1 95.0 °C 10:00 
3 step 1 50 95.0 °C 00:15 
3 step 2  60.0 °C 01:00 
 
 
Real time assay to determine amplicon size 
The size of the amplified DNA fragment containing the dhfr locus was determined 
with a sybr green based assay. The genomic context of dhfr was analysed on 
PlasmoDB (www.plasmodb.org) and the neighbouring genes were checked for 
Material and Methods 
	   43	  
amplification. Primers were designed for genes at different distances upstream and 
downstream of the dhfr locus are listed in Table 2-2. 
 
 
The oligonucleotides (150nM) were designed with Primer Express 2.0 and are listed 
in detail in Table 2-2. Primer names are composed of gene accession numbers, RT 
(real time) and for (forward)/rev (reverse). A reaction mix was set up as follows: 
Power SYBR green master mix (ABI) 2 x    12,5µl 
DNA/mRNA       50ng 
Gene of interest  Forward primer   900nM 
   Reverse primer   900nM 
With the usage of the sybr green master mix each gene is analysed in an individual 
well. The internal controls are not adjusting for pipeting errors and the quantification 
is less accurate compared to a Taqman probe. Nevertheless, it is clearly possible to 
determine amplification.  The Power SYBR green master mix (ABI) was used with the 
following Cycling conditions. 
 
Table 2-6 Standard real time PCR cycling conditions (sybr) 
Stage Repetitions Temperature Time 
1 1 95.0 °C 00:15 
2 40 95.0 °C 00:15 
  58.0 °C 00:15 
  60.0 °C 00:45 
3 (Dissociation) 1 95.0 °C 00:15 
  60.0 °C 01:00 
  95.0 °C 00:15 
Figure 2-1 Genomic context of Pfdhfr (adapted from plasmoDB). Boxes indicate 
genes. (grey) PDF0780w - PDF0820w, (purple) PDF0825w, (yellow) dhfr, (blue light) 
PDF0835c, (magenta) PDF0840w, and (grey downstream) PDF0865c. Distances are 
shown below in kilo bases. Small black lines represent the primer pairs in each open 
reading frame.  
A     A2    mid     B 
!"#$%& !'!$%& !()$%& !#($%& !#*$%& !+($%& !+,$%& !+*$%& !,#$%&&&&&&&&&&&&&&!)"$%& !*,$%&
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Analysis of the results 
The real time PCR analysis was performed with the ΔΔ ct (cycle threshold) method. 
The threshold was set at the exponential phase in the lower third of the curve and the 
cycle threshold (ct) was read in the analysis table for all the curves selected (ABI 
7500 system software). As each reaction was performed at least in duplicates, the 
mean ct value was calculated. The delta ct (Δct) and the delta delta ct (ΔΔct) were 
then calculated as shown below. 
 
Δct = ct(internal control) – ct(gene of interest) 
 
ΔΔct = Δct(reference) – Δct(treated) 
 
Plasmodium falciparum β-tubulin (PF10_0086) or gapdh (PF14_0598) served in all 
experiments as endogenous control to standardize the amount of DNA in each 
reaction. The reference genome varied depending on the experimental set up and 
will be mentioned in the corresponding chapter of the results. 
2.2.1.14 Restriction endonucleases digest 
Restriction endonucleases recognise a specific sequence of mostly 4 to 6 bp in 
double stranded DNA and cleave at this site the phosphodiesterbond thus generating 
two or more DNA fragments.  
Genomic DNA, PCR products and bacterial vectors were cut by restriction enzymes. 
The restriction digest of genomic DNA was preferably carried out in higher volumes 
(100 – 200 µl), for PCR fragments and bacterial vectors a total reaction volume of 10 
– 20  µl was sufficient. The 10x reaction buffer was adjusted to the final volume as 
well as the units of the restriction enzyme. The restriction digest was carried out at 
37°C and over night to ensure complete digestion of the DNA. 
2.2.1.15 Southern blot 
The southern blot was performed with a nonradioactive, digoxigenin (DIG) labelled 
probe, which is detected by a chemieluminescence reaction. The result can be 
visualized on a light sensitive film. The DIG High Primer DNA Labeling and Detection 
starter Kit II (Roche, Mannheim) was used in this experiment.  
Labelling of the probe 
The DNA for probe was obtained from a PCR reaction of two times 50µl reaction 
volume. The used oligonucleotides are listed in Table 2-2 and are ladled with Gene 
name and the addition “Southern”. 
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The reaction was purified and eluted in 20µl of double distilled water. The 
concentration of the DNA was measured in a nanodrop machine. Up to 2µg of DNA 
were used for the labelling reaction. The DNA was denatured at 99°C for 10 min, 
cooled on ice and 4 µl of the DIG-High Prime labelling enzyme were added. The 
reaction was incubated over night at 37°C. To stop the labelling reaction, the probe 
was incubated at 65°C for 10 min and then stored at 4°C.  
gDNA preparation and restriction digest 
Parasites were cultured until a parasitaemia of 10% was reached in the trophozoite 
stage. The parasites and the DNA were isolated as described in the corresponding 
chapters (2.2.3.3 and 2.2.1.1). Two µg of genomic DNA were digested with restriction 
enzymes in a total reaction volume of 100µl. To choose an appropriate set of 
restriction enzymes 30 kilo bases surrounding the Pfdhfr locus (PFD0830w) and the 
Pfactin (PFL2215w) locus were carefully analysed with the program EnzymeX 3.1. 
The sequence information was down loaded from www.plasmoddb.org. Three 
combinations of restriction enzymes were suitable for the analysis. The expected 
fragments are easily separable with a low percentage agarose gel electrophoresis. 
 
Table 2-7 Restriction enzymes and buffers used for Southern blot analysis 
Restriction enzyme NEB buffer Pfactin expected size Pfdhfr expected size 
EcoRV Buffer 3  6891 bp 8018 bp 
EcoRV + NheI Buffer 2 6154 bp 4935 bp 
EcoRV + EcoRI EcoRI buffer 5494 bp 2461 bp 
 
The reaction was performed at 37°C over night and an additional µl of each enzyme 
was added for one hour the next morning to ensure complete digestion of the 
genomic DNA. The DNA was precipitated (2.2.1.6) and re-suspended in 10µl of 
double distilled water.  
Running condition for the agarose gel and its preparation for the blot 
The DNA was loaded on a 0,7% agarose gel supplemented with 1 x SYBR® safe 
DNA gel stain and run over night at 20V in 0,5 x TBE buffer. A picture was taken with 
the Geldoc XR (Biorad) and the gel was bathed for 15 min in 0,25 M HCL to de-
purinate the DNA to facilitate following transfer. The gel was shortly rinsed in double 
distilled water and incubated in denaturing buffer for 30 min under constant agitation 
on a platform shaker. Denaturing of the DNA prepares the strands for later 
hybridization. The denaturing buffer was poured off and the gel was again shortly 
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washed with double distilled water and then neutralized and equilibrated in 10 x SSC 
for 30min.  
Southern blot 
The membrane and two extra thick filter papers were cut to the exact size of the gel 
and the membrane was equilibrated for 10 min in 2 x SSC buffer. The transfer was 
conducted from top to bottom, which has the advantage that it also uses gravity as a 
driving force for the buffer and the DNA. The blot was built as shown in Figure 2-2. A 
stack of paper towel served as basis in a tray. On top one extra thick Whatman® 
paper soaked in 10 x SSC was placed followed by the membrane, the gel and 
another extra thick Whatman® paper also soaked in 10 x SSC. The connection with 
the two elevated container filled with 10 x SSC was established with two 2 mm 
Whatman® papers as shown in Figure 2-2. Air bubbles between the different layers 
were carefully avoided. Transfer was performed for a minimum of 5 h to ensure 
complete transfer of the DNA.  
	  
	  
Cross-linking, prehybridization and hybridazation with the probe 
Before processing the membrane after the transfer, the pockets of the gel were 
marked with a pencil on the membrane and the upper right corner was cut with clean 
scissors. The membrane was then laid with the DNA side facing up on a 2 mm 
Extra thick 
Whatman® paper 
10 x SSC 10 x SSC 
Membrane 
Agarose gel 
Paper 
2 mm Whatman® paper 
Extra thick 
Whatman® paper 
Figure 2-2 Southern blot. (Green boxes) containers filled with 10xSSC on elevation. 
(blue sheets) paper with high power ob absorption, (black thick line) extra thick 
Wahtman paper, (red line) positively charged. Blotting was performed minimum 5 h.  
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Whatman® paper soaked with 2 x SSC. The DNA was cross-linked with a UV 
stratagene cross linker and the program auto crosslink. 
The membrane was then immediately rinsed in double distilled water and pre-
hybridized for 30min in 25ml of DIG Easy Hyb granules at 37°C in a glass tube 
rotating in a hybridization oven. The pre-hybridization solution was poured off and 
20ml of hybridization solution supplemented with 10µl of Pfdhfr and 10µl of Pfactin 
DIG labelled probe were added. Hybridization solution was incubated over night.   
Washing, blocking and detection 
All the following steps were carried out in the glass tube rotating in the oven at 37°C. 
The formulations of the buffers are listed in chapter 2.1.5. The membrane was 
washed 2 times for 5 min with Step 1 washing solution (3 x SSC, 0,5 % SDS) and 2 
times for 15 min with Step 2 washing solution (2 x SSC, 0,5% SDS). The membrane 
was then briefly rinsed in washing buffer and blocked for 1h in 100ml of 1x blocking 
solution (10 x blocking solution diluted in maleic acid). The blocking solution was 
discarded and 20 ml of fresh blocking solution supplemented with 1µl of Antibody 
solution (Anti-Digoxigenin AB) was added onto the membrane and incubated for 30 
min. The membrane was then carefully washed twice with ample volumes of washing 
buffer for 15 min. With clean forceps the membrane was pulled out of the glass tube 
into a small dish with 20 ml detection buffer to equilibrate it for 5 min.  
The membrane was then put with its DNA side facing up into a development folder in 
a plastic bag. On 100 cm2 of membrane 1ml of ready-to-use CSPD was added and 
immediately evenly spread out on the membrane with the help of the closing plastic 
bag. Air bubbles were carefully avoided, as well as drying out of the membrane, 
which both causes uneven and high background. The cassette was incubated at 
37°C for 10 min to enhance the luminescence reaction. 
In the dark room an Amersham HyperfilmTM ECL, a high performance 
chemiluminescence film was cut to the appropriate size and exposed onto the 
membrane for 5 to 15 min and developed. Additionally a Kodak BioMax MR film was 
exposed for 30 min to 90 depending on the strength of the signal. 
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2.2.2 Microbiological methods 
2.2.2.1 Bacterial transformation 
The bacterial system was used to clone and amplify single DNA molecules. 
Fragments were ligated with the TOPO vector (2.2.1.12), which contains a selection 
marker for ampicillin. Only cell containing the plasmid were then able to grow on 
LBamp Agar plates. 
Top 10 competent cells (Invitrogen) were used for bacterial transformation. Cells 
were stored at -80°C and thoroughly thawed on ice. 5 µl of the ligation (2.2.1.12) 
were given to 40µl of competent cells and kept on ice for 20 min. Cells were heat 
shocked at 42°C for 30sec and immediately put back on ice. 100µl of SOC medium 
were added and the transformed cells were incubated shaking at 37°C for 1h. After 
one hour cells were shortly pelleted, 80µl of medium was withdrawn and the rest re-
suspended and plated on a LBamp Agar plate and incubated at 37°C over night. 
Colony screening 
Colonies were first screened with PCR. Standard master mix with insert specific 
primer was aliquoted into PCR tubes. One colony at the time was picked with clean 
tips and kept for 1 to 3 minutes in a single PCR tube with the master mix. Tips were 
removed and the reaction was started. Results were analysed on an Agarose gel and 
positive colonies were confirmed with plasmid preparation (2.2.1.6) from a bacterial 
culture (2.2.2.2) of the indentified colony.  
2.2.2.2 Bacterial culture of transformed colonies 
One colony was picked with a clean tip and used to inoculate 5 ml of LBamp medium 
supplemented with 100µg/ml in a sterile tube for bacterial culture. The culture was 
grown over night in a shaker at 37 °C and harvested by a stepwise centrifugation in a 
2 ml Eppendorff tube. The plasmid preparation is described in chapter 2.2.1.4 
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2.2.3 Methods of Plasmodium falciparum 
2.2.3.1 Plasmodium falciparum culture conditions 
Plasmodium falciparum was cultured in vitro in T75 or T25 cell culture flasks from 
Greiner in the incubator Heracell 150 (Heraeus / Thermo) at 37°C. Complete cell 
culture medium (2.1.5) was prepared and the parasites were grown in the presence 
of O+ or A+ blood (5% haematocrit) and a gas mixture of 5% CO2, 5% O2 and 90% 
N2. The parasite population was kept between 0,1 and 10% (parasites/erythrocytes) 
with regular change of medium and the addition of fresh blood. 
Staining of P. falciparum culture with Giemsa (thin blood slide) 
The growth of the parasite culture was controlled with regular thin blood smears. A 
drop of the sedimented erythrocytes was given onto the surface of a clean glass slide 
and spread evenly, air dried and fixed for 1 min in 100% methanol. The fixed cells 
were then stained in 5 – 10% Giemsa solution for 10 min. Slides were examined on a 
light microscope using a 100x objective under oil immersion. 
Freezing of parasites 
On a regular basis aliquots of parasite cultures were preserved and stored in liquid 
nitrogen.  
A re-suspended culture was centrifuged for 3 min at 2100 rpm in a 50 ml falcon tube 
in a Megafuge 1.0 R (Heraeus). The supernatant was discarded and 1 volume of the 
freezing solution (2.1.5) was added to the erythrocyte pellet. The suspension was 
evenly divided into 1 to 3 cryo-tubes and frozen in liquid nitrogen. 
Thawing of parasites 
When parasites are thawed, the glycerol is replaced by a high salt concentration 
(12% NaCl). During the thawing procedure the salt concentration is slowly decreased 
to the culturing conditions. This change of osmotic pressure has to be carried out 
very carefully to allow the cells to adapt to each solution and avoid lyses. 
One aliquot of frozen parasites was slowly warmed in a water bath (37°C) and 200 µl 
of the thawing solution 1 (12% NaCl) (2.1.5) were slowly added. 9 ml of thawing 
solution 2 (1,6 % Nacl) (2.1.5) were added at a rate of 1 drop per second to avoid 
lyses of erythrocytes. The suspension was centrifuged at 2100 rpm for 3 min in a 
Megafuge 1.0 R (Heraeus). Supernatant was discarded and thawing solution 3 (0,9% 
Nacl + 0,2% Glucose) (2.1.5) was added in the same careful way. Again another 
centrifugation step followed and the erythrocyte pellet was washed with 10 ml of 
complete medium (2.1.5) before it was re-suspended in 14ml of complete medium 
Material and Methods 
	   50	  
and given in a culture flask with 500 µl of fresh A+ or O+ erythrocytes. The newly 
awaked parasites were kept in the incubator for at least 48 h without interruption. 
Synchronizing the parasite population 
Plasmodium falciparum parasites grow in an asynchronous population in in vitro 
culture when untreated. For some experimental designs, synchronized parasite 
population were needed. Synchronization is performed when ring stages are seen in 
a blood smear culture. The culture was then centrifuged and the medium was 
replaced by 5 % sorbitol and incubated for 10 min at 37 °C. After the incubation the 
sorbitol was removed by centrifugation and replaced by complete medium. The 
culture was brought back to normal culturing conditions. This treatment depletes the 
culture of all mature blood stages, i.e. trophozoites and schizonts. Ring stages are 
not affected by the treatment. To obtain complete synchronisation the procedure was 
repeated in two to three consecutive cycles. 
2.2.3.2 Cloning out single parasites from a population 
The parasite population that had lived under constant and increasing drug pressure 
had become an inhomogeneous population due to mutational changes in the 
genome. One single parasite had to be isolated to obtain a clonal population, which 
was then analysed in further experiments. Therefore the parasitaemia of the culture 
was determined and with the help of a serial dilution a 20 ml culture with 500 µl of 
erythrocyte concentrate and 10 parasites in total was pipetted. These 20 ml were 
evenly spread on a 96 well plate with each well obtaining 200 µl. Change of medium 
was performed once a week. The parasite growth was controlled by small blood 
smears first after 2 weeks and then every second day until parasites were visible 
under the microscope. The positive cultures of single wells were then taken into a T 
25 culture flask and grown in standard culture conditions as described in 2.2.3.1. 
 
2.2.3.3 Plasmodium falciparum parasite isolation from culture 
For DNA and RNA isolation from Plasmodium falciparum, 35 ml of parasite culture 
with parasitaemia of 10 % were centrifuge at 2100 rpm in a 50 ml falcon tube. The 
supernatant was discarded and the erythrocyte membrane was lysed with 2% 
Saponin in 1 x PBS. The parasites were separated with an additional centrifugation 
step at 3800rpm for 3min and washed with 1 x PBS. The purified parasites were re-
suspended in 200 µl 1 x PBS for DNA purification or re-suspended in an appropriate 
volume (300µl or 600µl) of RLT buffer (Qiagen) for total RNA isolation. 
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2.2.3.4 In vitro drug sensitivity assay (IC50) 
Drug sensitivity of the culture-adapted parasites was measured with an in vitro drug 
response rate assay. The four drugs chloroquine, pyrimethamine, trimethoprim and 
cycloguanil were analysed in one 96 well plate. Each assay was repeated at least 3 
times on different days and means with standard deviations were calculated. One 
mother plate was generated on which 11 dilutions of each drug were arranged 
horizontally in duplicates. The accuracy of each new mother plate was verified with 
3D7 in a control assay. Only if the measured values for 3D7 were in the range of the 
expected, the mother plate was used to determine the drug sensitivity of the field 
isolates. 15 assays were performed with one mother plate and it was kept for up to 4 
weeks at 4°C. The 96-well plate in which the drug sensitivity assay was performed is 
called daughter plate. 
Mother plate: 
A stock solution of each test compound was diluted in culture medium to the desired 
starting concentration, which was determined based on the predicted drug sensitivity 
level within the population of the isolates.  
A 96-well plate was used to prepare serial (3 fold) dilutions of the drugs. 200 µl 
medium were pipetted into each well. 100 µl of stock solution of each drug is added 
in the second column and leaving the first with only medium. The first drug in well 2A 
and 2B, the second drug into well 2C and 2D… The serial dilution is performed with a 
multipipett. 100µl are transferred from column 2 to column 3 and well mixed by 
pipetting. From column 2 again 100µl are transferred to the next column (4). This 
procedure is repeated until well 12. The mother plate was immediately used or stored 
for up to 4 weeks at 4°C. 
Daughter plate for the assay: 
The IC50 were measured at 1% ring stage parasite culture (2% haematocrite). 100µl 
of the culture was added into each well from column 2 to 12 and in wells 1A to 5A. 
12,5µl of the mother plate was added into the corresponding wells (column 1 to 
column one…). The negative control consisted of erythrocytes (2% haematocrite) in 
6A, 7A and 8A. The plates were incubated at standard culture conditions for 72h. 
After 72h 100µl lysis buffer (0,02% Sybr green) was added and incubated 1 h before 
measuring the fluorescence in a fluostarOPTIMA.  
The IC50 values were calculated with the help of an Excel sheet, in which means of 
the duplicates are calculated as well as means of positive and negative controls. The 
curve and the slope for each drug were calculated and the IC50 was read in ng/ml.  
 
Material and Methods 
	   52	  
2.2.3.5 Induction of resistance 
Resistance was induced by culturing plasmodium falciparum 3D7 and FCR3 under 
increasing pyrimethamine pressure. Starting concentration of the drug pressure 
experiment was determined by measuring the respective IC50 (2.2.3.4) value of 
pyrimethamine for both strains. The IC50 of 3D7 was 20nM and 60nM for FCR3 (Table 
3-2). I therefore decided to start the experiment with a pyrimethamine concentration 
of 20nM. The drug concentration was increased in 20nM steps up to 200nM, then 
directly to 300nM and subsequently up to 400nM, to 800nM and finally to 1,6 µM 
pyrimethamine. At each concentration parasites were cultured until they regained 
their usual replication rate. Generally the parasites adapted within two weeks (7 
cycles) to the new concentration. A parasite pellet was collected at every 
concentration to isolate DNA and RNA. Both strains were kept in parallel in 35ml of 
complete medium in a T75 culture flask. Regularly parasite aliquots were frozen in 
liquid nitrogen. 
A genetic and phenotypic analysis of the drug-adapted parasites was performed. All 
results were analysed relative to baseline parasites.  
Phenotypic changes were assessed in an in vitro drug sensitivity assay (2.2.3.4). 
Relative transcriptional changes of the five enzyme of the folate pathway were 
determined with a real time PCR assay (2.2.1.13) using cDNA (2.2.1.2 and 2.2.1.7) 
as template.  
Gene copy numbers variances (CNV) of the five enzymes of the folate pathway were 
analysed during the experiment. Relative CNVs were also determined with a real 
time PCR assay (2.2.1.13) using genomic DNA as a template.  
Single nucleotide polymorphisms (SNP) were determined by sequencing (2.2.1.17) 
with GATC-biotech. Additionally, a restriction digest of a 651 bp PCR fragment of dhfr 
was established revealing the S108N point mutation. The restriction enzymes cuts 
the parasite sensitive (3D7) dhfr sequence AGCT resulting in two fragments of 323 
base pairs and 328 base pairs which were distinguished on agarose 
gelelectrophoresis from the uncut PCR fragment of 651 base pairs.  
2.2.3.6 Competitive fitness assay 
The relative fitness of the resistant parasite lines was assessed in a competitive 
fitness assay. 3D7 wild type parasites were mixed in a 1:10 dilution with the 3D7 
resistant strains. Both lines were in synchronous cultures in the ring stage. Changes 
in the dhfr gene copy number served as indicator for the two lines. DNA was isolated 
after the first, the second and the third cycle and then again after 3 weeks. 
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2.2.4 Clinical methods 
2.2.4.1 Study site Pingilikani 
We conducted both studies at the Pingilikani study site, which is operated jointly by 
the Kenya Medical Research Institute (KEMRI) and the local Ministry of Health (Sasi 
et al, 2009). Malaria transmission in the area is perennial but with peaks trailing 
typically two annual rainy seasons (O'Meara et al, 2008). Coinciding with previously 
described reductions in severe malaria admissions to Kilifi District Hospital (O'Meara 
et al, 2008) we observed a reduction of the average annual proportion of malaria 
cases among non-immune infants between 6 and 12 months presenting with febrile 
disease at the Pingilikani health care facility from 62% in 2003 to 26% in 2005 and 
13% in 2008. Between the introduction of AM-LM as first-line treatment in Kilifi 
District in December 2006 and the end of the study, 2,585 malaria episodes in 3,271 
passively followed-up patients in Pingilikani received ACTs. Both studies were 
approved by the National KEMRI Ethical Review Committee, Kenya; the Oxford 
Tropical Research Ethics Committee, UK; and the Ethics Committee of the 
Heidelberg University School of Medicine, Germany. 
2.2.4.2 Study design of amodiaquin study (Sasi et al, 2009) 
The study was designed as a prospective observation of pediatric outpatients 
attending the Pingilikani Dispensary. Eligible patients received a supervised oral 
course of amodiaquine targeting a dose of 10 mg/kg/day for 3 days and were 
subsequently followed up for 28 days. The study was conducted from March through 
July 2006. Detailed describtion of the study is found in (Sasi et al, 2009). 
2.2.4.3 Study design of artemisinin combination therapy (ACT) study 
We enrolled paediatric outpatients aged 6-59 months with uncomplicated P. 
falciparum malaria who met the following selection criteria: reported or documented 
fever ≥37.5ºC, P. falciparum mono-infection, microscopically determined peripheral 
asexual parasite density of 2,000-200,000/µL, body weight >5 kg and signed 
informed consent by parent or legal guardian. We excluded patients with known 
allergies, severe malaria or danger signs, participation in an investigational drug 
study within previous 30 days, ECG abnormalities requiring urgent management, other 
relevant clinical conditions or severe malnutrition (defined as weight for height <70% of 
the median NCHS/WHO reference).  
Study drugs were administered orally with food or drinks under direct supervision by 
study nurses. DHA-PPQ was given 24-hourly for 3 days at single target doses of 2.25 
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mg of DHA/kg body weight and 18 mg of PPQ/kg (formulated as paediatric or adult 
strength fixed dose combinations of 20/160 mg and 40/320 mg, respectively; 
EurartesimTM, SigmaTau, Italy). AM-LM was administered according to the 
manufacturer’s instructions in 6 doses over 3 days at single target doses of 2 mg of 
AM/kg and 12 mg of LM/kg (CoartemTM, Novartis, Switzerland). Participants who 
vomited or rejected the study drug within 30 min received a second full dose, and 
those who vomited or rejected the study drug after 30 min but within 1 h received a 
second half dose. Vomiting or rejecting the second dose led to withdrawal from the 
study and administration of rescue medication (3-day oral regimen of atovaquone-
proguanil). Stability tests conducted in 2009, >10 months after completion of the 
study, on study drug batches used in the trial demonstrated that the titre and the 
degradation products of DHA/PPQ and AM/LM were within stringent specifications as 
submitted to the regulatory authorities (Swissmedic and EMEA, respectively; data not 
shown). 
During the 3-day treatment phase patients were admitted to the KEMRI research 
ward in Pingilikani to ensure strict adhesion to dosing intervals. Patients were seen 
by a study clinician for baseline assessment before administration of the first dose of 
study medication on days 0, 1, 2 and 3 and then for weekly follow-up visits until day 
63 and finally on day 84 (or whenever clinically indicated). Patients who failed to 
return for scheduled appointments were actively followed up in the community. On 
each visit during the treatment and follow-up phase, a medical history was obtained, 
vital signs were checked, axillary temperature was measured, thick and thin blood 
smears were prepared from a fingerprick blood sample, and adverse events were 
documented. To distinguish recrudescences from new infections, aliquots of EDTA–
treated blood samples obtained on day 0 and on the day of reappearing asexual 
parasitaemia were stored at -80°C for PCR-based genotyping analysis. In addition, 
blood samples were collected in Vacutainer tubes (BD) containing acid citrate 
dextrose and transport medium for adaptation of P. falciparum in culture on day 0 
and the day of parasite reappearance for in vitro drug-sensitivity assays. 
2.2.4.4 Day 7 
During clinical visit on day 7, one ml of venous blood was directly given into 10 ml of 
RNA/DNA Stabilization reagent for blood (Roche) and stored at 4°C until transport to 
KEMRI site in Kilifi town where the samples were stored at -80°C until purification. I 
analysed in total 156 samples from children who were either enrolled in the 
amodiaquine study (2.2.4.2) or the ACT study (2.2.4.3). 
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I isolated mRNA with mRNA Isolation Kit for blood and bone marrow (Roche) and re-
suspended the mRNA in 12 µl of double distilled water. The samples from the ACT 
study were treated with DNase before cDNA synthesis. 
From both sample sets 1 µl of isolated mRNA was used in a one step reverse 
transcription reaction with the SuperScript III one-step RT-PCR System (Invitrogen) 
and the remaining 10 µl were transcribed into cDNA with oligo dT primers and the 
RETROscript (Ambion). For the one step system the Pfresa specific primers a) and 
d) were used to amplify a ring stage-specific transcript and to distinguish PCR 
products originating from transcripts or genomic DNA. The designed oligonucleotides 
were intron spanning and thus allowed such differentiation and specific detection of 
viable asexual parasites circulating in the peripheral blood. To increase the sensitivity 
of the assay a second nested PCR was run using the first product as template. The 
primers used for this reaction were also resa specific (b and c) Table 2-2. 
The cDNA synthesised with oligo dT primers and the RETROscript (Ambion) was 
also analysed with a nested PCR protocoll and the Pfresa specific primer a) and d) in 
the first round and the primer pair b) and c) in the second round. The reaction was 
repeated at least three times for each sample. 
The sensitivity of the assay was determined with in vitro parasite culture. A dilution 
series was performed and parasite were detected down to 10 parasites /ml blood. 
This corresponds to 104 parasites in the total body and thus increases the sensitivity 
of 103 compared to a microscope. 
2.2.4.5 Merozoite surface protein 2 (msp2) genotyping 
Msp2 genotyping is a commonly used method to differentiate parasite lines in vivo. 
Recrudescent infections are distinguished from new infections after treatment. In the 
course of the Day 7 project the msp2 genotyping was used for the in vivo 
differentiation. But msp2 genotyping was also used to distinguish parasite 
populations in vitro after culture adaption of the isolated from the patients. 
The underlying mechanism is the restriction fragment length polymorphism of a 
highly polymorphic region of the genome: msp2. The alleles of msp2 fall into two 
allelic families (Smythe et al, 1990): 3D7 and FC27 with conserved regions and 
polymorphic repeat regions. 
A primary and a nested PCR were performed with specific oligonucleotides in a 
conserved region of the locus, as described by Felger and Beck (Felger & Beck, 
2002). Both reactions were performed with the same protocol and PCR program. 
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Protocol: 
1 x Reaction buffer with KCL   Fermentas 
200 µM d’NTP’s Mix    Fermentas 
1,5 mM MgCl2     Fermentas 
0,5 µM Oligonucleotide each   MWG or Invitrogen 
2,5u/50µl Taq Polymerase   Fermentas, 
 
 
     Table 2-8 Cycling conditions for msp2 genotyping. 30 cycles (Step2 – Step4) 
 
The amplified fragment was incubated over night at 37°C with HinfI to ensure 
complete digest. This specific pattern of fragments was analysed on an agarose gel. 
Both families are clearly distinguishable: in FC27 the restriction digest generates two 
conserved fragments (137bp at the 5’ end and 115 bp at the 3’ end). Between these, 
the two variable repeats are located (36bp and 96bp) The repeats themselves are 
conserved in size but vary in copy number. One 96bp repeat is present in all 
members of this family. If a second is present the fragment will appear on the gel with 
increasing intensity. The 36bp repeat is responsible for the variable and countable 
fragments on the gel. One 36bp repeat results in a 162bp fragment, two repeats give 
a fragment of 234 and three of 270bp. Exceptions to this rules are described, one of 
them being a partial deletion reducing the size of the 162bp fragment to 126bp 
(Felger & Beck, 2002). 
3D7 the representative of the second family is also characterized by two conserved 
fragments (70 and 108bp), both originating from the 3’ end of the msp2 PCR product. 
One, further variable fragment is generated by the restriction digest but the variable 
region of 3D7 is not as clearly definably as in the FC27 family since the repeats not 
only vary in copy numbers but also in size. If the two conserved fragments are 
subtracted, a variable fragment of approximately 250 to approximately 550bp results. 
Initial denaturation of the template DNA 4:00 min 94°C 
Denaturation of the DNA (Step 2) 0:30 min 94°C 
Annealing of the oligonucleotides (Step 3) 2:00 min 55°C 
Extension of the fragments by the Taq polymerase (Step 4) 2:00 min 70°C 
Final Extension to ensure complete amplification 7:00 min 72°C 
Pause  4°C 
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3. Results 
3.1 Drug parasite interaction in vivo 
Malaria control relies mainly on prompt and effective case management of 
uncomplicated disease episodes. The efficacy of the chemotherapeutic regimens is 
commonly determined by the in vivo test in which parasite persistence or 
reappearance is monitored for up to 8 weeks through microscopic analysis of blood 
smears. 
Here, the attempt was made to replace this long lasting and rather insensitive test by 
a more sensitive method at an earlier time point, i.e. 7 days after initiation of 
treatment of infection. Particularly the discrepancy between prolonged parasite 
clearance time in vivo and the absence of an increased 50 % growth inhibition 
concentration in vitro, show the importance of new tools to detect arising drug failure. 
The results are presented in the following paragraph.  
The project was embedded in two clinical studies: an in vivo efficacy trial of 
amodiaquine and a comparative study of two artemisinin combination therapies 
(ACTs): artemether-lumefantrine (AM-LM) and dihydroartemisinin-piperaquine (DHA-
PPQ). Both were conducted at the Pingilikani Clinical Trial facility as acollaborative 
peoject between the Dep. Of Infectious Disease, Heidelberg University School of 
Medicine (PI Dr. Steffen Borrmann) and the Kenya Medical Research Institute 
(KEMRI), Centre for Geographic Medicine Research-Coast (CGMR-C) (Directors 
Prof. Kevin Marsh and Dr. Norbert Peshu), which is located 20 km south of the town 
of Kilifi, on the Kenyan coast. 
3.1.1 Artemether – lumefantrine and dihydroartemisin – piperaquine  
The project was embedded in a comparative study in which patients received either 
AM-LM or DHA-PPQ. Samples were collected on day 7 after start of treatment and 
processed and analysed as described in 2.2.4.4. 
In 48/105 (45.7%) samples we detected metabolically active persistent asexual 
parasites 7 days after start of treatment (i.e., 4 days after last dose) (Figure). This 
high proportion contrasts with a three-fold lower Kaplan-Meier estimated failure rate 
of 15% by day 84 across both treatment groups. Persistence of infection on day 7, 
however, poorly agreed with subsequent recrudescence at the individual level. 
Twenty-nine children with detectable parasite populations surviving in their blood on 
day 7 either cleared the parasites in the following 77 days or were re-infected, as 
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determined by msp2 genotyping. And 18 patients with undetectable parasite 
population presented with recrudescent parasites in the following 21 days. This 
discrepancy did not depend on treatment. In the patient group treated with DHA-PPQ 
45.83 % had cleared the parasites by day 7 and 45.61% in the AM-LM group. 
Therefore I studied the relationship between potential confounding factors such as 
age as the best-established clinical correlate of acquired immunity, baseline parasite 
density, during-treatment parmacodynamic parameter (24-hour parasite reduction 
ratio) and 7 plasma concentrations of the long half-life companion drugs LM-PPQ. 
LM and PPQ are expected to remove residual and potential resistant parasite 
populations, which may have survived the potent but short acting doses of AM or 
DHA, respectively. Because transmission intensity decreased over the last years in 
Kilifi (O’Meara et al., 2008), we decided to split the analysis in two periods (2005-
2006 and 2007-2008). 
In Figure 3-1 a box graph depicts the median baseline parasite densities in patients 
with or without subpatent parasitaemia on day 7. Panel A shows the results obtained 
from the first phase of the study, panel B from the second phase of the study. We 
found that baseline parasite density correlated with prevalence of subpatent 
parasitaemia on day 7 in the second (p<0.03), but not the first, phase of the study 
suggesting that predicted decline in immunity over the same time period exposed the 
expected relationship between initial parasite biomass and persistence (Figure 3) 
and thus, indirectly also supported the validity of my sensitive RT-PCR approach.  
Figure 3 Box plots of baseline parasite density over PCR results on day 7. A) Phase 
one (2005 – 2006) B) Phase two (2007 – 2008) The parasite density at baseline did not 
significantly differ between patients who had cleared parasites by day 7 and those carrying 
subpatent parasitaemia during the first period of the study (A). In the second period of the 
study (B) the parasite density at baseline showed a significant increase in patients with 
subpatent parasitaemia on day 7 (p<0,03) 	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Figure 3-1 shows that prevalence of subpatent parasitaemia on day 7 is independent 
of the parasite reduction ratio within the first 24 hours after treatment. Again panel A) 
shows the results obtained from the first phase of the study, panel B) from the 
second phase of the study. We found that the 24 hours parasite clearance ration (the 
best available in vivo correlate of drug potency in an infection at peak plasma 
concentration) was not associated with persistence of parasite until day 7 after 
treatment. This was surprising since I had postulated that parasite persistence by day 
7 would primarily be related to drug effects. 
 
Figure 3-2 demonstrates that the observed prevalence of subpatent parasitaemia on 
day 7 cannot be explained by differences in PPQ or LM plasma concentration of 
individual patients. During the entire period of the study, no difference in plasma 
concentration of PPQ or LM was observed between patients presenting with 
subpatent parasitaemia and patients, who had cleared parasites on day 7. 
Figure 3-2	  Box plot of Day 7 piperaquine (A) and lumefantrine (B) concentration over 
PCR results on day 7. Piperaquine and lumefantrine serum concentration on day 7 
showed no clear relationship over the both phases of the study and between the two 
groups. 
	  
Figure	   3-1 Box plot of parasite reduction ratio by 24 hours and subpatent 
parasitaemia on day 7. A) Phase one (2005 – 2006) B) Phase two (2007 – 2008). No 
difference in the parasite elimination rate was found in the two groups with subpatent and 
cleared parasite by day 7 in the two periods of the study.	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Intriguingly, I found a strong correlation of platelet counts on day 0 with the 
prevalence of subpatent parasitaemia on day 7 (Figure 3-3). Patients were 
categorised according to baseline platelet counts (<125,00/µl or >125,00/µl). The y-
axis represents the proportion of subpatend infections by day 7. Interestingly the 
platelet counts on day 0 were inversely correlated with clearance of parasites by day 
7  (Figure 3-3) suggesting either a direct killing effect (McMorran et al, 2009) and/or 
perhaps, progressive depletion of platelets.  
 
Finally, I studied the effect of patient age as clinical correlate of acquired immunity on 
the day 7 prevalence of subpatent infections. Figure 3-4 shows that patient age was 
not associated with the prevalence of parasitaemia on day 7 in the first phase of the 
study. I detected a weak association with age and prevalence of parasites in day 7 
(p=0.13) the first phase of the study. 
 
Figure 3-3	   Bar charts showing the relationship between subpatent P. falciparum 
infections and platelet counts on day 0. A) Phase one (2005 – 2006) B) Phase two 
(2007 – 2008) In both periods of the study a significant correlation was found for the two 
parameters. Higher baseline platelets counts were associated with a negative PCR result on 
day 7 (p < 0.014 Phase 1, p < 0.03 Phase 2) 
	  
Figure 3-4	  Correlation of age with persistence of subpatent parasitaemia until day 7 
A) Phase one (2005 – 2006) B) Phase two (2007 – 2008) In the first phase of the study, 
older patients were more likely to clear the parasites until day 7. In the second phase of 
the study no difference in age was found in the two groups. 
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In summary, I found a poor correlation between presence of asexual parasites on 
day 7 as a marker of incompletely eliminated persistent blood stage infections and 
subsequent risk of recrudescence. Vice versa, we failed to detect asexual blood 
stage infections in children who later experienced recrudescence of their primary 
infection according to msp2 genotyping, likely reflecting the difficulty of capturing very 
low biomass infections due to daily fluctuations in sequestered vs. circulating blood 
stage forms. 
Interestingly, I observed that baseline parasite density correlated with prevalence of 
subpatent parasitaemia on day 7 in the second, but not the first, phase of the study 
(Figure 3-1) correlating with a predicted decline in adaptive immunity over the same 
time period, which may have exposed an expected relationship between initial 
parasite biomass and persistence. The weak association with age in the first phase 
of the study (Figure 3-4) supports this interpretation. Platelets, an important 
component of the innate immune defence against microbial pathogens, were strongly 
associated with clearance of infections by day 7 (Figure 3-3). 
3.1.2 Amodiaquine 
The results presented in this paragraph were obtained from patients, enrolled in an in 
vivo efficacy trial of amodiaquine (Sasi et al, 2009) in the years 2005 and 2006 at the 
same time as the first period of the previously presented data on ACT 3.1.1. 
In 16/51 (31%) samples we detected metabolically active persistent asexual 
parasites 7 days after start of treatment (i.e., 4 days after last dose). Persistence of 
infection on day 7, however, poorly agreed with subsequent recrudescence at the 
individual level. Age as a reliable indicator of acquired immunity did not correlate with 
our results obtained on day 7. Likewise, children with or without positive samples on 
day 7 differed only marginally in the initial parasite load Figure 3-5 
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Figure 3-5 A) Correlation of age with persistence of subpatent parasitaemia until day 
7, B) Box plots of baseline parasite density over PCR results on day 7.  
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3.2 In vitro characterisation of phenotypic and genotypic 
signatures of naturally acquired drug resistance in P. 
falciparum 
The focus of the analysis was the folate pathway involving the anti-folates 
pyrimethamine, cycloguanil (one active metabolite of proguanile) and trimethoprim to 
assess in vitro sensitivity.  
In the following paragraphs I will describe the genotypic analysis of parasite isolates 
collected from children with uncomplicated P. falciparum malaria in Kilifi, Kenya. I will 
correlate these results with in vitro drug response rates of culture-adapted parasites.  
3.2.1 Culture adaption of parasites and msp2 genotyping 
Paediatric patients presenting with uncomplicated P. falciparum malaria at the 
Pingilikani clinic in coastal District of Kilifi often carry multiple infections determined 
by msp2 genotyping on the day of admission and the day of recurrence (Sasi et al, 
2009). Parasites were culture adapted from the same blood and thus the starting 
material for culture adaptation was not necessarily a homogenous parasite 
population but consisted of up to 6 clones as shown below in Table 3-1. The 
procedure of adapting parasites to culture can take several weeks and only when the 
parasites showed a constant replication rate at standard culture conditions, genomic 
DNA was isolated and their in vitro response to drugs were analysed. The adapted 
parasites were compared to the initial parasites population in the patient. This 
analysis gave insights in diversity and survival rate when adapting parasites from in 
vivo to in vitro culture. 
Figure 3-6 A) shows the electrophoretic mobility of PCR-amplified msp2 fragments 
after HinfI restriction on 4% agarose gel (2% tiny agaorse, 2 % standard agarose). 
Pairs of lanes are labelled with isolates IDs.  
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Table 3-1 the results obtained from the Hinf I restriction digest of the msp2 locus in 
Figure 3-6 are analysed and represented in a tabular format. Clones were counted by 
three independent persons and assigned to the 3D7 and FC27 two families at 
admission and after culture adaption.  
Figure 3-6 Hinf I restriction digest of msp2 locus on agarose gel. The first lane of each pair 
shows the analysis of parasite population directly isolated from the patient. The second lane the 
results obtained from the parasites population surviving the adaption to culture for four weeks and 
more. In B) the picture is inversed. The first lane shows the analysis of culture adapted parasite 
population and the second lane the initial parasite population directly isolated from the patient. 
Above the panel the letters indicate from which study the samples were isolated. AK : ACT study, 
AQ: amodiaquine study and the numbering indicates the patient number. Black bars with size 
indication (kilobases) at either side mark the conserved fragments 2.2.4.5 of the 3D7 and the 
FC27 families generated by a Hinf I restriction. 	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Most of the isolates appear to consist of multiple clones (multiple infection). Out of 
the 20 isolates analysed with this method only AK 649 showed a single infection. The 
remaining 19 isolates were multiple infections consisting of two to six clones. In 
summary, we detected an average of 3.4 clones / patient. 
During the procedure of cell culture adaption 4 isolates lost all their clones except 
one (AQ 84, AK 560, AK 648, and AK 668). They can therefore be regarded as clonal 
parasite populations in the following work. In these cases the predominant clone from 
the infection is not always identical with the predominant parasite clone in the 
adapted culture. In the two isolates AQ 84 and AK 648 the different clones at 
admission contribute in comparable size to the total parasite biomass and one of 
these equally represented clones survived the adaption to culture.  
 
 
Table 3-1 Analysis of the Hinf I restriction digest of the MSP 2 locus. Number of clones of 
each family was counted before and after cell culture adaption. (I) one clone, (-) no clone. 
 
 
 
Parasites isolated 
directly from patient 
Parasites isolated 
from adapted cell culture 
Isolate Nr. Nr. clones FC 27 Nr. Clones 3D7 Nr. clones FC 27 Nr. Clones 3D7 
AQ 20 IIII - IIII - 
AQ 22 - II - II 
AQ 28 IIII - II - 
AQ 43 IIII - IIII - 
AQ 73 III II I I 
AQ 74 I II I II 
AQ 75 - III - II 
AQ 84 I I - I 
AQ 86 I III - III 
AQ 89 III III II I 
AQ 104 I III - II 
AQ 105 I II I II 
AQ 121 I  I I I 
AQ 124 II - II - 
Art 560 III I - I 
Art 582 II I I I 
Art 589 II I II - 
Art 648 III II - I 
Art 649 - I - I 
Art 668 I III - I 
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In the two isolates AK 560 and AK 668 one minor clone, which was initially 
represented by a very week band became the predominant clone in culture. From the 
16 remaining isolates a variable number of parasites survived the procedure of 
culture adaption. These cultures are non-clonal parasite population in culture.  
In summary, we detected an average of 2.15 clones/culture and a loss of 1.25 
(36.8%) clones per culture adaption procedure. Figure 3-7 shows the loss of clones 
through culture adaption.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Multiplicity of infection before and 
after culture adaptation. The magenta box 
shows the mean number of clones carried by the 
patients. The white box indicated the mean 
number of clones surviving in a culture adaption of 
each infection (p < 0.0009) 
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3.2.2 Analysis of P. falciparum isolates after natural exposure 
The culture-adapted parasites were analysed for single nucleotide polymorphisms 
(SNP) and copy number variation (CNV). The phenotypic analysis was performed in 
an assay with chloroquine, trimethoprim, cycloguanil and pyrimethamine.  
The genetic analysis was only performed with the five enzymes directly involved in 
the folate pathway. These are: GTP cyclohydrolase (Pfgch, PFL1155w), 6-
pyruvoyltetrahydropterin synthase (Pfptps, PFF1360w), dihydropteroate synthetase 
(Pfdhps, PF08_0095), dihydrofolate synthase / folylpolyglutamate synthase (Pfdhfs 
PF13_0140) and bifunctional dihydrofolate reductase-thymidylate synthase (Pfdhfr 
PFD0830w). I analysed for SNP’s by sequencing and for CNV’s by a real time PCR 
assay. 
3.2.2.1 Single nucleotide polymorphisms in enzymes of the folate pathway 
A genotypic analysis of the folate pathway was performed in the set of field isolates 
described above. The five enzyme of the pathway were sequenced with the primer 
pairs listed in the methods parts (Table 2-2 and 2.2.1.11) and the sequencing reaction 
was performed and analysed as described. 
Pfgch (PFL1155w) 
Two single nucleotide polymorphisms (SNPs) are annotated on PlasmoDB  
(www.plasmodb.org	  Version 6.2, 13 Nov 09)	  at nucleotide position 262 and 689. One 
of our isolates (AQ 89) showed an adenine instead of a guanine at position 689. This 
exchange results in an amino acid substitution (230) replacing arginine by lysine. 
When aligning the protein sequence from E. coli in which the active sites of the 
enzymes are well characterised (Nar et al, 1995), the result shows that this exchange 
is right next to one of the key amino acids of the active site Figure 3-8.  
Figure 3-8 Amino acid alignment of active site of GTP cyclohydrolase E. coli and of 
Plasmodium falciparum. In yellow the active residues for E. coli (Nar et al, 1995) are shown 
in cyan the position in the protein. The red mark shows the amino acid exchange in isolate 
AQ 89, right next to an active site residue. 
 
                    65  68  
EcGCH 39  IAGHMTEIMQLLNLDLADDSLMETPHRIAK--MYVDEIFSGLDYANFPKITLIENKMKVD  96 
         I+ H+ +I+ +  L   D  L  T  R A+  +Y+   ++ LD     K +L +   K + 
PfGCH 206  ISKHIYKILNISKLPKCD-ILKRTNRRYAETFLYLTNGYN-LDIEQIIKRSLYKRMYKNN  263 
  
  AQ 89  K 
 
 
               110 112/3                132 135/6 138           151/2 
EcGCH 97  EMVTVRDITLTSTCEHHFVTIDGKATVAYIPKDSVIGLSKINRIVQFFAQRPQVQERLTQ  156 
  ++ V  I + S C+HH +  +G   + YIP   +IGLSK +RIV  F++R Q+QE LT  
PfGCH 264 SIIKVTGIHIYSLCKHHLLPFEGTCDIEYIPNKYIIGLSKFSRIVDVFSRRLQLQEDLTN  323 
 
 
  
                      179 181  185 
EcGCH 157 QILIALQTLLGTNNVAVSIDAVHYCVKARGIROATSATTT  196 
            I  AL+  L    + VSI A H C+  RG++   + T T 
PfGCH 324 DICNALKKYLKPLYIKVSIVAKHLCINMRGVKEHDAKTIT  363 
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The amino acids defining the active site are highlighted in yellow. The position at 
which I found a nucleic acid substitution is marked in red. Whether this amino acid 
substitution has consequences for the activity and efficiency of the enzyme or 
whether it is involved in development of resistance further downstream the pathway 
remains to be solved.   
In addition, I found two previously unidentified synonymous point mutations at 
nucleotide position 327 and 564 in isolates AQ 121 and AK 560 respectively. 
 
Pfptps (PFF1360w) 
No SNP is currently annotated on PlasmoDB for ptps (www.plasmodb.org Version 
6.2, 13 Nov 09). In the isolates I only found one SNP at the nucleotide position 5. 
Thymine is replaced by a guanine resulting in an amino acid exchange from 
methionine to arginine. The sequence published on PlasmoDB starts with ATGATG, I 
found that one of our isolates showed the sequence ATGAGG, indication of a 
potential different transcription start site. 
Pfdhps (PF08_0095) 
Pearce et al, identified five major haplotypes, when analysing samples from 50 
locations across Africa from 1997 until 2007 at nucleic acid position S436A/F, A437G 
and K540E of Pfdhps (Pearce et al, 2009). Three resistant haplotypes SGE, SGK 
and AGK were previously identified. SAK is regarded as the ancestral haplotype and 
AAK as an alternative wild type haplotype. In our samples, collected on the Kenyan 
cost, I found two isolates (AQ 20 and AQ 105) carrying the ancestral SAK haplotype. 
All the remaining isolates harboured the SGE haplotype, dominant in East Africa 
(Pearce et al, 2009).  
The mutation at nucleotide position 581 described to emerge in northern Tanzania 
(Gesase et al, 2009) was not found in our set of samples from Kilifi, Kenya.  
Pfdhfs (PF13_0140) 
Two nucleotide polymorphisms are known at codon positions 1 and 75. No mutation 
was found within the first 520 nucleotides of this gene. 
Pfdhfr (PFD0830w) 
It has been shown that several specific nucleotides substitutions in Pfdhfr result in an 
amino acid changes and thereby confer a stepwise increase of resistance to anti-
folates (Sirawaraporn et al, 1997). The genomic sequence of dhfr was fully 
sequenced in the isolates presented here.  
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All the isolates (21/21, 100%) harboured the codon-changing mutations from Ser to 
Asn at codon position 108 (S108N) and 19 out of 21 (90,5%) also harbour the 
substitution of Asn by Ile at codon position 51 (N51I). The mutation from Cys to Arg 
at the codon position 59 (C59R) was detected in 14 out of 21 (66,6%). No mutations 
were found at the codon positions 16, 164 and 184 (0/21, 0%).  
The two major haplotypes, AIRNIT (14/21, 66,6%) and AICNIT (5/21, 23,8%) were 
found in the parasite population from Kilifi. One parasite was found with the rare 
haplotype ANRNIT (AQ 74, same as Dd2) and another parasite with haplotype 
ANCNIT (AQ 86). AQ 86 was the only isolate with only one point mutation at all six 
known polymorphic positions. However I found an additional previously unidentified 
synonymous mutation at position 533. Because the SNP is located at the binding site 
of the real time probe for dhfr I was unable to generate dhfr gene copy data for this 
isolate. 
In summary, I found 12 isolates harbouring the triple-mutant dhfr (N51I, C59R and 
S108N) and the double-mutant dhps (A437G and K540E), associated with highly 
resistant phenotypes for pyrimethamine and sulfadoxine, respectively. Six isolates 
were double mutant dhfr (one with C59R and S108N instead of N51I and S108N) 
and double mutant dhps. Two isolates were triple-mutant dhfr but wild type or 
sensitive at the dhps locus. And one isolate harboured only the S108N at the dhfr 
locus but double mutation at dhps. 
In addition to the commonly found SNPs, we found one previously unidentified SNP 
in the dhfr gene and one amino acid substitution adjacent to the predictive active site 
of gch. 
3.2.2.2 Copy number variations (CNV) in enzymes of the folate pathway 
I analysed copy number variations (CNV) in the folate pathway genes with a real time 
PCR based assay described in chapter 2.2.1.13. The field isolates were analysed in 
reference to the P. falciparum laboratory strains: 3D7, FCR3, Dd2 and D10. Genomic 
DNA (2.2.1.1) for the assay was isolated from regular adapted parasite culture 
(chapter 2.2.3.1). To control the amount of DNA used in each reaction, I used the 
gene coding for β-tubulin (PF10_0084) as internal control.  
The methodology allows a robust relative quantification of copy numbers. To facilitate 
the interpretation, the copy number from the reference genome is always set at one.  
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Pfgch copy number variation in field isolates 
First the available laboratory strains (3D7, FCR3, Dd2, D10, 7G8, HB3 and NF54) 
were analysed for copy number variation (CNV) with the established assay. In Figure 
3-9 the graph displays the relative gene copy numbers of the individual laboratory 
strains in reference to D10. The parasite lines Dd2 and D10 were found to give the 
lowest value for GCH copy numbers and were therefore used as reference genome 
for the analysis of the field isolates. 
3D7, FCR3 and NF 54 show significantly more genomic copies of gch compared to 
D10, Dd2 and HB3. The bigger error bar in 3D7 may indicate heterogeneity in the 
parasite population, i.e. there are genomes with 3 and some maybe 4 copies of the 
gene. The genotype seems to be stable, as no reduction in the signal was observed 
over the culturing period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The field isolates were then measured in reference to Dd2 and the results are shown 
in Figure 3-10 on the x-axis the 21 different field isolates are plotted with their initials 
and on the y-axis the relative copy numbers are indicated. One isolate was measured 
in at least 3 independent assays. 
While no significant variation in gch copy numbers was found within the field isolates 
and in comparison with the two reference genomes Dd2 and D10, 3D7 and FCR3 
Figure 3-9 P. falciparum GTP cyclohydrolase gene copy 
numbers in laboratory strains. Gene copy numbers were 
analysed in a real time PCR assay, in which β-tubulin served 
as internal control. Means with standard deviation are plotted 
in the graphic, each bar representing the result from at least 
independent experiments. D10 served as reference genome 
since this strain gave the lowest value. 
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had significantly more (p<0.001) genetic copies compared to Dd2 and compared to 
the field isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pfdhfr copy number variation in field isolates 
The 20 isolates of this study were analysed for copy number variances at the dhfr 
locus. First the available laboratory strains (3D7, FCR3, Dd2, D10 and 7G8) were 
analysed for copy number variation (CNV) with the established assay. The results 
show no significant variation within the laboratory strains Figure 3-11.  
The results for the field isolates are shown in Figure 3-12. On the x-axis the 21 
different field isolates are plotted with their initials and on the y-axis the relative gene 
copy numbers are indicated. One isolate was measured in at least 3 independent 
assays and the means with standard deviations are plotted in the graphic, each bar 
representing the results for one parasite isolate. 
No significant variation in Pfdhfr copy numbers was found in the field isolates from 
Kilifi and in comparison with the two reference genomes 3D7 and FCR3. 
Figure 3-10 P.falciparum GTP cyclohydrolase gene copy 
numbers in field isolates from Kilifi (purple), Kenya. Gene 
copy numbers were analysed in a real time PCR assay, in 
which β-tubulin served as internal control. Means with standard 
deviation are plotted in the graphic, each bar representing the 
result from at least independent experiments. Dd2 served as 
reference genome. 3D7 (grey) and FCR3 (black) are also 
shown on the graph as control AQ: samples from amodiaquine 
study, AK: samples from ACT study. 
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The isolate AQ 86 gives no signal at the locus under investigation as the isolate 
carries a rare point mutation (3.2.2.1) in the sequence were the real time probe binds 
to the DNA. I confirmed the presence of the dhfr gene using conventional PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11 P. falciparum dhfr gene copy numbers in 
laboratory strains. Gene copy numbers were analysed in a 
real time PCR assay, in which β-tubulin served as internal 
control. Means with standard deviation are plotted in the 
graphic, each bar representing the result from at least 
independent experiments.  
 
Figure 3-12 P.f. DHFR gene copy numbers in field isolates 
from Kilifi (purple), Kenya. Gene copy numbers were 
analysed in a real time PCR assay, in which β-tubulin served 
as internal control. Means with standard deviation are plotted 
in the graphic, each bar representing the result from at least 
independent experiments. Dd2 served as reference genome. 
3D7 (grey) and FCR3 (black) are also shown on the graph as 
control AQ: samples from amodiaquine study, AK: samples 
from ACT study. 
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3.2.2.3 Phenotypic analysis of field isolates 
The same P. falciparum isolates, which were adapted to culture and genotyped for 
SNPs and CNVs were subjected to a phenotypic analysis. The in vitro drug response 
rate for anti-folates was measured with a validated and well-established 
fluorescence-based assay described in chapter 2.2.3.4. I tested the activities of 
pyrimethamine (Figure 3-16), cycloguanil (Figure 3-15) and trimethoprim (Figure 3-14). 
Chloroquine (Figure 3-13) served as experimental control.  
In Figure 3-13 the IC50 results for chloroquine are presented. The measured IC50 
values vary between 10 nM and 350 nM. The results can be divided into two clearly 
distinct groups. 3D7 and 9 out of 21 parasites (42,9%) had an IC50 value smaller than 
25 nM and are therefore considered sensitive to the drug. For Dd2, FCR3 and 12 
isolates (57,1%) an IC50 value of greater than 100 nM was measured. These strains 
are therefore considered resistant to the drug. The responsiveness against 
chloroquine did not correlate with any SNP combination of dhfr. 
The results are in accordance to the previously reported decline of chloroquine 
resistant phenotypes after its withdrawal in Kenya (Mwai et al, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13 Chloroquine in vitro response rates in Kenyan 
P.f. isolates. (cyan) triple dhfr mutant, (purple) double dhfr 
mutant I, (yellow) single dhfr mutant, (black) double dhfr mutant 
II, (grey) 3D7 and FCR3. IC50s were calculated for each isolate 
from at least three independent experiments and are plotted in 
nM on the y-axis. The isolates are sorted on the x-axis by IC50 
values < 100nM and >100nM. AQ is the abbreviation for 
samples originating from the amodiaquine study and AK for 
samples originating from the ACT study. The numbers indicate 
from which patient the isolate is adapted. 
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In Figure 3-14 the in vitro response rates for trimethoprim are shown. The measured 
values vary between 0,6 µM and 380 µM. The results cannot be divided into distinct 
groups but follow a steady increase. In 13 out of 21 isolates (61,9%) the determined 
IC50 was smaller than 200 µM. Only 8 out of 21 (38,1%) showed a value greater than 
200 µM. 3D7 with 4 µM and FCR3 with 0,6 µM have to be considered as the most 
sensitive strains from the parasites measured in this work.  
The responsiveness against trimethoprim did not correlate with any significant SNP 
combination of Pfdhfr (p=0.2238). Only FCR3 with a very particular haplotype (A16V 
and S108T) at the dhfr locus shows a significantly (p=0.0039) higher responsiveness 
against trimethoprim. The presumably wild type 3D7 with no mutations in dhfr was 10 
fold less sensitive against trimethoprim. But since only one parasite strain with the 
combination of mutation A16V and S108T was available, no general conclusion can 
be drawn from this result.  
AQ 86 with a single mutation at position S108N is the most sensitive one of the 
collected field isolates. AQ 74 could not be measured, as the responsiveness was so 
low that the values lay outside of the measurable range of the assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14 Trimethoprim in vitro response rates in Kenyan 
P.f. isolates. (cyan) triple dhfr mutant, (purple) double dhfr 
mutant I (yellow) single dhfr mutant, (black) double dhfr mutant 
II, (grey) 3D7 and FCR3. IC50 were calculated for each isolate 
from at least three independent experiments and are shown in 
µM on the y-axis with standard deviation. The isolates are sorted 
on the x-axis by increasing IC50 values. AQ is the abbreviation 
for samples originating from the amodiaquine study and AK for 
samples originating from the ACT study. The numbers indicate 
from which patient the isolate is adapted. 
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In Figure 3-15 the measured IC50 values for cycloguanil are given. The measured 
values vary between 160 nM and 3400 nM with no distinct groups of responses. 3D7 
with a mean 14,35 ± 6.2 nM is the most sensitive strain and FCR3 with 3265 ± 1267 
nM one of the most resistant ones. The IC50 values for cycloguanil correlated 
significantly (p=0.004) with dhfr haplotypes. AQ 86 (yellow bar), which harbours only 
a single SNP at codon position S108N, had the lowest mean IC50 in the studied field 
isolates (264,7 ± 26,03 nM). The five neighbouring parasite isolates were found to 
harbour two SNP’s, at the codon position S108N and N51I (purple bars). The 
parasite isolates with a cyan coloured bar were found to be triple mutant. FCR3 with 
the particular haplotype (A16V and S108T) was highly resistant to cycloguanil. This 
finding points towards an inverse mechanism of resistance of cycloguanil and 
trimethoprim, to which FCR3 was highly sensitive (Figure 3-14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-15 Cycloguanil in vitro response rates in Kenyan 
P.f. isolates. (cyan) triple dhfr mutant, (purple) double dhfr 
mutant I (yellow) single dhfr mutant, (black) double dhfr mutant 
II, (grey) 3D7 and FCR3. IC50 were calculated for each isolate 
from at least three independent experiments and are shown in 
nM on the y-axis. The isolates are sorted on the x-axis by 
increasing IC50 values. AQ is the abbreviation for samples 
originating from the amodiaquine study and AK for samples 
originating from the ACT study. The numbers indicate from 
which patient the isolate is adapted. 
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Interestingly the two less commonly found double mutant (C59R with S108N) in AQ 
74 (black bar) and Dd2 (black bar) clustered with the triple mutant (cyan) and not with 
the commonly found double mutant (N51I S108N) in purple, suggesting that the 
mutation at position 59 is more important for the development of cycloguanil 
resistance.  
Figure 3-16 shows the IC50 values for pyrimethamine. The mean values vary between 
26 nM and 80 µM. 3D7 and FCR3 were the most sensitive strains with means of 
26.84 nM ± 1.8 nM and 61.37 nM ± 31.3 nM respectively. The most sensitive Kilifi 
isolates was AQ 86 with a mean of 6.8 µM. There was a correlation between the 
number of mutated residues in dhfr and the in vitro responsiveness against 
pyrimethamine (p=0.041).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16 Pyrimethamin in vitro response rates in Kenyan 
P.f. isolates. (cyan) triple dhfr mutant, (purple) double dhfr 
mutant I (yellow) single dhfr mutant, (black) double dhfr mutant 
II, (grey) 3D7 and FCR3. IC50 values for each isolate were 
calculated from at least three independent experiments and are 
shown in µM on the y-axis. The isolates are sorted on the x-axis 
by increasing IC50 values. AQ is the abbreviation for samples 
originating from the amodiaquine study and AK for samples 
originating from the ACT study. The numbers indicate from 
which patient the isolate is adapted.The dashed black line 
indicates pyrimethamine peak plasma concentration, measured 
after a single dose of SP . 
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The maximum plasma concentration of pyrimethamine after a single dose of SP was 
estimated at 860 µg/L (35 µM) (Minzi et al, 2007). Seven out of 21 Kilifi isolates 
displayed IC50 values greater than the peak plasma concentration of pyrimethamine. 
Only fourteen isolates showed an IC50 value below that. Considering that IC50 values 
are well below the minimum inhibitory concentration (IC99), it is obvious that parasites 
have developed high levels of resistance. 
In summary, anti-folate resistance appears to be highly prevalent in Kilifi. Resistance 
is due to SNPs and not to CNV, which were not detected. 
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3.3 Induction of drug resistance in vitro 
In the human host, parasites are exposed to a variety of factors determining the 
parasite’s survival and, its propagation. The immune status and the genetic 
disposition, pharmacokinetic properties and potency of the drug are important 
determinants. The complex interactions between these factors make it difficult to 
assign causes and effect. 
To directly study the impact of a drug on the parasite and its ability to adapt and 
escape drug pressure, I performed a drug pressure experiment as described in 
2.2.3.5. 
3.3.1 Drug pressure experiments in vitro 
There are two well-described genetic mechanisms for the development of drug 
resistance in Plasmodium falciparum: amplification and single point mutations at 
gene loci coding for drug target or drug transporter proteins. Thus far, both 
mechanisms have been regarded as entirely independent outcomes of selection. In 
the present work I studied the relationship between these two mechanisms. The 
results presented in this chapter strongly suggest that gene amplification is an 
important intermediate step that accelerates the acquisition of single point mutations. 
This question was addressed with the development of anti-folate resistance in vitro in 
the two parasite strains 3D7 and FCR3. I have confirmed that gch, the first enzyme of 
the folate pathway, is amplified in some lab strains (Figure 3-9). In contrast to data 
from Thailand I did not find evidence of amplification in our set of samples from Kilifi 
(Figure 3-10). Downstream of gch, the pyrimethamine drug target dhfr confers 
resistance to pyrimethamine by a series of three to four single point mutations in a 
step-wise manner (Sirawaraporn et al, 1997).  
3D7 and FCR3 were subjected to increasing pyrimethamine pressure over a period 
of 10 months. Gene expression analysis was performed, parasite genomic DNA was 
analysed for gene amplification and emergence of single point mutations. 
Phenotypically the parasites were analysed in in vitro growth inhibition assays. 
3.3.1.1 Phenotypic analysis in vitro drug response rate after adaption 
Two laboratory strains 3D7 and FCR3 and three Kilifi isolates (AQ 84, AQ 86 and AQ 
104) were subjected to sequentially increased pyrimethamine pressure over a period 
of 10 months. The experiment started with pyrimethamine concentration of 20 nM 
and was then stepwise increased up to 1600 nM. The protocol is described in detail 
in chapter 2.2.3.5.  
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Phenotypic characterisation was performed at baseline and whenever parasite 
replication rates had adapted to 200 nM (3D7200nM, FCR3200nM), 800 nM (3D7800nM, 
FCR3800nM) and 1600 nM (3D71600nM, FCR31600nM) of pyrimethamine in the medium. 
The IC50 values for chloroquine, pyrimethamine, cycloguanil and trimethoprim were 
determined (Figure 3-17, Figure 3-18, Figure 3-19 and Figure 3-20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As expected, pyrimethamine drug pressure did not affect the responsiveness against 
chloroquine (Figure 3-17 and Table 3-2) demonstrating that the resulting resistant 
phenotype was a specific response to selection with pyrimethamine.  
IC50 values for the three anti-folates pyrimethamine, cycloguanil and trimethoprim 
correlated with rising drug pressure. 3D7 and FCR3 parasite strains not only lost their 
responsiveness against pyrimethamine to which they had been exposed but also to 
Figure 3-17 In vitro Chloroquine response rates during 
and after drug pressure experiment of 3D7 and FCR3. 
Both strains were adapted to 200 nM, 400 nM, 800 nM and 
1600 nM (x-axis) of pyrimethamine in a step-wise manner. 
IC50 (y-axis) for chloroquine were measured at each 
pyrimethamine concentration. (grey) 3D7, (white) FCR3. 
Each bar represents the mean with standard deviation of 
at least three independent experiments. 
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trimethoprim (Figure 3-19 and Table 3-2). 3D7 also became resistant to cycloguanil 
(Figure 3-20 and Table 3-2). This points clearly towards a mechanism of cross-
resistance, as none of the parasites have to the best of my knowledge ever been 
exposed to cycloguanil and trimethoprim.  
The IC50 value for pyrimethamine dramatically increased during the drug pressure 
experiment, for both lines. The values are plotted in Figure 3-18 and listed with 
standard deviation in Table 3-2.  In 3D7 a 10-fold increase of IC50 values was 
observed from baseline to 3D7200nM, a 250-fold increase from baseline to 3D7800nM 
and a 330-fold increase from baseline to 3D71600nM. In FCR3 a 4-fold increase of IC50 
values was observed from baseline to FCR3200nM, a 56-fold increase from baseline to 
FCR3800nM and a 86-fold increase from baseline to FCR31600nM. 
From these results, I concluded that the relationship between drug pressure and 
decreased responsiveness was not linear and that it may be better characterised by 
an exponential dose-response equation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18 In vitro pyrimethamine response rates during 
and after drug pressure experiment of 3D7 and FCR3. Both 
strains were adapted to 200nM, to 400nM, to 800nM and to 
1600nM (x-axis) of pyrimethamine in a step-wise manner. IC50s 
(y-axis) for pyrimethamine were measured at each 
pyrimethamine concentration. (grey) 3D7, (white) FCR3. 
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In the following it is shown that a cross-resistance with the two anti-folates, 
cycloguanil and trimethoprim, was generated in the selection process. Not only the 
IC50 values for pyrimethamine, the drug the parasite have been exposed to increases 
significantly but also the sensitivity against the two anti-folates cycloguanil and 
trimethoprim, decreased significantly. This is demonstrated by the increased IC50 
values for the two drugs. 
The results for trimethoprim (Figure 3-19) are presented in this paragraph. Exact 
values are listed in Table 3-3. In 3D7 a 5-fold increase of IC50 values was observed 
from baseline to 3D7200nM, a 22-fold increase from baseline to 3D7800nM and a 21-fold 
increase from baseline to 3D71600nM. In FCR3 a 3-fold increase of IC50 values was 
observed from baseline to FCR3200nM, a 35-fold increase from baseline to FCR3800nM 
and a 36-fold increase from baseline to FCR31600nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-19 In vitro trimethoprim response rates during and 
after drug pressure experiment of 3D7 and FCR3. Both 
strains were adapted to 200nM, to 400nM, to 800nM and to 
1600nM (x-axis) of pyrimethamine in a step-wise manner. IC50 
(y-axis) for trimethoprim were measured at each pyrimethamine 
concentration. (grey) 3D7, (white) FCR3. 
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In Figure 3-20 IC50 values of cycloguanil for 3D7 are shown before and after the 
exposure to pyrimethamine. Exact values with standard deviation are listed in Table 
3-2. In 3D7 a 9-fold increase of IC50 values was observed from baseline to 3D7200nM, 
a 28-fold increase from baseline to 3D7800nM and a 3-fold increase from baseline to 
3D71600nM. The IC50 for cycloguanil could not be measured in FCR3 parasites, as the 
baseline parasite population was already highly resistant to this drug (Figure 3-15). 
The exposure to the anti-folate pyrimethamine for several months further increased 
the resistant phenotype until the value lied outside of the measurable range of the 
assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary the results show a high degree of cross-resistance for the 3 anti-folate 
drugs. The increase of the IC50 values for pyrimethamine is most impressive with a 
>300-fold increase in 3D7. The cross-resistance for cycloguanil and trimethoprim is 
less developed (20- to 36-fold).  
Figure 3-20 In vitro cycloguanil response rates 
during and after drug pressure experiment of 
3D7. 3D7 was adapted to 200nM, to 400nM, to 
800nM and to 1600nM (x-axis) of pyrimethamine in 
a step-wise manner. IC50 for cycloguanil (y-axis) 
were measured at each pyrimethamine 
concentration.  
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Table 3-2 IC50 values for 3D7 and FCR3 before and during drug pressure experiment. 
Values were measured at baseline, 200nM, 800nM and 1600nM for chloroquine (CQ), 
pyrimethamine, cycloguanil and trimethoprim. (n.a.) not available. 
 3D7 
 CQ (nM) Pyrimethamine (nM) Cycloguanil (nM) Trimethoprim (nM) 
Baseline 16.12 ± 3.30 19.3 ± 7.1 10.59 ± 1.73 2031 ± 890.1 
200nM 8.45 ± 1.17 225.9 ± 9.1 94.4 ± 15.1 10759 ± 5628 
800nM 20.25 ± 1.14 4880 ± 958 293 ± 22 45645 ± 7541 
1600nM 17.64 ± 6.15 6446 ± 3230 344 ± 191 41934 ± 8541 
     
 FCR3 
Baseline 193.1 ± 43.45 61.37 ± 31 3630 ± 1163 533 ± 265 
200nM 196 ± 48 268 ± 55 n.a. 1831 ± 355 
800nM 319 ± 153 3470 ± 663 n.a. 18436 ± 5233 
1600nM 232 ± 40 5297 ± 560 n.a. 19032 ± 3758 
 
In the following paragraphs the results obtained from the in vitro drug pressure 
experiment are compared with parasites isolates from Kilifi, Kenya with different 
Pfdhfr hapolytpes. For this purpose 3 isolates were chosen with a constant 
replication rate in cell culture and a consistent phenotype correlating to three different 
Pfdhfr haplotypes. AQ 84, AQ 86 and AQ 104 were found to be suitable for the 
analysis. The isolate AQ 84 represents the group with a triple mutant (N51I, C59R 
and S108N), the isolate AQ 86 is an example with a single mutant (S108N), and AQ 
104 shows the phenotype of a double mutant (N51I and S108N). None of them 
showed any copy number variation in the Pfdhfr (Figure 3-12) and pfgch (Figure 3-10). 
The IC50 values were plotted separately for each drug for better comparison (Figure 
3-21). It can be seen that IC50 values of the drug-exposed parasites are comparable 
to IC50 values of AQ 86, which harbours only one dhfr SNP. The Kilifi isolates carrying 
two or more mutations exhibit higher resistant phenotypes for pyrimethamine, 
cycloguanil and trimethoprim than the isolate AQ86 and 3D71600nM and FCR31600nM. 
Two explanations are conceivable. First, it could be that 3D7 and FCR3 were 
exposed to lower drug pressure during the in vitro (1.6µM) experiment compared to 
Kilifi isolates in vivo. The peak plasma concentration of pyrimethamine after a single 
dose of SP (Fansidar®) was estimated 35µM (Minzi et al, 2007). The observed 
discrepancy between the IC50 values of the Kilifi isolates and the resistance-induced 
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parasites could therefore be explained by the difference of applied drug 
concentration. Then 3D71600nM and FCR31600nM have to be regarded as intermediate 
phenotype before the acquisition of a highly resistant phenotype. Or secondly, 
differences in the genetic background between the Kilifi isolates and the laboratory 
strains (3D7 and FCR3) limit the development of high anti-folate resistance in vitro. 
Figure 3-21 IC50 values in comparison to Kilifi isolates with four different Pfdhfr 
haplotypes. A) pyrimethamine B) cycloguanil C) Trimethoprim D) Chloroquine. (grey) 
3D7 and (white) FCR3. The coloured bars show IC50 of field isolates without being 
exposed to drug pressure and with different SNP combinations. (cyan) triple mutant 
dhfr, AQ 84 (N51I, C59R, S108N), (pink) double mutant dhfr, AQ 104 (N51I, S108N), 
(yellow) single mutant AQ 86 (S108N), (black) rare double mutant Dd2 (C59R, S108N). 
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3.3.1.2 Expression analysis of folate enzyme in the resistant strains 
Parasites adapted to pyrimethamine were subjected to an expression analysis of the 
five enzymes of the folate pathway. A real time PCR assay was used and the 
methodology is described in detail in chapter 2.2.1.13. Parasites (baseline and 
3D7200nM/FCR3200nM) were synchronised and then harvested at trophozoite stage with 
10% parasitaemia. mRNA was isolated, treated with DNase and cDNA synthesised 
for a quantitative real time PCR assay. To exclude genomic DNA contamination, a 
negative control with only mRNA was always run in parallel and the results were only 
analysed if no signal was detected in these samples. Ptps was never detected in the 
expression analysis (Figure 3-22). This may have been due to very low to absent 
expression in the trophozoite stage. Technical problems can be excluded, as the 
designed ptps probe produces a strong signal on genomic DNA (data not shown) and 
the same cDNA successfully served as template for the expression analysis of the 
four other enzymes. Gch and dhps showed minor fluctuation in expression (Figure 
3-22). Dhfs, the enzyme which catalyses the step in the folate pathway prior to dhfr, 
gave inconsistent results. Some, but not all runs indicated an elevated expression in 
lab and field strains (data not shown), when cultured in the presence of 
pyrimethamine (Figure 3-22). I therefore focused my investigations on dhfr as this 
enzyme displayed the most dramatic and consistent changes in the level of 
expression (Figure 3-22). In 3D7200nM and FCR3200nM a twelve and thirteen fold 
increase of dhfr expression in comparison to baseline was observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22 Expression analysis of folate enzymes in resistant 
and baseline parasites. (black) baseline parasite population 3D7 and 
FCR set one by definition, (purple) 3D7200nM, (magenta) FCR3200nM. 
Values were determined with real time PCR in reference to baseline 
and with the internal control β-tubulin. 
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3.3.1.3 Copy number determination 
As shown in the previous paragraph (3.3.1.2) dhfr displayed a dramatic increase of 
expression in pyrimethamine drug pressure-adapted parasites. I then asked whether 
this was due to heritable or simply transient transcriptional activation. Copy number 
variations (CNV) were studied for four of the five genes in the folate pathway. I could 
not measure genomic copies of dhfs since the Taqman probe was intron spanning 
and therefore unsuitable for genomic DNA analysis. The copy numbers were 
determined in reference to Dd2, D10 and to 3D7 and FCR3 baseline. Presented are 
the results obtained in reference to Dd2 (gch) and in reference to baseline (dhfr). As 
internal control served the gene PF10_0084 coding for β-tubulin.  
I could not detect CNVs at gch (Figure 3-23), ptps, and dhps during the drug pressure 
experiment (data not shown). In addition to 3D7 and FCR3, the three Kilifi isolates, 
AQ 84, AQ 86 and AQ 104, grown in 400nM, 800nM and 1600nM of pyrimethamine, 
are also plotted on the graph. In none of the measured strains, the gch copy number 
varied in relation to drug pressure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-23 Variation of Pfgch copy numbers with 
increasing pyrimethamine concentration in the medium. 
Real time PCR results are shown from three independent 
experiments with standard deviation. (black circle) 3D7, 
(magenta square) FCR3, (diamond) AQ 84, (clear circle) AQ 
86, (clear square) AQ 104. 
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In stark contrast copy numbers of dhfr increased significantly with increasing drug 
concentrations (Figure 3-24) indicating that elevated gene expression is mainly 
regulated by gene copy variation as opposed to differential transcriptional control. 
The results are shown for 3D7 and for FCR3 in Figure 3-24. In 3D71600nM the dhfr is 
amplified > 30 fold, in FCR31600nM only 9 fold at the same pyrimethamine 
concentration. First evidence for amplification was detected at pyrimethamine 
concentration of 100 nM, i.e. after 10 weeks of drug pressure. This finding is 
consistent with existing literature (Thaithong et al, 2001). Once amplification was 
introduced in the population, additional copies were integrated within two weeks 
when the pyrimethamine concentration was further elevated. Various mechanisms for 
gene duplication have been proposed but all involve a step in which homologous 
sequence regions or repeats of all sorts play a major role.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When comparing the relative expression (Figure 3-22) with genomic copy numbers, I 
found that on average each additional copy generated two and three surplus 
transcripts in 3D7 and FCR3 respectively. 3D7200nM harbours 6.1 genomic dhfr copies 
and expresses 13.5 dhfr transcripts, whereas FCR3200nM carries 4.5 genomic copies 
Figure 3-24 Variation of Pfdhfr copy numbers with increasing 
pyrimethamine concentration in the medium. Real time PCR 
results are shown from three independent experiments with 
standard deviation. Copy numbers were calculated in reference to 
baseline copy numbers of each strain, which is set at one. (black 
circle) 3D7, (magenta square) FCR3, (diamond) AQ 84, (clear 
circle) AQ 86, (clear square) AQ 104. 	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and expresses 12 transcripts, when baseline expression and copy numbers are set 
to one. The expression data are very preliminary and will have to be confirmed (also 
at different pyrimethamine concentrations), but if FCR3 requires fewer genomic 
copies to exhibits similar expression levels, this could explain the observed 
discrepancy in dhfr copy numbers between 3D7 and FCR3 (Figure 3-24). 
Since I had determined in vitro growth inhibitory concentrations (3.3.1.1), the exact 
relationship between copy numbers and IC50 values could be investigated. As shown 
in Figure 3-25 there was evidence for a linear correlation in both strains. The slope in 
3D7 (0.004) was steeper than in is FCR3 (0.001). Table 3-3 summarises these 
findings. 
 
 
 
Table 3-3 Relative increase of copy numbers and IC50 values compared to baseline. The 
values listed in this table are relative IC50 and copy number values. 
 3D7 FCR3 
 IC50 Pfdhfr copies IC50 Pfdhfr copies 
Baseline 1 1 1 1 
200nM 11 x 6.1 x 4 x 4.5 x 
800nM 253 x 19.6 x 56 x 6.7 x 
1600nM 335 x 31.15 x 86 x 9 x 
 
Figure 3-25 Correlation of copy numbers (dhfr) and pyrimethamine IC50 values. 3D7 and 
FCR3 copy numbers were plotted against the respective IC50 values determined at the same 
concentration.  
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3.3.1.4 Evidence for the emergence of resistant S108N mutation in amplified 
Pfdhfr locus 
It has previously been shown that the appearance of serine to asparagine mutation at 
codon position 108 is the first step to the development of double and triple mutant 
dhfr (Cowman et al, 1988). I therefore analysed genomic DNA in regular intervals for 
the emergence of this point mutation. The emergence of S108N could easily be 
monitored with a restriction digest (AluI) over night of previously amplified region of 
the DHFR sequence. The methods are described in detail in chapter 2.2.1.14. Alu I 
recognises and cuts the double stranded DNA with the sequence AGCT. The wild 
type, pyrimethamine sensitive allele of dhfr carries a G at the nucleotide position 323 
(codon position 108). If guanine is replaced by adenine, the amino acid serine (AGC) 
is also replaced by asparagine (AAC). In this case the DNA sequence remains uncut 
by the restriction enzyme Alu I. This undigested fragment is seen in a week band, 
framed by a red box, in the four restriction digests represented in Figure 3-26.  
 
Figure 3-26 AluI restriction analysis of previously PCR amplified dhfr 
fragment. Pfdhfr SNP forward and Pfdhfr SNP reverse were used in the PCR 
reaction and the restriction digest was performed with Alu I over night to ensure 
complete digest. A) 3D7 and FCR3 at baseline and to 400nM and to 800nM 
pyrimethamine adapted parasites. B) 3D7 at baseline (BL) and at concentrations 
from 100 to 800nM of pyrimethamine. Primer pairs: dhfr 5’ UTR for and dhfr SNP 
rev were used in this analysis creating two fragment with different sizes, when cut 
with Alu I. C) 3D7 baseline (BL) and three 800nM parasite population. D) 3D7, nine 
parasite clones adapted to 800nM were analysed. Undigested dhfr fragments, 
indicating a mutation at position 323 in dhfr, are framed in red. 
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A BL   100   200  300  400   800 (nM) 
3D7 
B 
3D7 800nM 
        BL    800(1) 800(2) 800 (3) C 
3D7 800nM 
Singel parasite clones (1 – 9) D 
746bp 
418bp 
330bp 
651bp 
330bp 
323bp 
651bp 
330bp 
323bp 
651bp 
330bp 
323bp 
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In panel A) it is demonstrated that Alu I never cuts the dhfr locus of FCR3 (alternative 
wild type sequence ACCT, S108T) and that the dhfr of 3D7 and 3D7400nM (wild type 
sequence AGCT) is completely cut by AluI. Only in 3D7800nM parasites a small, 
undigested fraction remains (red frame). In panel B) the frame shows that the 
mutation only appeared when the parasites were exposed to 800nM of 
pyrimethamine in the medium. In panel C) the equally faint band in the three frames 
shows that the number of parasites carrying the mutation does not increase over 
time. The genomic DNA isolated from the culture was taken, once the parasites had 
adapted to 800nM of pyrimethamine in the culture and showed a constant replication 
rate (1), 48 hours later (2) and 120 hours later (3) than the first appearance of the 
mutation. No significant increase is observed. The thickness of the undigested 
product does not change over time. To investigate whether only a small 
subpopulation carried the newly acquired mutation, the parasite population was 
cloned out via serial dilution. All the nine recovered clones shown in panel D) harbour 
the newly arisen mutation at the codon position 108, conferring higher pyrimethamine 
resistance. 
To rule out the possibility of undigested fragments due to loss of enzyme activity over 
time, the band was excised from the gel, purified, amplified with PCR and sequenced 
by standard Sanger method. This was done for the baseline parasite population 3D7, 
3D7200nM, 3D7400nM, 3D7800nM and 3D71600nM. 
The sequencing reaction proved that a nucleotide exchange from adenine to guanine 
at position 323 in the dhfr gene had indeed occurred. It also confirmed that the 
mutation first appeared in the 800nM adapted parasites and persisted in the 1600nM 
adapted parasite population (Figure 3-27). Electropherograms of sequences obtained 
from 3D7, 3D7200nM, 3D7300nM, 3D7400nM, 3D7800nM and 3D71600nM clearly demonstrated 
that the nucleotide was replaced in 3D7800nM and 3D71600nM. The still detectable 
adenine originates from the undigested wild type allele. Sequencing of the dhfr locus 
of parasites adapted to 300nM and 400nM (data not shown) of pyrimethamine 
showed the same results as wild type 3D7 and 3D7200nM (Figure 3-26). 
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Figure 3-27 Electropherogram of sequencing reaction of dhfr (nucleotides 
227 – 241). A) 3D7 baseline parasites B) 3D7 200nM adapted C) 3D7 800nM 
adapted D) 3D7 1600nM adapted. Baseline 3D7 parasites (A) and 200nM (B) 
adapted show a single clear green peak at position 323. In panel C) and D) a 
double peak consisting of a green and a black peak indicate that a guanine 
replaced the adenine at position 323 (framed in red). 
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I then attempted to quantify the number of mutated dhfr copies in the parasites 
population and in individual parasites. The dhfr locus was first amplified in 3D7800nM 
and cloned-out-3D7800nM parasites with a PCR reaction and cloned in the TOPO 
vector (methods described in detail in chapter 2.2.2). After colony screening for 
integration of the insert, the PCR product of single colonies were subjected to AluI 
restriction digest. An example is shown in Figure 3-28. 
 
 
 
 
It was possible to detect colonies, which remained uncut and thus confirmed again 
the mutation at nucleotide position 323. However, the quantification gave inconsistent 
results and was therefore abandoned. Possibly too many PCR steps biased the 
outcome. A plasmid preparation was performed but Alu I cuts the TOPO vector at 
multiple sites and therefore, a direct analysis of purified plasmids without additional 
PCR amplification or excision of the insert from the gel was not feasible. Excision 
from gels is not a suitable method for large-scale analysis, which would be needed 
for quantification. 
In summary, it was shown that mutation S108N was introduced in the population 
once the gene copy number of dhfr had increased significantly. Recently it has been 
reviewed and hypothesised that gene amplification might accelerate the rate of 
acquisition of antibiotic resistance in bacteria (Sandegren, 2009).  Here, I presented 
first evidence that a similar mechanism operates in P. falciparum.  It also highlights 
the remarkable plasticity of adaptive genetic mechanism in Plasmodium.  
Figure 3-28 Restriction analysis of colony screening of 
dhfr cloned in the TOPO vector. 32 bacterial colonies 
were screened with PCR and analysed with AluI restriction 
enzyme. 
1  2   3   4   5  6   7   8   9  10 11 12 13 14 15 16  
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3.3.1.5 Amplicon size determination and characterization 
In the process of gene amplification, surrounding sequences and potentially whole 
genes will be co-amplified. To address this question, the amplified locus containing 
the Pfdhfr gene of the anti-folate resistant 3D7 and FCR3 strains was further 
analysed during the whole selection experiment. Two different methods were used. 
Genomic DNA surrounding the dhfr gene of resistant parasite lines was first analysed 
by real time PCR assay. Secondly after treatment with restriction enzymes, I 
analysed by southern blot (2.2.1.15). To reveal possible double strand break points in 
the genomic DNA I used standard PCR and sequencing methods. 
Genomic DNA was isolated from parasite cultures at different time points and 
pyrimethamine concentrations. Real time PCR assay was performed with DNA 
isolated from the baseline parasite population and from parasites adapted to 200 nM, 
300 nM, 400 nM, 800 nM and 1600 nM of pyrimethamine from both 3D7 and FCR3. 
 
Quantitative real time PCR (sybr green based) assay to determine amplicon size 
Genes adjacent to dhfr (Table 3-4 and Figure 3-29) were analysed for evidence of co-
amplification with methods described in chapter 2.2.1.13. Figure 3-32 illustrate the 
genomic context of dhfr.  
 
Table 3-4 Open reading frames with accession number and annotation from PlasmoDB 
surrounding the dhfr locus. For each of the genes at least one primer pair was designed to 
determine amplification in a sybr green-based real time PCR assay. 
Accession Nr. Annotation on plasmoDB 
PFD0780w glutamyl-tRNA(Gln) amidotransferase subunit A, putative 
PFD0795w conserved plasmodium protein, unknown function 
PFD0810w small GTP-binding protein sar1 
PFD0815c Conserved protein, unknown function 
PFD0820w Conserved protein, unknown function 
PFD0825w RNA-binding protein of pumilio/mpt5 family, putative 
PFD0830w bifunctional dihydrofolate reductase-thymidylate synthase 
PFD0835c LETM-like protein, putative 
PFD0840w conserved Plasmodium protein, unkown function 
PFD0865c cdc2-realted protein 
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As the specific primer for the genes only cover a small sequence region of the gene 
under investigation, the results cannot provide information on whether amplicons 
contain complete, i.e. functional additional gene copies.  
 
 
Figure 3-30 shows a graphic representation of the co-amplification surrounding the 
dhfr locus in 3D7, obtained in the pyrimethamine drug pressure experiment. In Figure 
3-31 the graphic for FCR3 is shown. The distance on the x-axis does not represent 
the actual distance in kilobases on the chromosome. Distance information’s are given 
in Figure 3-29. It is important to note, that the results obtained with this experiment are 
not comparable with the copy number determination in 3.3.1.3 in which a probe was 
used. The sybr green assay is less accurate to determine the exact copy number but 
identifies amplification or loss of copy.  
Amplicon size determination for 3D7 
Upstream of dhfr (PFD0830w), only the probe for the directly adjacent PFD0825w 
revealed co-amplification at all stages of the drug pressure experiment. Downstream 
of dhfr, the adjacent PFD0835c did not reveal gene amplification compared with 
baseline parasite population. Further downstream, PFD0840w A and PFD0840w A2 
showed in the 5’ region of the open reading frame gene amplification in reference to 
the baseline parasite population and at the same level as dhfr. PFD0840w A2 was 
measured only for 3D7800nM and 3D71600nM, which explains the straight connecting line 
between PFD0840w A and PFD0840w A2 for 3D7200nM, 3D7300nM and 3D7400nM. 
PFD0840w A2 and PFD0840w mid are separated by a large 7980 bp fragment, the 
likely location of the amplicon breakpoint. 
To confirm the loss of PFD0835c in the amplicon, an additional primer pair was 
designed in the intergenic region of PFD0835c and PFD0840w (PFD0835c – 840). 
A     A2    mid     B 
!"#$%& !'!$%& !()$%& !#($%& !#*$%& !+($%& !+,$%& !+*$%& !,#$%&&&&&&&&&&&&&&!)"$%& !*,$%&
Figure 3-29 Schematic of the dhfr locus (plasmoDB). The boxes illustrate single genes 
with their accession number from PlasmoDB. (black lines) primer pair for sybr green based 
real time PCR assay. The values below the gene boxes indicate approximate position of the 
genes on the chromosomes 4 (PlasmoDB). The red box is magnified in Figure 3-30. 
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This sequence revealed also no co-amplification, suggesting an intact wild type 
locus. The distance between the two missing primer pairs was of 3564 bp and the 
distance between the next two present primers (dhfr and PFD0840 A) was of 7767 
base pairs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further upstream (PFD0820w, PFD0815w PFD0810w, PFD0795w, PFD0780w) and 
downstream (3’ end of PFD0840w and PFD0865c) no evidence for gene 
amplifications was found. PFD0820w was only measured for 3D7800nM and 3D71600nM, 
which explains the straight connecting line between PFD0815w and PFD0825w for 
3D7200nM, 3D7300nM and 3D7400nM. The primer pairs of PFD0820w and PFD0825w are 
separated by 1685 base pairs in which the breakpoint most likely is situated. 
Figure 3-30 Co–amplification of genes surrounding dhfr locus in 
3D7. On the x –axis genes adjacent to dhfr are ordered without 
representing actual genetic distances. The y –axis gives copy 
numbers. Values are means with standard deviations determined in at 
least three independent real time PCR assays. The size of the 
amplicon was determined for each pyrimethamine concentration, 
represented by different colours. The areas under the curves are filled 
out to illustrate the amplification. The exact breakpoints of the amplicon 
at the edged and in the middle for 3D7 are not shown in this figure. 
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Amplicon size determination in FCR3 
Upstream of dhfr (PFD0830w), the adjacent PFD0825w and PFD0810w revealed co-
amplification at all stages of the drug pressure experiment and downstream of dhfr, 
the adjacent PFD0835c showed co-amplification compared with the baseline parasite 
population.  
Further upstream (PFD0795w and PFD0780w) and downstream (PFD0840w and 
PFD0865c) no evidence for gene amplification was found. These genes were found 
in a single copy in the genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31 Co–amplification of genes surrounding the dhfr locus in 
FCR3. On the x – axis the neighbouring genes of dhfr are listed without 
considering the actual distance between them. On the y – axis the copy 
numbers of each gene in reference to its baseline are plotted. The values 
are means with standard deviations determined in at least three 
independent sybr green – based real time PCR assays. The size of the 
amplicon was determined for each pyrimethamine concentration, 
represented with the different colours. The areas under the curves are filled 
out to illustrate the amplification. The exact breakpoints of the amplicon at 
the edged are not shown in this figure. 
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Southern blot analysis of gDNA of 3D7 and FCR3 with amplified dhfr locus 
A southern blot was performed to confirm the amplification of the dhfr locus and to 
further characterise the amplicon and its size in the two strains 3D7800nM and 
FCR3800nM. Figure 3-32 show a scheme of the dhfr locus. A small horizontal line on top 
of the genes represents primer pairs used to determine amplification. The two primer 
pairs highlighted in the red box are the ones, which did not reveal amplification in 
3D7 (Figure 3-30). As a consequence restriction sites, represented with vertical 
coloured lines, within this region are also missing in the amplicon. For PFD0840w 
four primer pairs were designed (A, A2, mid and B).  
 
 
 
 
 
 
 
The southern blot was performed as described in detail in 2.2.1.15. The aim was not 
to detect a shift in size of the chromosomal region, but to confirm the results obtained 
with the sybr green based real time PCR assay. Therefore enzymes were chosen to 
cut within the amplicon (Figure 3-32) and thus, to produce an increase in hybridisation 
signal as opposed to a shift. The same amount of DNA was loaded in each lane and 
additionally a probe against actin (PFL2215w) was designed and synthesised to 
serve as loading control. Unfortunately the signal of actin was to weak (data not 
shown) to be detected in the conditions, used here.  
Figure 3-32 Schematic representation of dhfr locus. Each coloured box 
represents a gene with the accession number of PlasmoDB marked on it. On top 
of the boxes the short black lines illustrate the primer pair, which was used to 
determine amplification. Restriction sites of EcoRV (dark blue line), EcoRI (light 
blue line) and NheI (green line) are shown in the scheme and the black lines 
underneath illustrate the resulting fragment with size indication. 
EcoRV 
       a 
EcoRV 
                 e 
NheI EcoRV 
 b                         cd 
A     A2         mid                B 
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EcoRI 
2461 bp 
4935 / 5395 bp 
8018 bp 
15030 / 15121 bp 
21854 bp 
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Figure 3-33 shows the southern blot. The last panel confirms the amplification of the 
dhfr locus in 3D7800nM and FCR3800nM compared to the baseline parasite lines, 
untreated (-).  
 
Eco RV and Eco RI cut very close upstream of dhfr and at the 3’ end of its open 
reading frame generating in both lines a fragment of 2461 bp (Figure 3-32). 
Fragments from parasite lines subjected to pyrimethamine pressure showed a much 
stronger hybridisation signal compared to unexposed parasites, thus confirming the 
amplification of the locus in both strains.  
As the amplicons of 3D7 and FCR3 are of different sizes and composition, the 
analysis of the EcoRV and the double digest (EcoRV and NheI) will be presented in 
detail in the following paragraph, separately for 3D7 and FCR3, starting with FCR3. 
The double digest (EcoRV and NheI) generates in FCR3 and FCR3800nM a fragment 
of expected size (4935bp), which confirms the results obtained by real time PCR. 
The part of gene PFD0835c where the restriction site is located and where the real 
time primers were designed to bind is co-amplified in FCR3800nM. The restriction 
analysis of EcoRV alone shows similar results but needs to be interpreted in 
consideration with the results presented in paragraph “breakpoint identification of 
FCR3” (see below). In this paragraph it is shown that the amplicons in FCR3 are 
arranged head to tail and the breakpoints were identified down to 200 base pairs. 
The restriction site of EcoRVb between PFD0835c and PFD0840w (Figure 3-32) was 
found to be beyond the edges of the amplicon. Instead, another EcoRV restriction 
site (not shown) in the co–amplified PFD0810w at the 5’ end of the amplicon (Figure 
3-31) generates in combination with EcoRVa an approximately 7200bp fragment. 
Figure 3-33 Southern blot of genomic DNA of 3D7 baseline (-) and 3D7800nM and 
FCR3 (-) and FCR3800nM digested with EcoRV, EcoRV + NheI and EcoRV + EcoRI. 
Sizes are indicated on the right hand side of each picture. The same amount (3µg) of 
genomic DNA was loaded in each lane, the loading control actin was not detectable (not 
shown). 
EcoRV EcoRI 
   3D7     FCR 3 
  -   800nM    -    800nM 
2461 bp 
EcoRV Nhe I 
   3D7     FCR 3 
  -   800nM    -    800nM 
4935 bp 
EcoRV 
   3D7     FCR 3 
  -   800nM    -    800nM 
! 7000 bp 
21226 bp 
8018 bp 
21226 bp 
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This is an approximate value, generated and calculated from PCR analysis and 
sequencing information. 
In conclusion, the southern blot experiments confirmed the real time PCR results 
regarding both size and composition of amplicon. However, they provide no further 
information on the exact genomic location of amplicons. 
The amplicon arrangement in 3D7 is more intriguing. Two possible breakpoints and 
thus arrangements are conceivable. Assuming intact wild type locus, the amplicon 
could be one continuous fragment containing a gap (loss of PFD0835c), which 
positioned next to the wild type locus or anywhere in the genome. Alternatively, but 
also under the assumption of an intact wild type locus, two separate amplicons on 
either side of the wild type locus could generate the results obtained with the real 
time PCR (Figure 3-30). Three results suggest the existence of an intact wild type 
locus. First, the unamplified regions were detected at baseline level, proving their 
presence in the genome (Figure 3-30). Secondly two PCR reactions within and on one 
side probably beyond the unamplified region were successful proving the existence 
of a 6 kb segment exactly as the wild type locus (presented and discussed in detail 
below, Figure 3-36). Finally, the weak signal in 3D7 and 3D7800nM in the southern blot 
at 4935 base pairs, resulting from the EcoRV and the NheI restriction analysis (Figure 
3-33). The fact that this signal is one of the weaker signals in the lane of 3D7800nM 
indicates that the wild type locus is present only once. The three upper bands of 
different sizes give an intense signal and are of the same size as the bands resulting 
from EcoRV restriction alone. This points toward the absence of both NheI restriction 
sites in the amplicon(s), in accordance with the real time data (Figure 3-30). As the 
two restriction sites are separated by only 460 base pairs, it is also very unlikely that 
one would be present and the other be missing.  
An explanation for the three resulting bands from the EcoRV restriction and from the 
double restriction analysis of EcoRV and NheI remains to be found. The next 
restriction site EcoRV b is also missing in the amplified fragment (Figure 3-30 and 
Figure 3-32). EcoRV c and d are present and co – amplified and would produce a 
15030 base pair long fragment. From this the lost sequence of at least 3564 bp 
(amplicon size determination of 3D7, see above) has to be subtracted, which would 
result in a fragment of 11466 bp. The size identification of the bigger fragments in the 
southern blot is under these conditions difficult to determine, but one of the three 
bands could thereby be explained. This implies that not only the wild type locus is 
intact, but also the existence of a single amplicon with a gap at PFD0835c and not 
two amplicons on either side of the wild type locus, but this is speculation and still 
Results 
	   99	  
does not explain the remaining two fragments clearly apparent on the southern blot. 
Unfortunately even further PCR analysis of the breakpoints did not clarify the 
arrangement of this amplicon in 3D7 (shown below). 
Identification of the amplicon breakpoint in FCR3 
In the previous paragraph I demonstrated, that drug exposure led to amplification of 
dhfr and surrounding sequence fragments in 3D7 and FCR. However real time PCR 
and southern blotting only permitted an approximation of the amplicon’s size. To 
further determine the exact location of amplicon breakpoints, I designed a set of PCR 
reactions (2.2.1.9) with different primer pair combinations (2.1.8.1). Sizes were 
estimated with the help of agarose gel electrophoresis and purified fragments were 
sequenced. The primers for sequencing reactions are listed in the paragraph 2.1.8.1. 
Two possible arrangements of amplicons are conceivable: a head-to-tail or a tail-to-
tail positioning on the chromosome. Both hypotheses were tested. Figure 3-34 
illustrates a head-to-tail arrangement of two neighbouring amplicons. Coloured boxes 
represent genes (accession numbers) dhfr is highlighted in yellow. The black box 
shows the original chromosomal locus. If a gene amplification occurs and the newly 
synthesised DNA is arranged in a head-to-tail manner, the DNA fragment, shown 
underneath is produced. This results in a unique, newly generated sequence at the 
breakpoint, where a PCR reaction is possible (indicated by the red line) in the 
amplified but not in the wild type locus.  
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Figure 3-34 Model of amplicon arrangement in FCR3. Two FCR3 amplicons were 
positioned head-to-tail. The red line indicates a newly generated chromosomal sequence, 
which is absent in parasites with a wild type locus. A PCR reaction was successfully 
performed over this sequence part.  
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First real time PCR primers of two potentially adjacent genes were used in an 
attempt to amplify the breakpoint. PFD0835c is positioned on the (-) strand whereas 
PFD0815w is located on the (+) strand, so in both cases the reverse real time PCR 
primers were used. “Reverse” indicate reverse with respect to the open reading 
frame. Following successful amplification, I designed four additional primers to close 
in on the breakpoint. 
 
 
 
 
 
 
 
 
 
 
 
The primer pairs from the real time PCR (PFD0835c and PFD0810w) amplified a 
product of approximately 1,5 kb (Figure 3-35 (1)), which was sequenced 
bidirectionally. The baseline parasite population gave no signal (data not shown). 
The success of amplifying a fragment with these primers supports the hypothesis of a 
head-to-tail conformation of the amplicon in FCR31600nM. The sequencing data 
showed that from PFD0835 rev on approximately 700 bp were readable and 300 bp 
from PFD0810w rev. Taken together these were 1000 base pairs and around 500 bp 
were still missing in between. In the PFD0810w a poly A stretch after 300 bp hinders 
the sequencing reaction and in PFD0835c the sequencing reaction reached with 700 
bp already a maximum of achievable length. So the additionally designed primers 
were set right after the end of the already successfully identified sequences. In 
PFD0810w the two newly designed primer (PFD0810w rev new 1 and PFD0810w rev 
new 2) produced together with PFD0835c rev two products of approximately 680 bp 
and 850 bp (Figure 3-35 (2) and (3)). This confirms the existence of the sequence 
were the new primers were set. Unfortunately these products were never 
successfully sequenced, even though several attempts have been made. The 
breakpoint is probably not identical between all the amplicon or at least not as 
identical as a sequence reaction would require it to be. The degradation in the PCR 
analysis (Figure 3-35 (2) and (3)) could support this hypothesis, but this is pure 
1 kb 
500 bp 
750 bp 
 (2)         (3)       (4)      M 
2 kb 
1 kb 
    (1)        M 
Figure 3-35 PCR analysis of FCR31600nM amplicon breakpoint. 
(1) PFD0835crev and PFD0810wrev. (2) PFD0835crev/PFD0810w revnew1 
(3) PFD0835c rev/PFD0810w rev new 2. (4) Negative control. The reaction 
was also performed for FCR3 baseline and no product was amplified (data 
not shown) confirming the head to tail arrangement. 
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speculation. 228 base pairs separate the primer PFD0810w rev new 1 from the ATG 
of the gene (primer included). If the ATG is included in the amplicon and if these 
parasites thus carry an additional functional copy of PFD0810w is not possible to 
determine with these results. 
In PFD0835c the two newly designed primers gave no amplification in the PCR 
reaction, indicating that this sequence is not part of the amplicon. Interestingly the 
breakpoint is approximately 300bp after the transcription start site of PFD0835c. So 
FCR31600nM has only amplified part of the gene but carries no additional functional 
copy. Interestingly 3D7 had built its amplicon around this gene (PFD0835c), 
suggesting that overexpression of PFD0835c might be toxic for Plasmodium.  
As the last sequencing reaction did not succeed, the exact breakpoint could not be 
identified but it has to be located within these last 200 base pairs. No obvious 
repetitive sequences were identified within these 200 bp and an alignment of the 
relevant sequence part around the possible breakpoint did not reveal significant 
homology between the two sequences. 
Identification of the amplicon breakpoint in 3D7 
The results obtained from real time PCR and the southern blot for 3D7 were already 
more intriguing and not as conclusive as for FCR3. The identification of the 
breakpoint and the arrangement of the amplicon could also not be solved by 
standard PCR, even though numerous primer pairs were designed (2.1.8.1) and 
tested in various combinations (2.2.1.9). 
At the edges, between PFD0820w and PFD0825w primers (named 5’ in 2.1.8.1) 
were designed as well as between PFD0840 A2 and PFD0840w mid (named “z” in 
2.1.8.1). Together with the real time primers, of which assured information of their 
presence or absence is available, a series of PCR reactions was performed without 
any positive result. A head to tail and a head to head conformation was considered. 
Both amplified regions on either side of PFD0835c were assumed to be independent 
or connected (as mentioned above) and no product was detected in the PCR 
reaction. 
The arrangement and positioning of sequences around the unamplified region of 
PFD0835c remained similarly unsolved. The real time primer of dhfr and the 
PFD0840w A are separated by 8000 base pairs. Numerous primers were designed at 
either edge (named 3’ of dhfr and 5’ of LETM in 2.1.8.1) of the identified gap, which 
was found to be of at least 3500 base pairs. In case of a single amplicon, carrying 
dhfr and parts of PFD0840w, a PCR reaction over the gap should have been feasible 
as the fragment could only be of maximum 4500 base pairs. Specially, when primers 
Results 
	   102	  
were designed to shorten the distance on either side, a PCR reaction was expected 
to work. Figure 3-36 shows the combination tested in a PCR reaction. The black lines 
underneath demonstrate the combinations tested without success, even when a 
special long range PCR Kit was used. 
 
 
 
 
 
 
While these reactions never gave a signal, a 
reaction from a primer, designed in the gap 
(PFD0835c) and two others primers, 31 bp 
and 991 bp after the stop codon of dhfr were 
successful (Figure 3-36 red line and Figure 
3-37) in 3D7 baseline (not shown) and 
3D7800nM. This proves that despite the 
amplification the wild type locus is present 
and intact at least once. As this is the only 
positive PCR result obtained, no further 
conclusion can be drawn from this series of 
analysis. From a negative PCR result, 
especially if it is a relatively long range PCR of over 3 kb, no assumption can be 
made. Various reasons are conceivable for the failing reaction, other than the simple 
non-existence of the sequence. Polymerases for example reach in vitro only a limited 
length before they fall of the template and the high A/T content in Plasmodium 
falciparum, particularly in intergenic regions, has to be considered, when analysing 
theses results. Nevertheless, it can be concluded that the wild type locus is present 
and intact in the strains with amplified dhfr and the amplicon in 3D7 seems to be 
arranged in a complex and unexpected way, especially when compared to FCR3. A 
possible explanation could be the potential toxicity of PFD0835c and its immediate 
proximity to dhfr, which renders a simple amplification of this gene with large 
surrounding sequence regions impossible. 
Figure 3-36 Enlarged model of dhfr and its downstream lying 
genes. (balck lines) unsuccessful PCR reactions (red lines) 
successful PCR reactions. (red box) unamplified region. 
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Figure 3-37 PCR analysis of 3D7800nM 
over the gap (PFD0835c). (1) 3D7 
3’for/1 LETM 5’ rev (2) 3D7 3’for2/LETM 
5’rev. Fragments of expected size for 
wild type locus 
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3.3.1.6 Competition 
Parasites carrying mutations or chromosomal rearrangements might have to cope 
with a fitness cost compared to wild type parasites. To address this question wild 
type 3D7 cultured in a one to ten ratio in the presence of 3D7800nM parasites for 8 
weeks without drug pressure. As a control 3D7800nM alone was also cultured without 
drug pressure.   
In the initial phase, for up to one week after the start of the experiment 3D7800nM 
parasites were dominant. However after 3 weeks the overall copy number in the co-
culture was already reduced to 6. It was impossible to distinguish whether 3D7800nM 
lost DHFR copies in the presence of wild type parasite or if they were overgrown by 
wild type 3D7 parasites.   
In contrast 3D7800nM cultured alone still carried all the amplified copies after 8 weeks 
suggesting stable integration of amplicons as opposed to episomal carriage of 
amplified DNA. 
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Figure 3-38 Competition and stability experiment. 3D7800nM were cultured with 3D7 wild 
type starting with a 10:1 relation without pyrimethamine in the medium. Copy numbers were 
monitored over 8 weeks. As control 3D7800nMcultured alone also without pyrimethamine over 
the same period of 8 weeks. 
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4. Discussion 
Malaria control and its elimination continue to rely on prompt and efficacious 
treatment of disease episodes. 
The malaria parasite has evolved a remarkable capacity to adapt to new conditions, 
e.g. antimalarial drugs. Chloroquine was successfully employed for decades until 
resistance emerged first in South-East Asia and subsequently spread globally. 
Resistance against anti-folates developed in much shorter time and first signs of 
failures of newly and massively distributed artemisinin combination therapies (ACT) 
are already reported within 13 years of their introduction (Dondorp et al, 2009). 
Because of the public health importance of drug-resistant P. falciparum malaria, the 
emergence and spread of resistance needs careful monitoring. Genetic composition 
and variation of parasite populations in different geographical regions is an important 
indication for existence and spread of resistance. However, in vivo and in vitro 
phenotypic analysis of parasite isolates are essential tools for confirming the 
emergence of drug-resistant infections.  
Beside surveillance of the natural parasites population, it is equally important to 
understand molecular mechanism of resistance and its development. Mechanism of 
resistance itself can be due to various changes in the parasite. Transporters change 
their substrate specificity, drug targets alter their protein structure and/or increase in 
abundance to compensate for the effects of inhibition. All mechanisms of resistance 
share common features. Mutation and chromosomal rearrangements form the 
heritable basis of the parasite’s ability to adapt. Whether these two mechanisms are 
independent or evolutionary related outcomes of adaptation is currently not known. A 
better understanding of the molecular events in the early phase of development of 
drug resistance is also of critical importance for improving the predictive accuracy of 
molecular surveillance tools in the field. 
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4.1 Drug parasite interaction in vivo 
Drug sensitive parasite populations that are exposed to drugs need to ensure 
survival of a minimal parasite population in order to develop resistance.  
In the first part of this work parasite survival and its determinants were investigated in 
vivo, i.e. in paediatric patients who received antimalarial treatment for uncomplicated 
P. falciparum malaria. Following recommendations by the World Health Organisation 
(WHO, 2008), drug efficacy is determined by the in vivo test. This tests monitors 
blood stage parasite recurrence by microscopic examinations of blood smears up to 
84 days after start of treatment. Re-infections are distinguished from recrudescence 
by genotyping of highly polymorphic genomic regions, most commonly using the 
msp2 locus. Sensitivity of this test remains very low and the classification of re-
infection in high endemic areas is inaccurate. I attempted to study the potential for 
replacing long lasting and expensive follow up periods by applying a highly sensitive, 
P. falciparum asexual stage-specific reverse transcriptase PCR on a single sample 
taken seven days after start of treatment. Assuming a parasite reduction ratio of 102 
to 105 parasites per 48 hours (White, 1997), I expected the parasite population to be 
detectable 7 days after start of treatment. The time point was also thought to be 
suitable for the analysis as it was also proposed for determination of drug plasma 
concentration (White et al, 2008) and sample collection could be minimized.  
The rational was to detect viable asexual parasites seven days after treatment and 
the aim was successfully achieved with a very high sensitivity and specificity. Positive 
and negative results on day 7 were highly reproducible. Surprisingly, there was a 
poor correlation between detection of asexual parasites on day 7 as a marker of 
incompletely eliminated persistent blood stage infections and subsequent risk of 
recrudescence.  
In the ACT study, in 48/105 (45.7%) samples metabolically active persistent asexual 
parasites were detected 7 days after start of treatment (i.e., 4 days after last dose). 
Persistence of infection on day 7, however, poorly agreed with subsequent 
recrudescence at the individual level. Twenty-nine with detectable parasite 
populations surviving in their blood on day 7 either cleared the parasites in the 
following 77 days or were re-infected, as determined by msp2 genotyping. And 18 
patients with undetectable parasite populations presented with recrudescent 
parasites in the following 77 days.  
In the amodiaquine study arm, in 16/51 (31%) samples metabolically active 
persistent asexual parasites 7 days after start of treatment (i.e., 4 days after last 
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dose) were detected. Persistence of infection on day 7, however, also poorly agreed 
with subsequent recrudescence at the individual level. 
There are three main possible explanations for the observed discrepancy between 
day 7 and subsequent recrudescence of primary infections. First, it is important to 
note, that no sensitive mRNA data are available for the period after day 7. Further 
monitoring of the parasitaemia was only performed by microscope and only if 
patients presented with fever in combination with a positive blood smear, DNA and 
RNA samples were taken, which were then analysed in my assay. Therefore, the 
possibility cannot be ruled out, that at least some of the healthy children carried 
undetectable, i.e. sub-patent parasitaemia until or beyond day 84. 
Secondly, although the presented assay was shown to be up to 104 times more 
sensitive than standard light microscopy (corresponding to an estimated total 
parasite mass of 104-105 in a 3 year old) persistent infections could have escaped 
detection if the majority of the parasite population would have been sequestered in 
the deep vasculatures at the time of sampling.  
Finally, another reason for the observed discrepancy between negative day 7 results 
and subsequent recrudescence could be found in the fact that the assay relies on 
correct genotyping. Even though the genotyping was performed with high accuracy, 
the possibility of misclassification cannot be ruled out and in endemic areas, children 
can be re-infected with the same parasites within a single household. 
With additional clinical data being available for the ACT study arm, I attempted to 
correlate my results of the ACT study to initial parasite density, parasite reduction 
ratio within 24 hours, age of the children, drug plasma level and platelet counts. The 
results showed correlation of initial parasite density with persistence of parasites until 
day 7 in the second phase of the ACT study. Malaria incidences in Pingilikani (Kilifi, 
Kenya) are declining in all age groups since 2003, when the project was started. With 
reduced transmission and reduced parasite prevalence in the community, the 
immunity status of each individual is also declining (O'Meara et al, 2008). The 
observed association between initial parasite biomass and presence of subpatent 
infections on day 7 may therefore simply reflect a reduced impact of immunity on the 
clearance of parasites in peripheral blood compared to the first phase on the study. 
It has been proposed that clearance time of a defined burden of 1012 parasite in the 
total body varies depending on the power of administered drugs (White, 1997). And 
the parasite reduction ratio is the essential parameter by which the power of the drug 
is measured in vivo. In this in vivo study presented here, two equally efficient drugs 
were used (Figure 4-1). The parasite reduction ratio is a constant, indicated by the 
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same slope in every infection, and thus, the prevalence of parasites on day 7 
depends directly on the initial parasite load. However, when semi-immunity is fully 
established, its effect may mask the pharmacodynamic relationship between drug 
potency and parasite clearance. Figure 4-1 shows a model for this initial phase. My 
model also allows for a lack of correlation with subsequent recrudescence. Day 7 is 
probably not a suitable time point to address the question of recrudescence. An 
explanation could be that the time laps between day 7 and the day of recrudescence 
is too large and that other, yet undefined confounding factors exist, most likely 
adaptive immune responses. 
 
 
 
 
 
 
 
 
 
Another interesting finding which merits further investigation in the future is related to 
the recent publication that low platelets counts during an infection are associated with 
poor outcome (Ladhani et al, 2002). In vitro studies have further confirmed their 
positive effect. Purified platelets were found to kill intraerythrocytic parasites in vitro 
Figure 4-1 Parasite elimination, persistence and recovery below the 
microscopic threshold – a black box. (red) infection with high baseline 
parasitaemia, detectable on day 7. (green) infection with medium baseline 
parasite density, detectable on day 7 and subsequently remains subpatent 
below the microscopic detection limit. (blue) infection with low baseline 
parasite density, undetected on day 7 but develops to recurrence, either a 
true recrudescence or a re-infection by the same parasite within a single 
household. (yellow) unrelated re-infection can appear in at any time in any 
patient. (question mark) illustrate that no correlation between results on day 7 
and individual outcome was found. Day 14 could be an alternative sampling 
time point to predict outcome.  
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(McMorran et al, 2009). Here, the observation of a high correlation of elevated 
platelet counts at baseline and clearance of parasites by day 7 was also observed 
throughout the study. Innate immunity seems to play a fundamental role in parasite 
clearance. Importantly, this relationship remained significant even when controlling 
for initial parasite load. 
In conclusion, parasite clearance time in our study is dependent on the potency of 
the drug (slope) and on the initial parasite load. Up until now, parasite clearance time 
has always been monitored by microscope, with a detection limit of 108 parasites in 
the total body. However, one to two days after start of treatment, the majority of 
patients carry an infection with a parasitaemia below this detection limit. With regard 
to the recent development of artemisinin resistance in western Cambodia (Dondorp 
et al, 2009) the observation that a high proportion of infections (up to 45%) persist 
after treatment with ACTs gains additional relevance. It may suggest that parasite 
populations frequently survive/escape the intense drug pressure exerted by the fast-
acting artemisinin component of ACTs without subsequent removal by the 
intrinsically less potent long half-life companion drug. The new test methodology in 
this study may give further insights into the complex host-parasite interactions in 
subpatent infections after treatment or in the general population. 
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4.2 In vitro characterisation of phenotypic and genotypic 
signatures of naturally acquired drug resistance in P. 
falciparum 
Parasite isolates obtained from patients with uncomplicated P. falciparum malaria 
were subjected to a phenotypic and a genotypic analysis with a particular focus on 
antifolate drug resistance. Before the introduction of artemether-lumefantrine (AM-
LM), sulfadoxine-pyrimethamine (SP) was used as first-line treatment in Kenya 
including in the Pingilikani sub-location of Kilifi District. The massive historic exposure 
to SP has favoured the survival of stably antifolate-resistant parasites. My results 
show that even several years after the removal of SP as first line treatment, the 
parasites still exhibit a very high resistance against anti-folates. Pyrimethamine, the 
most prominent anti-folate drug was found to be almost completely ineffective to 
inhibit in vitro growth. The most sensitive parasite isolate (AQ 86) had an in vitro 
inhibitory concentration (IC50) of 6.8 µM and the most resistant strain (AK 589) had 
an IC50 of almost 80 µM, which was about 2,000-fold higher than the value measured 
in sensitive reference strains (3D7 and FCR3). My data compare to previously 
published data (Sirawaraporn et al, 1997). Similarly, parasite isolates from Kilifi were 
also highly resistant to another DHFR inhibitor, cycloguanil. The IC50 of the most 
sensitive field isolates was 0.26 µM and of the most resistant one 3.3 µM. This is a 
20 and 200-fold increase respectively compared to the sensitive laboratory strain 
3D7 (14 nM). These values are also comparable to the literature (Sirawaraporn et al, 
1997). Trimethoprim was the least potent drug in our assay and inhibits parasite 
growth only in higher µM range. Even 3D7, the usually sensitive laboratory strain 
shows a relative high 50 % inhibitory concentration (4 µM). FCR3 was the overall 
most sensitive parasite measured in this work (0.6 µM). The weak anti-malarial 
activity of trimethoprim has already been demonstrated (Iyer et al, 2001) and 
trimethoprim is only of interest in regard to its usage as chemoprophylaxis in HIV 
patients (Anglaret et al, 1999; Mermin et al, 2006; Wiktor et al, 1999).  
Important for the evaluation of an assay is the repeatability and two distinct 
phenotypes. With the two laboratory strains 3D7 and FCR3 at least one sensitive 
control parasite line for each drug was available and measurable under the exact 
same conditions. Determining the anti-folate activity in vitro is critical and can be 
influenced and altered by addition or subtraction of pABA and folate to the medium, 
which demonstrates the parasite’s ability to use exogenous folate (Chulay et al, 
1984; Milhous et al, 1985). The folate salvage pathway (Krungkrai et al, 1989) was 
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shown to be functional in P. falciparum but to which extend it is able to recover anti-
folate resistance has not yet been determined. The physiological concentration of 
folate was demonstrated to be 0.01 mg/L (Hoffbrand & Newcombe, 1967) and 
exactly the same concentration is contained in standard cultural RPMI medium (2.3 
µM). The conditions of the in vitro assay were thus comparable to physiological 
conditions in a patient and the highly resistant phenotypes were thus directly of 
relevance for the in vivo situation. 
The genetic mechanism underlying the anti-folate resistance was first described by 
Cowman (Cowman et al, 1988). Pyrimethamine and cycloguanil are inhibitors of 
DHFR (Bzik et al, 1987) and mutations in this gene confer resistance (Peterson et al, 
1988). Cross-resistance between pyrimethamine, cycloguanil and trimethoprim is 
commonly found but often considered incomplete (Gregson & Plowe, 2005). Different 
combinations of mutated position in the dhfr gene confer differential resistance. The 
amino acid substitution at position 16 (A16V) co-exists with S108T and results in high 
cycloguanil resistance (1000 fold) (Sirawaraporn et al, 1997), without altering 
pyrimethamine sensitivity (Foote et al, 1990; Peterson et al, 1990). The laboratory 
strain FCR3 is a representative for this group of parasites and the results measured 
in this work confirm independently these data. In our field isolates the A16V mutation 
was not found and is generally not reported from field studies. Additionally I could 
demonstrate for the first time that the DHFR enzyme carrying the mutation A16V in 
combination with S108T (FCR3) is the only conformation of the enzyme, which 
exhibits sensitivity to trimethoprim (600 nM). According to these results the usage of 
trimethoprim as chemoprophylaxis in HIV patients would strongly select against this 
particular combination of mutation. These results suggest that counter selection by 
trimethoprim and the low catalytic activity of the enzyme carrying A16V alone and in 
combination with S108T (Sirawaraporn et al, 1997) are the reasons for its rareness. 
Mutations at codon position 51, 59 and 108 conferred gradual resistance in the case 
of pyrimethamine and cycloguanil with one mutation exhibiting a relative sensitivity 
compared to parasites carrying three mutations. These findings are in accordance 
with previous reports (Cowman et al, 1988; Peterson et al, 1988; Sirawaraporn et al, 
1997). Interestingly I did not find the mutation I164L, which is prevalent in south East 
Asia (Hyde, 2008) but has recently also been reported from western Kenya (Hamel et 
al, 2008; McCollum et al, 2006) and Kilifi (Kiara et al, 2009), where the samples from 
this study originated from. 
Gene copy number variation (CNV) as a possible mechanism of resistance was ruled 
out as no gene amplification was found in the five genes encoding for enzymes of the 
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folate pathway in field isolates, suggesting that different SNP combination in the dhfr 
gene account for the observed resistant phenotype of the field isolates compared to 
the sensitive laboratory strain 3D7. However, the existence of the previously 
mentioned salvage pathway (Krungkrai et al, 1989) may provide the parasite with an 
alternative source of folate and it can not be excluded that an additional yet unknown 
mechanisms in the salvage pathway explains the discrepancy between the 
measurements of laboratory strains and field isolates in the order of two to three 
magnitudes. An altered folate transport activity in field isolates compared to 3D7 and 
FCR3 could also contribute to the overall observed anti-folate resistance.  
Epidemiologically, the observed high prevalence of anti-folate resistance (67% triple 
mutant) even years after the withdrawal of SP from Kenya is intriguing. Parallel 
studies from Malawi and Tanzania confirm my data. The authors found triple mutant 
dhfr with a prevalence of 77-91% in southern and northern Malawi (Bridges et al, 
2009) and a prevalence of 52% in southwest Tanzania (Schonfeld et al, 2007). The 
often-discussed fitness cost of parasites carrying mutations in the absence of drugs 
seems to be less pronounced for mutations targeting dhfr. All isolates still carry at 
least one mutation (S108N), 90.5 % of the isolates carried also the mutation at codon 
position N51I and 66% carry mutation C59R. The number of parasites measured in 
this work is limited but clearly shows 100% prevalence of mutated dhfr. This is 
remarkable years after the withdrawal of the drug and questions the relevance of 
previous findings of lowered in vitro activity of the enzyme (Sirawaraporn et al, 1997). 
My results seem to support more recent studies on the catalytic activity of wild type 
vs. mutant enzyme, which concluded the opposite. The authors of this study found 
actually higher catalytic activity of the mutant enzyme compared to wild type dhfr 
(Sandefur et al, 2007). This may explain the persistence of mutant dhfr in Africa 
(exemplified by my results from Kilifi), in Southeast Asia (Masimirembwa et al, 1999; 
Ngo et al, 2003; Wang et al, 1997; Zindrou et al, 1996), in Tanzania (Gesase et al, 
2009) and in western, central and eastern Africa (Mita et al, 2009) even years after 
withdrawal of SP.  
Chloroquine (CQ) was used in a control assay to demonstrate that mutated SNPs in 
the dhfr gene were only associated to the resistance of anti-folate and not generally 
to resistance against antimalarials. The drug was found suitable for the analysis for 
two reasons. First, CQ is a 4-aminoquinoline and is therefore structurally and 
functionally unrelated to anti-folates and secondly, CQ was used before the 
introduction of SP as first line treatment in the area and the question arose of how 
long the resistant phenotype would persist in the population after its withdrawal. Of 
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the measured isolates 57.1% still exhibited complete chloroquine resistance (CQR). 
This is a reduction of CQR prevalence in accordance to the previously reported 
studies in Kenya (Mwai et al, 2009) and in Malawi (Bridges et al, 2009). However, 
elimination of chloroquine resistant phenotypes seems to be slow in our study site 
compared to almost complete elimination (0-8% prevalence) of mutant pfcrt in Malawi 
(Bridges et al, 2009). A still remarkable number of resistant parasites were detected. 
This is even more astonishing as the withdrawal of chloroquine happened even 
before the withdrawal of SP. An explanation for the persistence of resistant 
phenotypes in our study site could be massive use of amodiaquine (AQ) as interim 
first line treatment after withdrawal of SP and before the introduction of ACT. AQ is 
also a 4-aminoquinoline and could therefore have co-selected for CQR during the 
years of its usage. In this case, AQ retarded the immediate decline of CQR and the 
prevalence of CQR has to be reassessed. Under these circumstance, prevalence is 
already remarkably reduced in the study area and expected to decline even more 
rapidly in the next year in analogy to Malawi (Bridges et al, 2009) and Tanzania.  
In conclusion, it seems that CQR is accompanied by compromised fitness whereas 
mutant dhfr is not, even though the persistence of two different loci in the population 
is not comparable and both proteins are fundamentally different.  
About adapting parasites to culture and in vitro vs. in vivo findings 
The availability of standard culture protocols for P. falciparum blood stage parasites 
permits the convenient and reproducible characterisation of phenotypes in vitro. The 
adaptation of parasite isolates obtained from infected patients can last over several 
weeks and up until now partially conflicting information about parasite survival during 
this adaption procedure exists. My results highlight the importance of such an 
analysis. On average 36 % of initial clones were lost during adaption. The 
methodology of msp2 genotyping has limitations (discussed above). With further 
development of affordable whole genome sequencing technologies in the future, this 
question could be addressed in more detail. Nonetheless, the high proportion of lost 
clones (36%) may help to explain an often-observed discrepancy between in vitro 
susceptibility measured in adapted parasite isolates and in vivo outcome (Sasi et al. 
JID 2008). The reasons for differential abilities to adapt to culture conditions are 
unknown. Survival of the parasites could be stochastic, i.e. due to chance alone or it 
is linked to genetic factors, which may confer differential survival chances in vitro and 
in vivo. The latter is a concern when interpreting results of in vitro drug susceptibility 
assays as a representative picture of naturally occurring parasites. Some in vivo 
phenotypes might not be compatible with in vitro culture conditions and will therefore 
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elude their identification. An example could be the recently observed in vivo 
resistance phenotype against artemisinins (Dondorp et al, 2009), which still lacks a 
corresponding, stable in vitro phenotype. 
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4.3 Induction of drug resistance in vitro 
To investigate the emergence of anti-folate resistance in vitro and to better 
understand the molecular mechanism, parasites were grown in vitro under increasing 
pyrimethamine pressure. Two laboratory strains, 3D7 and FCR, were used for this 
experiment. Both strains are sensitive to pyrimethamine, but whereas FCR3 carries 
the mutation A16V and S108T, which confer a high cycloguanil resistance, 3D7 has 
wild type dhfr and is cycloguanil sensitive. Compared to field isolates, 3D7 (4 µM) 
and FCR3 (600 nM) exhibit sensitivity against trimethoprim, an overall weak 
antimalarial drug. But when exposing the parasites to pyrimethamine over a 
prolonged period, resistance developed not only against pyrimethamine (3D7 and 
FCR3) but also against cycloguanil in 3D7 (FCR being already highly resistant) and 
trimethoprim (3D7 and FCR3). The IC50 values for the three drugs increased 
significantly during the experiment, implying a mechanism of resistance, which 
confers cross-resistance to other anti-folates but not against unrelated anti-malarials. 
Responsiveness against chloroquine remained unchanged, except for FCR3800nM. 
When I further increased the pyrimethamine concentration in the growth medium, the 
IC50 value of chloroquine dropped back again and since I could not find a plausible 
explanation for this phenomenon, it was not further investigated.  
The increase of IC50 values did not follow a particular pattern, except for the first 
concentration measured. At 200 nM of pyrimethamine, both parasite lines had 
developed an IC50 of approximately 200 nM (3D7: 225 ± 9 nM; FCR3 268 ± 55 nM). 
The same parasites showed decreased cycloguanil sensitivity. The parasites had 
adapted to the concentration they were exposed to but multiplied with only half of 
their usual growth rate according to the measured IC50. Therefore the status of the 
parasite at that time point of the experiment should not be defined resistant. 
Resistance would be defined as uninhibited growth in the presence of the drug. 
Interestingly this was a rather stable phenotype, as the parasites were kept over 2 
month at 200 nM without noticeable change of their phenotype. When drug pressure 
was further increased a more complex pattern emerged. The concentrations of 
pyrimethamine necessary to inhibit 50% of maximal growth started to increasingly 
exceed the drug concentration in the medium. IC50 values of pyrimethamine were a 
multiple above the drug concentration in the medium: 4900 nM 3D7800nM, 3500 nM 
FCR3800nM, 6400 nM 3D71600nM and 5300 nM in FCR31600nM (pyrimethamine). Between 
3 and 6 fold higher was the measured concentration, which inhibits 50 % of parasite 
growth. This pattern correlated with a recovery of normal growth rates in these 
parasite lineages. Cross-resistance to trimethoprim was equally strong developed. 
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3D7 showed approximately 5 fold increase and FCR3 a 10-fold increase between the 
development of anti-folate tolerance at 200 nM and resistance at 800 nM, suggesting 
a highly developed cross-resistance between pyrimethamine and trimethoprim. 
Cycloguanil in contrast remains the most potent drug (290 nM in 3D7800nM and 340 
nM in 3D71600nM) and thus exhibits in these experiments less cross-resistance in 
accordance to results of previously reported studies (Ferone et al, 1969; Milhous et 
al, 1985; Nzila-Mounda et al, 1998). Interestingly, no change in IC50 values was 
observed when the drug pressure was elevated to 1600 nM in the growth medium. 
One explanation for this could be that selection pressure was not sufficiently strong 
as the parasites exhibited already an IC50 value greater than the drug pressure 
applied. The intriguing pattern in the rate of acquisition of stable resistance will be 
further discussed in the next paragraph.  
In the parasites line 3D7 a single point mutation at position S108N was identified for 
the first time at a pyrimethamine concentration of 800nM in the medium. The 
mutation replaced the wild type amino acid serine (S) by asparagine (N) and confers 
thereby the above described highly and stable pyrimethamine resistance. 
But before the introduction of the point mutation, an increased abundance of dhfr 
transcripts was found at 100nM of pyrimethamine, when an expression analysis was 
performed. Increased expression was due to amplification of the genomic locus 
containing the dhfr gene in both strains. The adapted laboratory strains developed 
resistance by increasing the abundance of the targeted enzyme to overcome 
inhibition. The malaria parasite’s ability to amplify dhfr in vitro has previously been 
reported (Inselburg et al, 1987; Thaithong et al, 2001) but no detailed analysis of the 
number of amplification, of the amplified locus itself and of the occurrence of a SNP 
within the additional copies has been performed until now. In this study a continuous 
amplification of the dhfr locus in both strains was observed. Once the amplification 
was introduced in the parasite population at around 100nM of pyrimethamine, 
additional copies were added within 7 asexual parasite cycles (two weeks). In my 
experiment the number of dhfr copies increased up to 31 in 3D7, but only 9 fold in 
FCR3. Thaithong, et al. is the only group having carried out a similar experiment. 
First, they estimated a 44-fold increase at the dhfr locus in a clone carrying 
previously to the selection process mutation A16V and S108T. Secondly, they 
observed an increase of dhfr copies in parasites carrying a wild type dhfr allele but 
without quantification. And thirdly, no amplification was found in a clone carrying 
S16V (Thaithong et al, 2001). The authors argued that this clone (S16V) was already 
sufficiently resistant against pyrimethamine (Thaithong et al, 2001). This hypothesis 
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would ultimately lead to the consequence that their wild type clone should harbour 
even more than the partially resistant clone (A16V and S108T with 44 copies). 
Unfortunately no estimation about copy numbers of the wild type clone is given and 
the hypothesis can thus not be reconfirmed. 
My results show a significant amplification in FCR3 parasites (carrier of A16V) but 
remarkably less pronounced compared to 3D7 (wild type) or to Thaithong’s findings. 
Two possible reasons could explain this difference. Further amplification of the allele 
carrying the mutation A16V and S108T may be limited due to functional constraints 
on this particular haplotype or simply by higher intrinsic level of resistance. In support 
of the first explanation a parallel can be drawn from studies on the multidrug resistant 
transporter gene (mdr) coding for Pgh1, a homologue to the human P glycoprotein 1. 
This gene was found amplified in field isolates and amplification was correlated to the 
wild type allele (Price et al, 1999) suggesting a disadvantage of amplifying mutant 
alleles. An argument for the latter explanation is the elevated IC50 in FCR31600nM and 
the relatively higher baseline IC50 of FCR3 (62nM) compared to 3D7 (20nM). The 
parasites are highly adapted at 1600nM (5300nM) and need no further amplification 
to encounter the drug in the medium, potentially due to their predisposition of A16V 
and S108T. 
So why did 3D7 accumulate 10 additional copies (one third of its total copy number), 
when brought from 800nM to 1600nM of pyrimethamine even though no obvious 
phenotypic benefit is apparent, i.e. in the absence of further increased IC50 values? 
The hypothesis, that copy numbers depend strictly on the drug pressure applied and 
the parasite’s need to escape the deteriorating effects of the drug, seems only 
partially be true. In the following paragraph an additional aspect is presented, which 
might give an indication for the above-described controversy. 
Since gene amplification alone could not account for the highly resistant phenotype 
observed, I looked into the occurrence of mutations within dhfr gene copies. As 
mentioned above, in the parasites line 3D7, dhfr was not only amplified but at a 
pyrimethamine concentration of 800nM a single point mutation at position S108N 
was identified for the first time in a small number of copies, which replaced the wild 
type amino acid serine (S) by asparagine (N). It is the first time that gene 
amplification is shown to precede the emergence of a single point mutation in 
Plasmodium falciparum and that a functional link between amplification and SNP 
occurrence can be drawn. I propose in analogy to bacteria (Andersson et al, 1998) 
that gene amplification in Plasmodium falciparum facilitates the acquisition of single 
point mutations through increased copy numbers of the target gene (i.e. dhfr). Even 
when assuming no change in the per-nucleotide mutation rate this is expected to 
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result in higher probability of errors during DNA replication. The estimated mutation 
rate of 10-9 (Paget-McNicol & Saul, 2001) in the DHFR locus of P. falciparum was 
increased by at least one magnitude. 
One single other study in P. chabaudi supports these findings. Selecting for 
pyrimethamine resistance in the rodent malaria parasite also showed dhfr 
amplification. Cowman and Lew found a 200kb region being amplified (Cowman & 
Lew, 1989) and later in a subsequent publication, a single point mutation at protein 
position 106 was identified within the amplified copies, which corresponds to 108 in 
P.falciparum (Cowman & Lew, 1990). Through amplification the emergence of a 
mutation in the amplified gene in P. chabaudi is facilitated. In P. falciparum though, 
no evidence for the existence of such mechanism was found until now. Thaithong et 
al found gene amplification as a mechanism of resistance in dhfr of P. falciparum and 
could also detect some mutations in the dhfr gene but not at position 108 and more 
importantly, they did not connect these two mechanisms as being functionally related 
(Thaithong et al, 2001). Other recent and past studies have only investigated the 
mutation rate of the dhfr gene in Plasmodium falciparum (Paget-McNicol & Saul, 
2001) and the stepwise acquisition of single mutations (Lozovsky et al, 2009) without 
taking into account gene amplification. Cowman et al. even concluded that the 
molecular basis for pyrimethamine resistance in P. falciparum is only mutated dhfr 
and gene amplification did not play a role in conferring resistance (Cowman et al, 
1988). 
With the introduction of a point mutation in the amplified copies, some of the 
apparent conflicting results could be explained. Firstly the sudden and disproportional 
decline of responsiveness from 3D7200nM to 3D7800nM could be attributed to the 
mutation of S108N. This gatekeeper’s substitution is known to be the first step in 
emergence of pyrimethamine resistance in P. falciparum field isolates (Peterson et 
al, 1991). Furthermore the responsiveness in vitro against pyrimethamine, 
cycloguanil and trimethoprim of AQ 86 (S108N only) is comparable to 3D7800nM and 
3D71600nM with amplified dhfr and S108N. The sudden establishment of resistance in 
3D7 could therefore be explained by the mutation and gene amplification contributes 
at this stage of drug exposure less to the resistant phenotype than at lower 
pyrimethamine concentrations. It remains a mystery though, why the parasites, in a 
genetic background of S108N, acquired continuously further dhfr copies, when it was 
transferred from 800nM to 1600nM. Even more striking are these findings, when 
additional copies do not alter the resistant phenotype. Two possible explanations are 
conceivable. First, it could be that the mutation mainly determines the phenotype and 
the lack of significant drug pressure at 1600nM leaves the parasites enough 
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tolerance to add or loose copies at random. Or secondly, it is most likely that not all 
parasites carry the mutation and the measured phenotypes as well as the determined 
copy numbers are the results of a mixed population. However, when 3D7800nM were 
cloned out, it became apparent, that all of the 8 recovered clones carried the 
mutation (confirmed only by restriction analysis) leading to the hypothesis that every 
single parasite carries the mutation in at least one dhfr copy. But to definitely resolve 
the further fate and prevalence of mutation and amplification in the selected parasites 
population, the drug pressure has to be increased at least at the level of the current 
IC50 or above. The continuous selection of the 3D7800nM cloned parasites could also 
give further insights in the differential contribution of dhfr copy numbers and dhfr 
mutation for resistant phenotypes. 
In summary, I conclude that both parasite strains have successfully amplified the dhfr 
gene in Plasmodium falciparum to overcome inhibition by pyrimethamine. I therefore 
suggest that amplification is a mechanism of resistance for the dhfr locus at low 
inhibitory concentration and that these amplifications facilitate introduction of a single 
point mutation to ultimately gain high pyrimethamine resistance. The high prevalence 
of CNVs in the Plasmodium genome (Cheeseman et al, 2009) further suggests that 
the relationship between copy number amplification and SNP acquisition rate may be 
a general, conserved mechanism that drives evolutionary adaptation in Plasmodium. 
In the presented work, the first amplifications were introduced in the parasite 
populations at around 100nM of pyrimethamine. This is in accordance to previously 
presented work by Thaithong, et al. (Thaithong et al, 2001). Here for the first time, a 
detailed analysis of the amplicon was performed. Surrounding sequences and open 
reading frames were analysed. Surprisingly, amplicons in 3D7 and FRC3 strains 
were distinctively different, although a notable feature was the absence of co-
amplification of PFD0835c, the immediately adjacent gene to dhfr. In 3D7 an 
amplicon was generated with a gap at PFD0835c and in FCR3 the amplicon 
contained only part of the gene without the transcription start site, i.e. non-functional 
copies. This suggested a strong selection pressure against co-amplification of 
PFD0835, as it is located in immediate proximity to dhfr. Both strains have 
undergone complex arrangements to avoid its co-amplification. By extension, this 
leads to the hypothesis, that PFD0835c might be toxic if over-expressed. PFD0835c 
is annotated as a LETM like protein. In yeast a protein with LETM1 domain is 
involved in K+/H+ exchange at the inner mitochondrial membrane (Froschauer et al, 
2005) and in Drosophila a LETM1 protein, a homologue to the mammalian LETM1, 
has been identified as a Ca2+/H+ antiporter (Jiang et al, 2009). In Plasmodium 
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falciparum no functional in vitro studies on the gene product of PFD0835c have yet 
been performed but a signalling sequence targeting the protein to the apicoplast was 
annotated for PFD0835c suggesting that PFD0835c is involved in K+ and or Ca+ 
homeostasis in the apicoplast of P. falciparum. Over expression could lead to 
breakdown of membrane potential and K+ / H+ / Ca+ homeostasis. The channel 
seems to be essential, as no complete loss of the sequence had occurred. The 
relatively complex genesis of the dhfr amplicon may also explain the lack of dhfr 
amplification in field strains. In summary, these findings generated testable 
hypotheses that can be addressed experimentally.  
The underlying mechanism of chromosomal rearrangement is not understood in P. 
falciparum. Various mechanisms described in model organisms and in human cancer 
have to be considered. Fundamentally two main mechanisms can be distinguished: 
chromosomal rearrangement and new DNA synthesis by copying sequence from 
other related or unrelated parts in the genome. From all current models, also 
presented in the introduction, I propose the FoSTeS (fork stalling and template 
switching) model (Lee et al, 2007) to be prim candidate for further studies. During 
DNA replication, the lagging strand disengages from its template and invades a 
neighbouring replication fork where it continues the replication but on the basis of a 
wrong template. The resultant sequence can be very diverse and randomly 
orientated since the strand switching can occur repeatedly at any place and in both 
direction for both longer and shorter sequences. No limitations are set for creation of 
newly copied and integrated sequences.  
In Plasmodium falciparum it has been suggested that the majority of DNA replication 
starts in 28 to 31 hours post invasion of erythrocytes and increases during the 
following 8 to 10 hours during which the genome is replicated several times (Arnot & 
Gull, 1998; Graeser et al, 1996; Inselburg & Banyal, 1984). To accomplish massive 
multiplication within such a short time, it can be assumed that many replication forks 
are built at the same time and the abundance of repetitive sequences in Plasmodium 
falciparum (Wickstead et al, 2003) could then facilitate the annealing of a disengaged 
lagging strand into a neighbouring replication fork. The reasoning for such 
speculation is the fact that the amplicon of 3D7 is interrupted and the resulting 
sequence is difficult to explain by simple chromosomal crossing over and 
rearrangements, especially because the missing sequence in the amplicon is 
approximately 3 kb long and chromosomal rearrangement occur over much greater 
distances. Once a duplication of the genome has been created by FoSTeS, further 
amplification could then be generated by non-allelic homologous recombination 
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(NAHR) within chromatids and sister chromatids. The more copies are available the 
higher the homology within and between the two sister chromatids and this could 
then facilitate recombination. Further analysis of the sequences that result from 
amplification will have to be performed to conclude about the parasites favourite 
mechanism to amplify genes - if there is one.  
The last aspect, which I will focus on, is fitness cost of parasites carrying 
amplification. Parasites carrying amplified pfmdr locus selected by mefloquine 
showed lower replication rates than parasites they were derived from 
(Preechapornkul et al, 2009). This is consistent with the results obtained in my 
experiment. dhfr amplification was stable in culture without drug pressure and when 
kept alone for at least 2 month but when grown in competition with wild type 
parasites amplification was lost or overgrown within two months. The stability of dhfr 
amplification is a small hint suggesting stable integration of amplicons as opposed to 
episomal carriage of amplified DNA. This question has not been addressed in more 
detail but will be part of future investigations.  
The findings presented in this work provide compelling evidence that evolutionary 
function of gene amplification as an intermediate step for the acquisition of stably 
heritable genetic changes. This work also provides a range of testable hypotheses 
that can be addressed experimentally using established genetic tools. 
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